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ABSTRACT
Background and Objectives: The impaired pressor response in patients with
cirrhosis of the liver may have implications for the pathogenesis and treatment of the
hyperdynamic circulation associated with this condition. Studies in patients and
animal models have not elucidated the cause(s) of this abnormality in the
vasculature. A small number of studies have demonstrated impaired adrenoceptor-
mediated contraction in hepatic arteries isolated from patients with cirrhosis.
However, although use of animal models has suggested that responses to other
vasoconstrictor agonists may also be altered in cirrhosis, this has not been addressed
using the human hepatic artery. The aims of this thesis were (i) to assess the effect of
cirrhosis on the responses of human hepatic artery to three vasoconstrictor agonists,
arginine vasopressin (AVP), 5-hydroxytryptamine (5-HT) and endothelin-1 (ET-1),
which may contribute to the development of the hyperdynamic circulation and (ii) to
clarify the mechanism(s) of any abnormality detected.
Methods: Vascular responses were investigated in vitro using organ bath
methodology. Method development was performed using porcine splanchnic arteries.
The suitability of using hepatic arteries from liver donors as controls was also
assessed by exposing porcine hepatic arteries to preservative solutions. Hepatic
arteries from liver recipients (cirrhotic), and age and sex matched liver donors (non-
cirrhotic), were studied. The presence of the endothelium was assessed functionally,
histologically and immunohistochemically. Cumulative concentration-response
curves to AVP, 5-HT, ET-1 and KC1 were constructed in denuded hepatic arteries.
The receptors responsible for agonist-mediated contraction were identified by
performing concentration-response curves following exposure of the arteries to
appropriate antagonists. Furthermore, the influence of nitric oxide synthase (NOS)
activity was assessed using immunohistochemistry and functionally using an
appropriate inhibitor.
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Results: The endothelium was shown to be damaged considerably in isolated human
and porcine hepatic arteries; hence, all subsequent studies used denuded vessels. The
protocol developed using porcine hepatic arteries demonstrated that preservative
solutions had no effect on contractile function but did alter endothelium-independent
relaxation. Responses to vasoconstrictors were altered in arteries from patients with
hepatic cirrhosis although the nature of this alteration was agonist-dependent: the
maximum contraction to AVP was impaired whilst that to 5-HT was augmented. In
contrast, the sensitivity of response to ET-1 was increased, whereas KCl-mediated
contraction was unchanged. The contractile responses to AVP, 5-HT and KC1 were
unaffected by NOS inhibition. There was no immunoreactivity for iNOS in donor
hepatic arteries nor in those from most patients: low levels of iNOS were only
detected in arteries from patients with alcoholic liver disease. Use of antagonists
demonstrated that AVP and ET-1 contracted human hepatic arteries via the Vi and
ETa receptors, respectively, whilst 5-HT acted predominantly via 5-HTi-like
receptors with a small contribution from the 5-HT2a subtype.
Conclusions: These studies demonstrated that cirrhosis of the liver is associated with
an agonist-selective alteration of receptor-mediated contraction in denuded human
hepatic arteries. Inducible nitric oxide synthase activity did not contribute to these
alterations and unaltered responses to KC1 suggest that these abnormalities are not
due to structural changes in the vessel wall. These results indicate, therefore, that
altered contractile functions in hepatic arteries from patients with cirrhosis are due to
changes in receptor activity and/or post-receptor signal transduction pathways.
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Cirrhosis of the liver is an important chronic health problem due to its profound
impact on morbidity and mortality (Liach et al., 1988). The outcome of this disease
predominantly depends upon associated vascular complications: portal hypertension,
ascites, variceal bleeding, hepatic encephalopathy and hepatorenal and
hepatopulmonary syndromes (Sikuler et al., 1985; Ryan et al., 1995; Agusti et al.,
1990). Irrespective of the aetiology of cirrhosis, patients develop a characteristic
cardiovascular dysfunction 'the hyperdynamic circulation' which leads directly to the
development of these life-threatening complications. One component of the
hyperdynamic circulation, consistently demonstrated over the last 50 years, is an
impaired response to exogenous pressor agents. This suggests that altered contractile
function in the vasculature may contribute to the hyperdynamic circulation. A
complete understanding of the mechanism(s) responsible for this altered pressor
response is crucial to understanding the pathogenesis of the hyperdynamic
circulation and to the development of potential therapeutic and preventive
interventions. The cause of this impaired pressor response remains unclear despite
extensive research, using both in vivo and in vitro methodology, in patients and
relevant animal models. This thesis describes studies performed, using isolated
human hepatic arteries, in an attempt to both demonstrate the impact of hepatic
cirrhosis on vascular function and to clarify the underlying mechanism(s) responsible
for functional abnormalities.
2
1.2. Cirrhosis of The Liver
1.2.1. Liver Function and Structure
The liver receives nutrient and toxin rich blood from the gastrointestinal tract. It
performs a wide range of important processes that can be classified under five
distinct headings: (i) excretory (producing e.g. bilirubin and urea), (ii) synthetic
(producing specialised proteins such as albumin and the clotting factors), (iii)
detoxification (of drugs and toxins), (iv) assisting digestion (supplying bile salts and
bicarbonate) and (v) maintaining blood levels of amino acids and glucose.
In order to perform these functions, the liver receives oxygenated blood via the
hepatic artery and blood from the gastrointestinal tract via the portal vein. It is
drained via three main hepatic veins. This blood supply is used as a basis for dividing
the liver into eight segments, in accordance with the subdivision of hepatic and portal
veins. Each segment is made up of many smaller units (lobules), which are
themselves formed of collections of the functional unit of the liver (the acinus;
Figure 1.1). Blood enters the acinus from terminal branches of the portal vein and
hepatic artery situated in the portal tract. It flows into the sinusoid (the capillary of
the liver) and finally drains into the central vein. Bile flows in the opposite direction,
from the hepatocytes, along bile canaliculi, and into the interlobular bile ducts
located in the portal tract. The sinusoids are highly permeable, being lined with
fenestrated endothelial cells and lacking basement membrane. This allows mixed
blood (from portal vein and hepatic artery), at very low pressure, to gain access to the
hepatocytes. Hepatocyte function varies depending upon position relative to the
portal tract and this structure allows the liver to perform its necessary functional
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objectives. The luminal surface of the sinusoidal endothelium is lined with Kupffer
cells (which are involved in phagocytosis) (Wisse et al., 1996) whilst hepatic stellate
cells in the space of Disse (Figure 1.1) are smooth muscle type cells with contractile
functional characteristics (Tanikawa, 1995). Several inflammatory cytokines and
growth factors can activate these stellate cells and induce the synthesis of fibrous
tissue (Friedman, 1990; Ramadori, 1991).
1.2.2. BloodSupply to the Liver
Considering its size, the liver receives a disproportionate component (-25%) of the
total cardiac output. Blood is supplied via the hepatic artery and portal vein which
provide roughly 25% and 75% of the total hepatic blood flow (but 70% and 30% of
the required oxygen), respectively (Greenway & Stark, 1971). Within the liver, these
vessels divide to supply individual segments, continue into the sinusoids and
terminate in the central vein. The central vein drains into the inferior vena cava via
the hepatic veins. Intrahepatic pressure falls along the hepatic arterioles and portal
veins, and reaches its lowest level in the hepatic veins. The hepatic venous system is
valveless and is sensitive to elevations of central venous pressure (Lautt et al.,
1986a). Any such increase is transmitted directly to the sinusoids and causes an
increased filtration of fluid and, thus, increased lymphatic drainage. This may lead to
production of ascites. The main site of intrahepatic resistance has proved
controversial with some investigations suggesting that blood pressure reduction
occurs mainly in the sinusoids (Mitzner, 1974) (where it is controlled by endothelial
Kupffer and stellate cells which can contract and swell to reduce patency of the








Space ofDisse Bile Duct -
Hepatic Stellate Cell KJ
Hepatic Artery
Figure 1.1. The Hepatic Acinus. This comprises the functional unit of the liver, in
which blood from the hepatic artery and portal venous system merge and come into
contact with hepatocytes before draining into the central hepatic vein. Hepatic
Stellate cells located in the space of Disse, the space between sinusoids and
hepatocytes.
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resistance in this circuit originates in the post-sinusoidal network (Lautt et al.,
1986b).
Regulation of blood flow to the liver is complex with contributions from both
intrinsic and extrinsic mechanisms (Lautt 1985; Lautt & Legare, 1987). Extrinsic
mechanisms include sympathetic nervous activity and the action of humoural factors.
An unusual component of nervous activity is "autoregulatory escape" in which
arterioles (but not venules) fail to maintain contraction in the presence of continued
nerve stimulation (Greenway, 1984). Humoral factors (including substances
absorbed from the gut and released by splanchnic organs) which are supplied by both
the hepatic artery and portal vein, gain access to the hepatic arterioles and can, thus,
influence hepatic resistance. Intrinsic regulatory processes (which, by definition, are
exclusive of nervous and blood-borne vasoactive factors and are also not dependent
on metabolism) include the "hepatic artery buffer response" and "autoregulation".
The hepatic artery buffer response regulates the intrahepatic resistance by
maintaining a constant total hepatic blood flow (Lautt et al., 1985); alterations in
portal venous flow are balanced by an inverse response in the hepatic artery
(although portal flow does not alter in response to changes in hepatic artery flow).
This is thought to be mediated by washout of locally produced adenosine (although
other possibilities include hepatic nerves, myogenic response, and systemic
vasoactive factors) (Lautt 1985; Ezzat & Lautt, 1987). Autoregulation describes
hepatic artery constriction in response to an increase in arterial perfusion pressure
and is probably a myogenic response (although washout of adenosine could also
explain this phenomenon) (Greenway, 1984; Hanson, 1973).
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1.2.3. Development ofHepatic Cirrhosis
The liver is susceptible to both acute (paracetamol poisoning; inherited syndromes;
hepatitis (alcoholic, pyogenic, viral)) and chronic insults. Chronic hepatitis has
several aetiologies and leads to the development of cirrhosis. Viral infection is the
most common cause of cirrhosis worldwide, whereas excess alcohol intake over a
long period is the most usual cause in the Western world. Other causes, however,
include autoimmune disease, cholestatic disease (primary and secondary biliary
cirrhosis, primary sclerosing cholangitis), hereditary conditions (haemochromatosis,
Wilson's disease, ai-antitrypsin deficiency) metabolic disorders (glycogen storage
disease, galactosaemia), drug toxicity (e.g. methotrexate) and some idiopathic
(cryptogenic) conditions.
Hepatic cirrhosis is the end stage of chronic inflammatory processes. Irrespective of
aetiology, persistent injury to the liver initiates a characteristic cascade of events;
inflammatory reactions lead to the death of hepatocytes, stimulation of Kupffer cells
and activation of stellate cells (Friedman et al., 1993). The latter results in excess
fibrous tissue formation, which blocks the fenestrations in the sinusoids and restricts
blood supply to the hepatocytes. Consequently, these changes cause further
impairment in the function of hepatocytes and considerably augment sinusoidal
resistance and intrahepatic pressure (Rockey et al., 1993).
1.2.4. Cardiovascular Complications ofCirrhosis
The development of hepatic cirrhosis is accompanied by characteristic changes in
cardiovascular function, which together are described as the "hyperdynamic"
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circulation (Murray et al., 1958; Kontos et al., 1964). This consists of an increase in
cardiac output and heart rate, accompanied by reduced mean arterial pressure and
systemic vascular resistance. An important consequence of these changes is the
development of portal hypertension, as this leads to the major life-threatening
complications of cirrhosis (variceal haemorrhage, ascites, encephalopathy). Portal
hypertension occurs as a consequence of increased blood flow into the portal system
(Bosch et al., 1988; Grose & Hayes, 1992) combined with obstruction of outflow
through the liver (resulting from destruction of the hepatic architecture). It has been
estimated that increased portal venous inflow contributes ~40%, and intrahepatic
resistance ~60%, to portal hypertension (Benoit et al., 1985).
1.2.5. The Hyperdynamic Circulation
The significance of the hyperdynamic circulation of cirrhosis is indicated by its role
in the development of life-threatening complications (Liach et al., 1988). It also has
prognostic significance as the severity of the hyperdynamic circulation reflects
hepatic dysfunction and disease progression (Gluud et al., 1988). An understanding
of the mechanism(s) that contribute to development of the hyperdynamic circulation
is, therefore, essential in the development of therapeutic approaches to management
of cirrhosis. Despite extensive investigation, however, the pathogenesis of these
circulatory abnormalities remains controversial.
The increased cardiac output and systemic vasodilatation in the hyperdynamic
circulation are evident despite activation of endogenous pressor systems (the
sympathetic nervous systems (SNS) (Henriksen et al., 1998; Arroyo et al., 1983;
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Bichet et al., 1982a), renin-angiotensin-aldosterone (RAAS) (Schroeder et al., 1976;
Iwao et al., 1994)), endothelin system (Gerbes et al., 1995; Kitano et al., 1996) and
synthesis of vasopressin (AVP) (antidiuretic hormone, ADH) (Bichet et al., 1982b;
Badalamenti et al., 1993). Indeed, increased pressor activity makes a significant
contribution to maintenance of blood pressure as pharmacological inhibitors cause
severe hypotension in these patients (Claria et al., 1991; Esler et al., 1992; Moreau &
Lebrec, 1995)). Furthermore, plasma concentrations of endogenous vasoconstrictors
are predictive of severity of cirrhosis and poor prognosis (Gines et al., 1993; Arroyo
et al., 1988). The currently accepted explanation for the pathogenesis of the
hyperdynamic circulation is the 'peripheral arterial vasodilatation hypothesis'
(PAVH) (Schrier et al., 1988). The PAVH integrates the major aspects of two
previous models: the 'underfill' (Atkinson & Losowsky, 1961; Epstein, 1979) and
'overflow' (Lieberman et al., 1970) hypotheses. The underfill hypothesis proposed
that increased portal pressure leads to loss of fluid from the vascular compartment,
thus activating pressor systems and renal sodium and water retention. In contrast, the
overflow hypothesis suggested that hepatic dysfunction and/ or portal hypertension
provided a stimulus for renal sodium and water retention with a reactive
vasodilatation occurring to accommodate this extra volume. The PAVH unified
components from these models with the proposal that peripheral arterial
vasodilatation is the initial event in development of the hyperdynamic circulation. It
is suggested that this dilatation occurs in response to changes in the liver, although
the underlying mechanism for this response has not been identified. Peripheral
vasodilatation leads to a reduction in peripheral vascular resistance (PVR) and
central blood volume (effective hypovolemia). Consequently, compensatory
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activation of endogenous vasopressor systems occurs in an attempt to restore normal
PVR. In this way, the over active vasopressor and water retention systems attempt to
restore blood volume and pressure (Schrier & Caramelo, 1988). This is effective in
patients with mild-moderate cirrhosis but in advanced disease the pressor response
and increase in blood volume are not sufficient to normalise the PVR, the pressor
systems remain activated and renal fluid retention continues. As a consequence,
portal hypertension becomes exacerbated and serious life-threatening complications
(ascites, variceal bleeding hepatic encephalopathy and hepatorenal and
hepatopulmonary syndromes) develop.
Despite its general acceptance, there are several problems with the PAVH. In
particular, neither the mechanism of arterial vasodilatation nor the primary site of
dilatation has been identified unequivocally. Several studies (in animals and humans)
have demonstrated that the splanchnic circulation is the main site of initial
vasodilatation (Vorobioff et al., 1984; Maroto et al., 1993; Iwao et al., 1997a) but the
exact mechanism has yet to be established. Furthermore, it has been suggested
recently, that an increase in cardiac output, causing a reactive peripheral
vasodilatation, is the initiating abnormality in the development of the hyperdynamic
circulation (Bernardi & Trevisani, 1997). This is attributed to increased cardiac pre¬
load as cardiovascular abnormalities were shown to be evident in patients with mild
cirrhosis only when seated (Lewis et al., 1992; Bernardi & Trevisani, 1997; Wong et
al. 1997; Iwao et al., 1997b). This suggests that the PAVH does not fully explain the
development of the hyperdynamic circulation and the exact cause(s) of this condition
have yet to be understood.
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1.2.6. ImpairedPressor Response
An unusual aspect of the hyperdynamic circulation of liver disease was identified in
studies of secondary aldosteronism in the 1950s (Laragh, 1962; Ames et al., 1965;
Mashford et al., 1962). These demonstrated an impaired pressor response to
exogenous vasoconstrictors in patients with cirrhosis. More recent investigations,
performed in the whole body (MacGilchrist et al., 1991b) and also in isolated
vascular territories such as in dorsal hand vein (DHV) (Wong et al., 1995), fore arm
blood flow (FBF) (Ryan et al., 1993) or in conjunctival vessels (Morandini &
Spanedda, 1966) have confirmed and supplemented these findings. In general, it has
been shown that patients with advanced cirrhosis have an impaired pressor response
to vasoconstrictors but several controversies remain. Angiotensin II (All) and
adrenoceptor-agonists (noradrenaline (NA), phenylephrine) are the agonists most
commonly used but it has yet to be established whether impaired contraction is
agonist selective or occurs with both All and NA. Furthermore, the causes of the
impaired pressor response have not been confirmed.
The impaired pressor response may be a significant component in the pathogenesis
of the hyperdynamic circulation. Reduced contractile responsiveness in the vascular
wall may contribute to the maintenance of systemic vasodilatation despite activation
of endogenous pressor systems. Furthermore, as vasoconstrictor analogues of AVP
are used to treat variceal haemorrhage, an impaired pressor response may have
significant implications for patient survival. A large number of investigations, in vivo
and in vitro, have been performed, using patients and animal models of cirrhosis
(Bomzon, 1990; Hadoke & Hayes, 1997), in an effort to determine the causes of the
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impaired pressor response. Interpretation of this work requires an understanding of
the structure and function of the healthy vascular wall.
1.3. Vascular Structure and Function
1.3.1. Structure and Function of the Blood Vessels
The cardiovascular system circulates blood throughout the body via veins and
arteries which are interconnected by venules and capillaries. Alterations of tone, and
hence lumen diameter, of arteries has an active role in ensuring optimum blood flow
to organs whereas most veins return blood to the heart and provide little resistance.
The vessel wall (with the exception of capillaries) is composed of three layers: the
tunica intima, the tunica media and the tunica adventitia (Figurel.2). This structure is
similar in arteries and veins but the latter tend to have thinner walls and larger cross
sectional diameter than equivalent arteries (Rhodin, 1980).
1.3.1.1. Tunica Intima
The intima is the innermost layer and in many blood vessels consists solely of a
monolayer layer of endothelial cells and a basement membrane. In large elastic
arteries and some (e.g. coronary) muscular arteries the intima includes a sub-
endothelial layer composed of collagenous bundles, elastic fibrils, smooth muscle
and perhaps, a small number of fibroblasts (Badimon et al., 1993). This sub-
endothelium however is scanty in most muscular arteries and absent from arterioles
(Rhodin, 1980). The endothelium has a major role in the regulation of vascular tone
and, consequently, blood flow (Searle & Sahab, 1992) and also modulates
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Vanhoutte, 1989; Marcus, 1990; Johns, 1991).
1.3.1.2. Tunica Media
The middle layer, or tunica media, is composed of multiple layers of smooth muscle
cells (SMCs) bounded on the luminal margin by the internal elastic lamina and on
the adventitial margin by the external elastic lamina. The major components of the
media are SMCs, which confer strength and enable the vessel to contract or relax in
response to stimuli, and elastic laminae, which provide the major mechanical
strength and resilience of the vessel wall. The relative proportions of these
components vary in elastic and muscular arteries. Elastic laminae are usually thicker
and well defined in large elastic (conducting) arteries, become gradually thinner in
muscular arteries and may be ill defined in small arteries. In particular, the external
elastic lamina gradually disappears from muscular arteries. In elastic arteries, the
elastic laminae withstand most of the tension exerted by blood flow; whilst in
muscular arteries this is done by SMCs (Bader, 1963). The arrangement of SMCs
differs in elastic and muscular arteries but in general is arranged helically in
concentric layers. The number of layers decreases towards the distal part of arterial
system. The SMCs are sheathed by thin sheets of connective tissue but at certain
points are electrically coupled in a syncytium (Beny & Connat, 1992). SMC tone is
regulated by blood borne factors, endothelium-derived substances and transmitters
released from the perivascular nerves (Moreau & Lebrec, 1995; Rembold, 1992;
Searle & Sahab, 1992; Mulvany & Halpern, 1976).
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1.3 .1.3. Tunica Adventitia
The outermost layer, the tunica adventitia, gives stability and strength, limits
distension, and connects the blood vessel to its surrounding tissues. The thickness of
the adventitia varies considerably depending on the type and location of a particular
blood vessel. For example, it is almost totally absent from cerebral blood vessels, is
thicker in large muscular arteries, than in elastic arteries and is thickest in veins
(where it forms the major bulk of the vessel wall) than in arteries. It becomes
gradually thinner towards the distal part of the vessels and is quite indistinct in
arterioles and venules. The adventitia also carries nutrient vessels (vasa vasorum
which supply the SMCs) and nerve fibres. The nerve fibres are usually unmyelinated
and, in most vascular beds, the amount of innervation increases with decreasing
vessel diameter (Nilsson et al., 1986; Smeda et al., 1988).
1.3.2. Regulation of Vascular Tone
Vascular tone is determined by the contractile state of medial SMCs, which in turn,
is regulated by a variety of factors: these include activity of the endothelial cells,
nervous and hormonal stimuli, pressure, stretch and metabolic activity. In addition,
smooth muscle in some vessels may be spontaneously active. In general, vascular
smooth muscle cells contract when the intracellular calcium concentration ([Ca2 ]i)
increases. Elevation of [Ca2"]j causes a calmodulin-mediated cycling of actin and
myosin cross bridges which causes shortening of the cell and, thus, contraction
(Adelstein & Eisenberg, 1980; Kuriyama et al., 1982). Relaxation occurs when
[Ca2+]j falls or dilator agonists interfere with mechanisms linking [Ca2+]i with the
contractile machinery.
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1.3.2.1 The Influence of the Endothelium on Vascular Tone
The endothelial cells can produce several vasodilators such as nitric oxide (NO),
prostacyclin (PGE) and endothelium-derived hyperpolarising factor (EDHF), and
vasoconstrictors (such as endothelin-1 (ET-1), prostanoids)) and plays a major role in
coordination and control of the vascular tone (Searle & Sahab, 1992). Furthermore,
the existence of certain important receptors for contractile agents (including 0.2- and
P-adrenoceptors (Martinez-Cuesta et al., 1996), as well as 5-HT2c (Cocks & Angus,
1983), V2 receptors (Martinez et al., 1994) and ETB (Schilling et al., 1995) enables
the endothelium to act as a local feedback control system. Stimulation of these
endothelial receptors induces vasodilatation predominantly via release of NO as well
as PGI2 or EDHF. Moreover, flow-induced shear stress also releases NO from the
endothelial cells and, therefore, plays an important role in modulating vascular tone.
Similarly vascular tone can be modulated by the vasoconstrictors, which are released
in response to anoxia, alteration of blood pressure or rapid stretching of the vessel
wall (Searle & Sahab 1992). Among them ET-1 can have a significant role, as it has
a potent vasoconstrictor effect. Therefore, the integrity of the endothelium is
important in maintaining normal vascular tone and assessment of the endothelium is
essential while investigating the vascular contractile function.
1.3.2.2. Regulation of Vascular Smooth Muscle Contraction
Processes that alter vascular tone can be separated into "Electromechanical" (those
that involve changes in membrane potential) and "Pharmacomechanical" (those that




In the normal resting state, the resting potential of the SMCs (> -50mV) is
determined primarily by a potassium ion (K+) gradient and permeability to sodium
ions. The Ca2+ pump and a Na+/ Ca2+ exchanger in the cell membrane maintain
[Ca2+]i at a concentration much lower than the threshold level necessary for
contraction. Depolarisation is dominated by Ca2+, which enters through L-type (long
acting) voltage-gated channels whereas repolarisation is mediated by efflux of K+
ions through several channel types. Some types of vascular smooth muscle may also
contain T-type (transient) calcium channels, which can contribute to the
manifestation of spontaneous activity and maintenance of basal tone (Katz, 1996).
1.3.2.2.2. Pharmacomechanical Coupling.
Smooth muscle also contains receptor activated Ca2+ channels, which are opened by
the binding of hormones or neurotransmitters, without a change in membrane
potential. In addition, activation of receptors results in generation of second
messengers (such as IP3), resulting in release of Ca2+ from intracellular stores. Most
vasoactive agonists stimulate pharmacomechanical coupling by activation of
membrane receptors (mostly those from the 7 transmembrane domain G-protein
coupled superfamily). This leads to a cascade of intracellular second messengers
resulting in release of Ca2+ from intracellular stores and influx from the extracellular
environment (Walsh, 1994). Relaxation occurs in response to factors that stimulate
production of cAMP or cGMP (by adenylate cyclase and guanylate cyclase,
respectively), which mediate Ca2+ efflux and reuptake by the intracellular stores
(Walsh, 1994). Alternatively, relaxation can occur through activation of potassium
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(K+) channels which hyperpolarises the cell membrane, blocking L-type calcium
channels and, thus, reducing the influx of Ca .
It is also worth noting that pharmacomechanical coupling can result in contraction
and relaxation that are independent of changes in [Ca2+]j. These involve sensitisation
or desensitisation of myosin phosphorylation, diacylglycerol (DAG)-mediated
stimulation of protein kinase C (PKC) isozymes and direct regulation of cross-bridge
cycling (Rembold, 1992; Walsh, 1994). This may be relevant to the vascular
abnormalities in cirrhosis as several agonists (e.g. noradrenaline, arginine
vasopressin and ET-1) can produce sustained contraction without further
enhancement of [Ca2+]i (Kubota et al., 1992; Tansey et al., 1992; Gong et al., 1992).
This process is called "Ca2+ sensitisation" (Fujiwara et al., 1989)
1.3.2.3. Second-Messenger Pathways.
Knowledge of the second messenger cascade has been exploited in an effort to
determine whether impaired contractile response in cirrhosis is due to changes in the
smooth muscle cell at a receptor or post-receptor level (Wu & Benoit, 1994; Huang
et al., 1997). Therefore, a clear understanding of these pathways is necessary for
interpretation of these investigations. The second messenger pathways involved in
pharmacomechanical contraction are illustrated in figure 1.3. Basically, receptor
stimulation by an appropriate agonist causes a Gq-mediated cascade of
phosphoinositide turnover. This results in production of inositol 1, 4, 5-trisphosphate
(IP3) and diacylglycerol (DAG), leading to Ca2' influx (Nelson et al., 1990) and
release release from intracellular stores (Berridge, 1993). Alternatively, some
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Figure 13. Mechanism of Agonist-Induced VSMC Contraction. Increased intracellular
calcium is the hallmark ofVSMC contraction, which combines with calmodulin to activate
phosphorylation of myosin light chain kinase, resulting in actin-myosin cycling inducing
contraction. Receptor (G-protein coupled receptor); otq, p and y subunit of G-protein; PC,
Phosphocholine; PLA2, phospholipase A2; PLC, phospholipase C; PIP2, phosphoinositol 4,
5-biphosphate; PIP3, inositol 1, 4, 5-triphosphate; PLD, phospholipase D; DAG, 1, 2-
diacylglycerol; PKC, proteinkiase C; PA, phosphatidic acid; AA, arachidonic acid; PGs,
prostaglandins; EPOs, epoxyeicosatrienoic acids; SR, sarcoplasmic reticulum; RyR,
ryanodine receptor.
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7-transmembrane-domain receptors are coupled to Gi proteins. Stimulation of these
receptors by an agonist produces a Gi-mediated inhibition of adenylate cyclase,
leading to a reduction in cAMP formation. This inhibits the active reduction of
[Ca2f]j (by reducing both efflux and re-uptake of Ca2+) and thus results in contraction
(Yildiz et al., 1998).
Pharmacomechanical relaxation occurs in response to stimulation of either adenylate
or guanylate cyclase (Walsh, 1994) (Figure 1.4). Stimulation of 7 transmembrane
domain receptors results in Gs-mediated activation of adenylate cyclase and, thus
production of cAMP. In contrast, cGMP is formed by receptor-independent
activation of soluble guanylate cyclase by, for example, nitric oxide (although some
atrial natriuretic peptide receptors have particulate guanylate cyclase activity). cAMP
and cGMP relax smooth muscle by a number of different mechanisms (Rembold,
1992) such as; (i) reducing [Ca2+]i concentrations, (ii) diminishing [Ca2,]i sensitivity
to phosphorylating process, or (iii) uncoupling the force from myosin
phosphorylation. These processes are mediated by cGMP-dependent (PKG) and
cAMP-dependent (PKA) protein kinases (Walter et al., 1988; Baltensperger et al.,
1990). In VSMCs, cAMP is more abundant than cGMP and can stimulate both PKA
and PKG (Rembold, 1992). Protein kinase activation results in (i) Ca2' re-uptake by
the SR and Ca2+ extrusion across the sarcolemma (Furukawa et al., 1988), (ii)
inhibition of agonist-mediated Ca2+ release from the SR (Hirata et al., 1995) (iii)
reduced sensitivity of contractile proteins to Ca2+, (iv) activation of K+ channels and
(v) hyperpolarisation of the cell (Rembold, 1992).
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Figure 1.4. Mechanism of VSMC Relaxation. Reduction of intracellular below a threshold
level induces VSMC relaxation. GC, guanylate cyclase; AC, adenine cyclase. Agents acting
via GC are: NO, nitric oxide; ANP, atrial natriuretic peptide, and acting via AC are: PG,
prostaglandin h & E2; CGRP, calcitonin-gene related peptide; VIP, vasoactive intestinal
polypeptide. PLC, phospholipase C; PIP3, inositol 1, 4, 5-triphosphate; cGMP, cyclic
guanosine monophosphate; cAMP, cyclic adenosine monophosphate and SR, sarcoplasmic
reticulum. Solid line, activation and broken line inhibition.
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1.3.2.4. Regulation ofReceptor-Mediated Contraction
Contractile responses mediated by G-protein coupled receptors can be regulated by
limiting the access of a ligand to its receptor (Grady et al., 1997). This can be
achieved either by: (i) agonist degradation (e.g. breakdown of ACh by
cholinesterase), (ii) agonist re-uptake (e.g. re-uptake of noradrenaline by neurones
and other cells) or (iii) occupation of the receptor by a false transmitter. Repeated
stimulation of a G-protein coupled receptor by an agonist can induce adaptive
changes, which attenuate the response to this agonist. This is highly relevant to
cirrhosis in which the plasma concentrations of many endogenous receptor-
dependent vasoactive agents are chronically elevated (Hadoke, 2001). Adaptations
include down regulation (depletion in the number of receptors) and desensitisation
(uncoupling of a receptor from its second messengers). Receptor down-regulation
occurs in response to prolonged (days-weeks) exposure of the receptor to its ligand
(Lohse, 1995; Hadcock & Malbon, 1993). In this scenario, either internalisation and
degradation of the receptor-ligand complex is increased or synthesis of new receptors
is inhibited (Garland et al., 1994). In contrast, desensitisation occurs within seconds
or minutes of receptor activation, which diminishes sensitivity of response to the
agonist (Grady et al., 1997). This is mediated by phosphorylation of the receptor,
which is, thus, uncoupled from its G-protein (Freedman & Lefkowitz, 1996).
The receptor-mediated response can also be altered by the activity of intracellular
second messenger systems. The intracellular second messengers become depleted or
uncoupled following repeated-prolonged activation of the post-receptor signalling
pathway either by a receptor-dependent or independent stimulation. The altered level
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and activity of the second messenger (Ca2+, IP3, DAG and PKC) therefore can also
modulate VSMCs contraction (Huang et al., 1995; Thrombino et al., 1998).
1.4. Altered Vascular Function in Hepatic Cirrhosis
The demonstration of an impaired pressor response in cirrhosis was confirmed in a
number of whole body experiments relatively soon (MacGilchrist et al., 1991b;
Pinzani et al., 1991) after the initial description (Laragh, 1962; Ames et al., 1965;
Lunzer et al., 1975). Some controversy remained, however, as to whether the
impaired response was seen with NA alone (Lunzer et al., 1975) or was evident with
both NA and All (MacGilchrist et al., 1991a). Indeed, two Italian studies suggested
an impaired response to NA and argued that results from the earlier investigations
could be interpreted to support such impairments (Morandini & Spanedda, 1966;
Morandini et al. 1967). It was not until the last few decades that a whole body
investigation was performed using both All and NA, plus a variety of selective
adrenoceptor agonists, in an attempt to clarify this situation (Lenz et al., 1985;
MacGilchrist et al., 1991a, b; Pinzani et al., 1991). However, whilst MacGilchrist et
al. (1991a) suggested a peripheral abnormality accounted for the impaired response
to these agonists, none of these studies identified the cause of the impaired pressor
response.
The lack of mechanistic detail obtained from whole body investigations in vivo
highlighted the weakness of this type of study and indeed, this approach has now
been largely superseded. The past decade has seen a rapid expansion in the use of
measurements of regional blood flow and in vitro investigations using isolated
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vessels (and also isolated organs and vascular territories), in an attempt to identity
the cause(s) of the impaired pressor response in patients with cirrhosis.
1.4.1. In Vivo Studies
Interpretation of whole body studies is hampered by the reflex changes induced by
systemic changes in vascular tone. This problem has been overcome in recent years
by the improvement of methods, such as venous occlusion plethysmography
(Benjamin et al., 1995) and dorsal hand vein compliance (Aellig, 1981), which allow
local infusion of vasoconstrictors and measurement of blood flow in the forearm.
These techniques use sub-systemic concentrations of an infused drug and, thus, do
not induce systemic cardiovascular or central sympathetic responses. Over the past
decade, these techniques have been used increasingly in an attempt to determine the
causes of vascular dysfunction in cirrhosis. The use of isolated fore-arm and hand
vasculatures have been criticised, however, for having little relevance to the
splanchnic territory which may be the primary site of vasodilatation in cirrhosis.
As with whole body investigations, the majority of studies in isolated vascular
territories have used a-adrenoceptor agonists or All (although a recent report
indicated a reduced response to ET-1 in cirrhosis) (Helmy et al., 2001)). Many of
these have supported the contention that contractile responses to these agonists are
impaired in cirrhotic patients (Ryan et al., 1993, 1996; Campillo et al 1995; Bierbrier
et al., 1994). However, this view is not unchallenged, with several reports that
contractile responses are unaltered in cirrhosis (Calver et al., 1994; Lunzer et al.,
1975). Furthermore, one study identified an impaired response to All but found no
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difference in response to exogenous NA or sympathetic stimulation, in cirrhotic
individuals (Newby etal., 1998b).
The reasons for these conflicting results are not clear, but the most likely
explanations are variations in patient population (including age, disease aetiology
and severity) and/ or methodology (Hadoke, 1999, 2001) between studies. For
example, in one study the patient group was older than the control group (Lenz et al.,
1985) and, whilst some studies infused a single bolus of agonist (Pinzani et al.,
1991), others use a continuous infusion (Ames et al., 1965; MacGilchrist et al.,
1991a,b). Methodological differences, however, may also be significant as
difficulties are encountered with venous occlusion plethysmography when
comparing two groups of patients with different basal forearm blood flow (Benjamin
et al., 1995; Rodriguez-Perez et al., 1993; Calver et al., 1994; Albillos et al., 1995;
Wong et al., 1996). Similarly, aetiology, severity of the disease, treatment process
such as, diuretic and steroid therapy, as well as alcohol intake, which can influence
the investigations (Ryan et al., 1993; Wong et al., 1996; Pickkers et al., 1997) are not
controlled in a similar way in different studies.
Despite the conflicting data, studies on isolated vascular territories in vivo generally
support the notion that an impaired response to exogenous vasoconstrictors does
occur in patients with cirrhosis. The agonist-selectivity of this impairment, however,
remains controversial and these studies have not identified the underlying alteration
in the vessel wall responsible for hyporesponsiveness.
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1.4.2. In Vitro Use ofIsolated Vessels
Isolated vessel studies using in vitro methodology enable direct assessment of
vascular responses in the absence both of systemic neuro-hormonal and reflex
influences (Mulvany & Aalkjaer, 1990) and of circulating vasoactive factors.
Moreover, these studies can investigate directly whether an impaired contractile
response is due to an alteration in the contractile pathways mediated by the receptor
or to remodelling of the vessel wall. Therefore, a large number of studies have been
performed using this methodology to identify the mechanism(s) underlying altered
responsiveness in cirrhosis.
1.4.2.1. Vessels Isolated from Animal Models ofCirrhosis
Due to the scarcity of suitable and viable human vascular tissue samples, most in
vitro studies have used vessels from animal models of cirrhosis/ portal hypertension
(Hadoke & Hayes, 1997). Three methods have been widely used to produce cirrhosis
and/ or portal hypertension in animals (generally using rats, although rabbits (Cahill
et al., 1996; Sitzmann et al., 1995) and dogs (Bomzon et al., 1990) have also been
used). These are: (i) treatment with carbon tetrachloride (CCI4) and phenobarbitone,
which provides a model of liver damage with portal hypertension but without
jaundice, (ii) bile duct ligation (BDL), which causes acute jaundice followed by liver
damage and portal hypertension, and (iii) portal vein ligation (PVL), producing
portal hypertension without significant liver damage or ascites.
Vessels isolated from animals with experimental cirrhosis/ portal hypertension have
been used to investigate the impaired pressor response to a-adrenoceptor agonists
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and All (Weigert et al., 1995; Gadano et al., 1997; Castro et al., 1993). The use of
All has been restricted, however, by the demonstration that this agonist often
produces only small, transient contractions in isolated vessel systems measuring
isometric response. Indeed, in many vessels, sub-maximal pre-contraction with an
alternative vasoconstrictor is required before All will produce a sustained
concentration-dependent contraction (Dunn et al., 1994; Falloon et al., 1995). Most
studies have reported impaired contractile responses to a-adrenoceptor agonists and
All agonists (Lee, et al., 1995; Karatapanis et al., 1994; Claria et al., 1994; Castro et
al., 1993), thus reinforcing the findings of in vivo studies of cirrhotic patients.
Almost inevitably, however, some investigations have also reported no alteration in,
or even an enhancement of, contractile responses to these agonists (Bomzon et al.,
1991; Cawley et al., 1995; Moreno et al., 1996).
Isolated vessel studies have also extended the in vivo observations by assessing
vascular responses to a variety of other vasoconstrictor agonists, including AVP,
5-HT and ET-1 (Sieber & Groszman, 1992; Cummings et al., 1986; Jacob et al.,
1991; Cahill et al., 1998). These studies have demonstrated both that altered
contractile function is not restricted to adrenoceptor agonists and All and that
impaired contractility may be agonist selective (Cummings et al., 1986; Sieber &
Groszman, 1992; Moreno et al., 1996). However, similar to adrenergic agonists and
All, responses to these agonists were also varied widely (reviewed by Hadoke &
Hayes 1997; Hadoke, 1999). For AVP, impaired contraction was reported in the
perfused mesenteric bed or tail arteries of portal vein ligated rats (Sieber &
Groszmann, 1992; Huang et al., 1995) while, the response was unaltered when CCI4
27
was used to induce cirrhosis (Ralevic et al., 1996) or even enhanced in mesenteric
veins of the portal vein ligated rats (Cummings et al., 1986; Moreno et al., 1996).
Several other studies have demonstrated that in rats, 5-HT-mediated contraction was
enhanced in aorta of CCI4 induced cirrhosis (Jacob et al., 1991) or in mesenteric vein
after portal vein ligation (Cummings et al., 1986; Kaumann et al., 1988; Moreno et
al., 1996), but was reduced in aorta and portal vein of bile duct ligated rats (Jacob et
al., 1991). Similarly, it was reported that in rats ET-l-mediated contraction in aortae
was enhanced following portal vein ligation (Cahill et al., 1998) but reduced in CCI4
induced-cirrhosis (Cailmail et al., 1995) and also reduced in mesenteric vein after
portal vein ligation (Moreno et al., 1996). Investigations using animal models
however, demonstrated that the several factors could contribute to conflicting
findings between studies. In particular, these studies indicate that the effect of
cirrhosis on vascular function may depend upon: the species of animal used, the
technique used to induce cirrhosis/ portal hypertension (i.e. the aetiology of disease),
the duration and severity of disease, the anatomical origin of the vessel, and the
selection of a vein or an artery for study (Hadoke & Hayes, 1997).
In general, these experiments with vessels from animal models of cirrhosis indicate
that cirrhosis/ portal hypertension produces an alteration in contractile function that
is maintained ex vivo. Strikingly, these studies also indicate that alterations in
contractile function may be agonist-dependent and may also depend upon the
aetiology, duration and severity of cirrhosis. This literature also, however, serves to
reinforce the limitations that must be acknowledged with isolated vessel techniques.
In particular, that data obtained in a single isolated vessel cannot be extrapolated to
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the entire vascular system. A major limitation, as ever, with animal models, however,
is the question of relevance to the disease in humans. No animal model provides an
ideal representation of human cirrhosis (Tsukamoto et al., 1990). Therefore, it cannot
be assumed that functional changes detected, or mechanisms of dysfunction
identified, will apply to the condition in patients.
1.4.2.2. Vessels Isolated from Patients with Cirrhosis
Relatively few studies have used isolated human vessels to investigate functional
alterations in cirrhosis, mainly because of the many difficulties encountered in trying
to obtain suitable, viable vessels. There is, however, an increasing body of literature
in which functional investigations have been performed on vascular tissue (hepatic
artery and portal vein) obtained at liver transplant (Smith et al., 1997; Hadoke et al.,
1998; Heller et al., 1999). In addition, one study used radial veins obtained by
elective biopsy (Ryan et al., 1996). Unfortunately, due to damage to the endothelium
in vessels obtained from theatre (and deliberate removal of the endothelium from the
radial vein), none of these studies has assessed the effects of cirrhosis on
endothelium-dependent function (Ryan et al., 1996; Hadoke et al., 1998; Heller et
al., 1999). These vessels do, however, allow investigation of the effects of cirrhosis
on VSMC function as well as the mechanism(s) responsible for any alteration..
As with in vivo studies, almost all in vitro studies using vessels from patients with
cirrhosis have investigated adrenoceptor-mediated contraction. In most cases, this
response has been found to be impaired in hepatic arteries (Smith et al., 1997; Heller
et al., 1999), portal veins (Heller et al., 1999) and radial (Ryan et al., 1996) veins
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from patients with cirrhosis. Only one study reported unaltered responses (to NA and
PE) in common hepatic arteries (Hadoke et al., 1998), although there is also a report
of enhanced contractility in intrahepatic arteries isolated from cirrhotic patients
(Battaglia et al., 1996). None of these studies, however, have clearly identified the
mechanism responsible for impaired contraction. Indeed, studies on the impact of
cirrhosis on adrenoceptor function in humans (Gerbes et al., 1986; MacGilchrist &
Reid, 1990) have mostly been performed using blood cells (leukocytes, platelets) as a
model for VSMCs. Similarly, although a wide range of vasopressor systems are
activated in cirrhosis (and data from animal models suggests that contractile
dysfunction is agonist selective) (Cummings et al., 1986; Moreno et al., 1996; Huang
et al., 1995) but the impact of cirrhosis on the function of human extrahepatic
arteries has not been assessed using agonists other than adrenoceptor-agonists (e.g.
AVP, 5-HT or ET-1).
1.5. Mechanism of Altered Vascular Function
Despite the extensive investigation detailed in previous sections, the exact causes of
vascular dysfunction in cirrhosis remain unclear. Several potential mechanisms have
been proposed, however, including: (i) increased vasodilator activity, (ii) impaired
activity of contractile receptors, (iii) alterations in intracellular contractile signalling
pathways, and (iv) structural changes in the vessel wall. Limited investigation of
these processes has been performed using tissue from animal models (and, in some
cases, patients) of cirrhosis.
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1.5.1. AlteredActivity of Vasodilator Systems
Given that individuals with cirrhosis exhibit peripheral vasodilatation, it seems
logical that excessive activity of endogenous vasodilators may contribute to the
vascular abnormalities in this condition (Groszmann, 1994a; Guarner et al., 1993;
Hayes et al., 1992). Potentially, both circulating vasodilators and those produced
locally within the vascular wall could be responsible for altered contractility.
1.5.1.1. Blood-borne Vasodilators
The circulating concentrations of a considerable number of endogenous factors with
vasodilator activity are increased in patients with cirrhosis (Abelmann, 1994; Hayes
et al., 1992; Groszmann, 1994b). These include atrial natriuretic peptide (ANP),
glucagon, prostaglandins H and E2, EDHF, kinins, lactate, adenosine, calcitonin-gene
related peptide (CGRP), vasoactive intestinal polypeptide (VIP), substance P,
adrenomedullin, and histamine (Iwao et al., 1997a; Pizcueta et al., 1990; Sitzmann et
al., 1991; O'Halloran & Bloom 1991; Lee et al., 1997; Guevara et al., 1998 ).
Furthermore, endotoxins, bile acids and cytokines (e.g. tumour necrosis factor
(TNF)), which can induce vasodilation are also elevated in cirrhosis (Khoruts et al.,
1991; Guldatana et al., 1993). Plasma concentrations of these vasodilators often
correlate with disease (cirrhosis) severity and haemodynamic alterations (Lavilla et
al., 1995; Benoit et al., 1986; Gupta et al., 1992). It is possible, therefore, that
increased vasodilator activity in the blood contributes to the development of the
hyperdynamic circulation and to contractile hyporesponsiveness. Indeed, kidneys
from patients with cirrhosis function normally when transplanted into non-cirrhotic
individuals and transfusion of blood from cirrhotic to non-cirrhotic animal induces
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circulatory abnormalities in the latter.
Although the elevated plasma concentrations of so many vasodilators suggest that
they all make some contribution to the hyperdynamic circulation in cirrhosis, this has
yet to be established. Furthermore, whether such activation is the primary cause, or
simply a consequence, of the hyperdynamic circulation is not clear. If, however,
contractile hyporesponsiveness was solely due to the action of blood-borne factors,
contractile function of vessels from cirrhotic individuals would be predicted to be
normal in vitro. Studies with vessels from both patients and animal models have
demonstrated that this is not the case, indicating that an alteration within the vessel
wall itself contributes to contractile dysfunction.
1.5.1.2. Nitric Oxide Activity
In the endothelial cells NO is synthesized from the amino-acid L-arginine, by the
enzyme NO synthase (NOS) (Palmer et a/., 1988). Three isoforms ofNOS have been
identified by molecular cloning (Hoggs et al., 1999). The first is a constitutive
isoform (nNOS or NOS I), whose activity is Ca2+/calmodulin dependent and is
mainly present in neural tissues. The second is a Ca2+ independent isoform (iNOS or
NOS II), which has been isolated from different cells (e.g. VSMCs, monocytes) after
induction with bacterial endotoxins or inflammatory mediators. The third is
Ca2+/calmodulin requiring constitutive isoform found in the endothelial cells (eNOS
or NOS III), which plays an important role in vascular haemodynamics (Hoggs et al.,
1999). Specific inhibitors of NOS have been developed, such as L-arginine
analogues -monomethyl-L-arginine (L-NMMA), N° -nitro-L-arginine (L-NNA),
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and N° -nitro-L-arginine methyl ester (L-NAME) (Moncada et al., 1991; Hoggs et
al., 1999) which can prevent NO production.
It was suggestion that in cirrhosis excessive nitric oxide (NO) production by the
vessel wall was responsible for peripheral vasodilatation (Vallance and Moncada,
1991). This hypothesis mentioned that in cirrhosis, gut-derived endotoxins induced
nitric oxide synthase (iNOS) activity in the vascular smooth muscle. This
explanation remains possible but, despite extensive investigation, is still
controversial. An alternative proposal is that, the activity of constitutive NO synthase
(eNOS) is up-regulated in patients with cirrhosis as a consequence of the
hyperdynamic circulation (Bomzon & Blendis, 1994). In this model, enhanced shear
stress causes increased production of NO from eNOS, within the splanchnic
circulation, one of the main sites of NO production. However, both enhanced eNOS
activity (resulting from increasing shear stress) and translocation of gut-derived
endotoxins are more likely to be significant in advanced, than in early, cirrhosis. A
contribution of NO, from either source, to vascular abnormalities is not indicated in
patients with mild cirrhosis (Forrest et al. 1996).
The role of NO in the vascular abnormalities of cirrhosis remains controversial. In
particular, the degree of endotoxaemia in cirrhosis, especially in early cirrhosis, is
debatable. Studies in animal models have provided conflicting data: many (although
not all (Sogni et al., 1992; Karatapanis et al., 1994)) have demonstrated that vascular
hyporesponsiveness is NO-dependent but the source of this NO has not been
established. Endothelium-derived (eNOS) (Ros et al., 1995; Martin et al., 1996;
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Niederberger et al., 1996; Weigert et al., 1995) and smooth muscle-derived (iNOS;
endothelium-independent) (Michielsen et al., 1995; Morales et al., 1995) NO have
both been shown to be responsible for contractile hyporesponsiveness in isolated
vessels. Initial studies with human vessels although reported that the induction of
iNOS was responsible for the impaired response to adrenergic agonists (Smith et al.,
1997; Ryan et al., 1996), however, recent studies have challenged these findings
(Heller et al., 1999; Hadokzetal., 1998).
1.5.2. Altered Contractile Activity in the Vessel Wall
Alterations in either vascular structure or in contractile signalling pathways within
the vessel wall could explain the altered contractile response demonstrated in vessels
isolated from cirrhotic individuals. Remodelling is a possibility as persistent
hypotension or hypertension can result in atrophy or hypertrophy, respectively, of the
vessel wall (Pang & Scott, 1985). In cirrhosis both atrophy and hypertrophy can
occur, as some vascular territories (splanchnic, pulmonary) become dilated (Iwao et
al., 1997a), whilst others (portal, cerebral, renal) are constricted (Arroyo et al.,
1988). An extensive remodelling in the portal venous territory was demonstrated
following portal vein ligation in the rat (Jensen et al., 1987). However, more recent
studies suggest that remodelling does not account for changes in vascular
contractility. In particular, the demonstration that contractile abnormalities are
agonist-dependent suggests a selective alteration to particular agonists, rather than a
general alteration in contractility.
Alterations in the contractile signalling pathways within the vascular wall may be
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indicated: receptor-mediated contraction is sensitive to chronic exposure to an
agonist (as described previously; section 1.3.2.3) and many endogenous
vasoconstrictors are chronically elevated in cirrhotic patients. Therefore, down-
regulation and/ or desensitisation of G-protein-coupled receptors could account for
impaired contractility (section 1.3.2.3). Alternatively, abnormalities in function could
result from changes induced in the receptor-signal transduction pathway,
downstream from the receptor (section 1.3.2.3).
1.5.2.1. Altered Receptor Function.
Very few studies have investigated receptor number and expression in vessels from
cirrhotic individuals. Those that are available, predominantly concerned with
adrenoceptors or the ATi (All) receptor. Some investigations have, however,
assessed the influence of cirrhosis on receptors stimulated by ET-1 (ETA and ETB)
(Cahill et al., 1998) and 5-HT (5-HT2a) (Cummings et al., 1986).
Altered receptor activity can be discounted in investigations where impaired
contraction has been shown to be solely a consequence of enhanced NO production
(Michielsen et al., 1995; Morales et al., 1995; Ros et al., 1995; Kanwar et al., 1996;
Niederberger et al., 1996; Smith et al., 1997). There are many demonstrations,
however, of NO-independent contractile hyporesponsiveness in vessels from animals
(Liao et al., 1994; Huang et al., 1995; Karatapanis et al., 1994; Huang et al., 1997)
and humans (Heller et al., 1999) with cirrhosis.
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1.5.2.1.1. a-Adrenoceptors
Despite the high circulating levels of NA in cirrhosis, down-regulation of
a-adrenoceptors do not appear to account for impaired vascular contraction. Reduced
contractile responses to NA have been demonstrated in vessels isolated from animal
models without any concomitant down-regulation or desensitisation of the oci-
adrenoceptor (Liao et al., 1994; Huang et al., 1996)
1.5.2.1.2. All Receptor (ATi-receptor)
It has been demonstrated that hyporesponsiveness of rat portal veins to All (in
cirrhotic/ portal hypertensive rats) was due to impaired activity of the AT i receptor
(Huang et al., 1997). In this study, phosphoinositide production was reduced in
response to AII (receptor stimulation) but not in response to compounds (PLC,
NaF/AlCl3, guanosine-5'-0-(3-thiotriphosphate)) that stimulate the contractile
cascade down-stream from the receptor. This may suggest receptor-desensitisation
(where uncoupling of the receptor from its G-proteins prevents contraction). In
contrast, the number of AT i-receptors was reduced in the portal vein and mesenteric
artery of portal hypertensive rabbits as well as in the aorta of bile duct-ligated rats,
indicating receptor down-regulation (Sitzmann et al., 1995; Tazi et al., 1997). The
situation is further complicated by the fact that ATi-receptor number was increased
in mesenteric arteries from CCU-induced cirrhotic rats but this was balanced by a
reduction in receptor affinity. It is possible, therefore, that the role of receptor
desensitisation/ down-regulation is dependent upon species, aetiology of cirrhosis
and anatomical origin of the vessel studied.
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1.5.2.1.3. ET-1 Receptors
ET-1 acts via ETA and ETB receptors located in the vessel wall; in VSMCs both
mediate vasoconstrictions, whilst the ETB receptor on the endothelium induces
vasodilatation (Gray & Webb, 1996; Haynes et al., 1995).
Up-regulation of ET-1 receptors has been reported in mesenteric arteries and aortae
from portal vein-ligated rats (Cahill et al., 1998). Similarly, ETA and ETB receptor
populations or mRNA expression in the intrahepatic circulation are elevated in
cirrhosis/ portal hypertension (Leivas et al., 1998). These findings are surprising
given that plasma ET-1 concentrations are elevated in this condition (Newby et al.,
1998b; Trevisani et al., 1997). The mechanism of up-regulation is not clear but has
been attributed to a compensatory hyper-activation resulting from increased
production ofNO (Redmond et al., 1996).
1.5.2.1.4. 5-HT Receptors
5-HT can induce vascular contraction via 5-HT2A and 5-HTi-like receptors (Hoyer et
al., 1994; Yildiz et al., 1998). A selective enhancement of 5-HT-mediated
contraction has been demonstrated in mesenteric veins (Cummings et al., 1986;
Kaumann et al., 1988; Moreno et al., 1996) and aortae (Jacob et al., 1991) from
portal hypertensive/ cirrhotic rats. These results clearly suggest an up-regulation of
5-HT receptors is responsible for this alteration. However, it was found that
hyperactivity of the 5-HT2A receptor was not responsible for augmented contraction
as affinity of this receptor was not enhanced (Cummings et al., 1986; Kaumann et
al., 1988). Moreover, a reduced response to 5-HT was demonstrated in portal veins
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from portal vein or bile duct-ligated rats (Jacob et al., 1991) indicating that the
mechanism of altered response could depend upon aetiology and the anatomical
origin of a particular vessel. At present, no studies appear to have assessed the
activity of 5-HTi-like receptors in cirrhosis. Therefore, the mechanism of altered
response to 5-HT is uncertain.
1.5.2.2. Alterations in Intracellular Signalling Pathways
It is possible that reduced activity of intracellular second messenger systems
accounts for contractile hyporesponsiveness in cirrhosis/ portal hypertension. For
example, intracellular second messengers (such as Ca2+, IP3, DAG and PKC) may be
depleted following sustained stimulation by the elevated plasma levels of the
vasoactive agents in cirrhosis (Castro et al., 1993; Huang et al., 1997; Thrombino et
al., 1998). Therefore, assessment of second messengers following stimulation with
receptor-dependent and -independent vasoconstrictors is necessary to identify the
mechanism(s) of impaired contractile function in cirrhosis. Certainly, both altered
activation of intracellular second messengers (Wu & Benoit, 1994; Huang et al.,
1996) and an impaired response to increases in [Ca2+]j (Karatapanis et al., 1994) have
been implicated in vessels from cirrhotic animals. Only a limited number of studies,
however, have directly investigated second messenger pathways in these tissues
(Huang et al., 1997; Wu & Benoit, 1994; Trombino et al., 1998). It has been
suggested that attenuated activity of the phosphoinositide messenger system is
responsible for impaired contractile response in vessels from portal hypertensive rats
(Huang et al., 1995,1997) whilst decreased PKC activity has been implicated in
aortic VSMCs from cirrhotic rats (Trombino et al., 1998). Further studies are
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required to confirm these results and to demonstrate their applicability to the
condition in humans.
1.5.3. Summary
Studies in both humans and animal models have largely confirmed that the
development of cirrhosis/ portal hypertension is accompanied by an impairment in
vascular contractile function. This impairment is maintained in isolated vessels ex
vivo but the mechanisms involved remain unclear. Most data, however, have been
obtained from animal models, with the few studies have used vessels from cirrhotic
patients restricted to assessment of a-adrenoceptor-mediated contraction. It is
unclear, therefore, whether altered contractile function in human arteries is agonist-
selective, as demonstrated in vessels from cirrhotic/ portal hypertensive animals.
Agonist selectivity could be clinically important given the fact that AVP and its
analogues, as well as 5-HT- and ET-l-receptor antagonists, can reduce portal
pressure (Freeman et al., 1998; Nevens et al., 1991, Sogni etal., 1998).
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1.6. Aims
This project investigated the hypothesis that the development of hepatic cirrhosis
would produce an agonist-selective alteration in contractile function of the hepatic
artery that would be maintained ex vivo.
The primary aim was to determine whether contractile responses elicited by AVP, 5-
HT and ET-1 were altered in hepatic arteries isolated from patients undergoing liver
transplant for cirrhosis. It was also intended to attempt to elucidate the mechanisms
responsible for any alterations in contractile function identified in arteries from
cirrhotic individuals. In particular, attempts would be made to identify the receptors
mediating responses to each agonist and to clarify the role of nitric oxide in altered
contractile function.
Initial studies were performed using porcine splanchnic arteries in order to develop
and refine the protocols used for assessing function in (relatively scarce) human
hepatic arteries. The use of porcine hepatic arteries as a model for the human vessels
was extended to determine whether hepatic arteries from liver donors (which are
stored in organ preservation solution during liver transplantation) were a suitable






2.1. Acquisition of Vessels
In order to study vascular reactivity in cirrhosis, hepatic arteries were obtained from
patients with cirrhosis undergoing liver transplantation. Hepatic and mesenteric
arteries were also collected from non-cirrhotic liver donors. In addition,
investigations were performed using hepatic and mesenteric arteries from piglets and
adult pigs to assess normal physiological vascular responses of these vessels.
2.1.1. Acquisition ofHuman Hepatic andMesenteric Arteries
Functional investigations using human blood vessels are largely restricted because of
unavailability of viable tissue samples. However, the Scottish Liver Transplantation
Unit (SLTU) at the Royal Infirmary of Edinburgh provided opportunities for
obtaining viable human splanchnic blood vessels both from liver donors (non-
cirrhotic) and recipients (cirrhotic). During retrieval of the healthy liver from an
organ donor, the surgical team routinely collects the entire hepatic artery and the
coeliac axis. These are stored with the donor liver, in a preservative (University of
Wisconsin) solution (UWS; NPBI International BV, Emmer-Compascuum, The
Netherlands and Du-Pont Pharmaceuticals Ltd., Herts, UK.) at 4°C. At the end of
liver transplantation, after anastomoses of the graft, residual hepatic artery samples
are discarded and so become available for functional analysis. Arrangements were
also made with the retrieval team to collect small sections of the mesenteric artery
from the liver donors. These were placed immediately into ice-cold oxygenated
Krebs'-Henseleit solution (KHS) and transported to the Royal Infirmary.
The (cirrhotic) liver removed from the recipient is routinely fixed in formal saline for
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histological analysis. Therefore, sections of hepatic artery were dissected directly
from the explanted recipient livers immediately following removal from the patient
and prior to fixing.
Donor and recipient hepatic, and donor mesenteric, arteries obtained from the
transplant theatre were placed immediately in fresh, ice-cold, oxygenated KHS and
transported to the laboratory for functional analysis. Sometimes, in these procedures
donor hepatic arteries are kept in UWS and mesenteric arteries in KHS, respectively,
up to 14 hours (maximal liver preservation time in the Scottish Liver Transplant
Unit), while recipient hepatic arteries are obtained immediately following removal
from the patients.
Ethical approval for use of human tissues was obtained from the Lothian Research
Ethical Committee and the arrangements were approved by the United Kingdom
Transplant Support Service Authority (UKTSSA).
2.1.2. Acquisition ofHepatic andMesenteric Arteriesfrom Piglets
Hepatic and mesenteric arteries were collected from piglets that were being killed in
the animal house at Edinburgh University for the purposes of a separate project.
Piglets (small white; 12-15 kg; aged 3-4 weeks) were obtained from the Roslin
Institute (Roslin, Scotland, UK) on the appropriate day and given free access to food.
Each piglet was anaesthetised with 30 mg/kg pentobarbitone sodium (Vet Drug,
Middlefield Ind. Est., Falkirk, UK) via the auricular vein and then killed with an
intravenous bolus of 150 mg/kg of the same drug. As soon as the heart stopped
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beating, a deep, midline ventral incision was made and a section of the aorta with the
coeliac axis, including the hepatic and mesenteric arteries, was removed. These
vessels were placed in ice-cold, oxygenated KHS and transported to the laboratory.
The piglets were treated in accordance with UK Home Office Guidelines (Scientific
Procedures Act, 1986).
2.1.3. Acquisition ofHepatic andMesenteric Arteriesfrom Adult Pigs
Hepatic and mesenteric arteries from male and female, large white pigs (6-8 months
old, 50-60 kg weight) were obtained from a local abattoir after the animals had been
killed. Following a ventral, midline incision the liver, stomach and intestines were
removed and, in order to obtain the hepatic artery, a portion of the liver around the
porta-hepatis was removed. Sections of superior mesenteric artery were also
collected. Tissues were placed immediately into ice-cold, oxygenated KHS and
transported to the laboratory.
2.2. Functional Analysis
2.2.1. Preparation ofArterial Rings
The hepatic and mesenteric arteries were carefully cleaned of adherent connective
tissue and fat, and if necessary, were stored in the refrigerator at 4°C in freshly
prepared oxygenated KHS. Whenever possible, experiments were performed
immediately after the retrieval of the arteries, no more studies were performed after
24 hours of collection in human hepatic arteries and 48 hours in porcine vessels,
respectively.
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Rings approximately 2mm in length were prepared from each artery. In some
experiments, it was necessary to remove residual endothelial cells from the luminal
surface. This was achieved by gently rubbing the luminal surface of the rings with a
wire probe while the rings were kept completely immersed in KHS on a petri dish.
2.2.2. Mounting ofArterial Rings
The arterial rings were mounted horizontally between two parallel, stainless steel
wire hooks in 10 ml organ baths filled with KHS (Mulvany & Halpern, 1976). The
lower hook was fixed to the base of the organ bath, whilst the upper hook was
attached to a force displacement transducer (Grass FT-03) connected to a
computerised data acquisition system (Dr H Brash, Dept. Medicine, Royal Infirmary
of Edinburgh) for the measurement of isometric force. The organ baths were
maintained at 37°C and continuously bubbled with a mixture of 95% O2 - 5% C02.
2.2.3. Assessment of Viability and Reproducibility
The rings were stretched gradually to their optimum resting force [previously shown
to be 4g (Hadoke et a/., 1998)] and allowed to equilibrate for 45-60 minutes. During
equilibration, the tension was regularly adjusted and the contents of the organ baths
replaced at frequent intervals. After equilibration, the viability and reproducibility of
contraction of each ring was tested by stimulating with a single concentration of KC1
(100 mmol/L). Rings were washed with KHS once the contraction had stabilised.
The procedure was repeated 3-4 times until reproducible, sustained contractions were
obtained (Hadoke et al., 1998).
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2.2.4. Test for the Endothelium
The endothelium has a profound influence on vascular function (Furchgott &
Zawadzki, 1980). Flepatic arteries obtained from the transplant theatre have usually
lost a significant quantity of the endothelium (Hadoke et al., 1997; Smith et al.,
1997). Therefore, it was necessary to assess the integrity of the endothelium in the
arteries used for functional analyses. Arterial rings (2mm in length) were pre¬
contracted sub-maximally with phenylephrine (PE, 10"6-3xl0"5 mol/L). After
achieving a stable contraction, the rings were exposed to cumulative concentrations
of acetylcholine (ACh, 10"x-3xl0"6 mol/L) (Vanhoutte & Miller, 1985). ACh induces
either relaxation or further contraction depending on the presence or absence of
intact endothelial cells covering the arterial wall (Figure 2.1) (Jeng et al., 1996a,b;
Nardo et al., 2000).
Endothelium-independent relaxation of these arteries was also assessed using
3'-morpholinosydnonimine (SIN-1, 10"10-3xl0"6 mol/L) after sub-maximal
contraction with PE (10~6-3xl0~5 mol/L) (Figure 2.2).
2.2.5. Functional Studies
Functional investigations were begun following equilibration of the arteries at their
optimum resting force and assessment of viability and endothelial cell integrity.
Contractile and relaxation functions of isolated arteries were assessed by producing
cumulative concentration-response curves to a variety of agonists in the presence or
absence of relevant antagonists. Experiments were performed according to the
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curve, the rings were washed repeatedly with KHS, allowed to return to baseline and
equilibrated for 20-30 minutes before the next agonist was applied. Usually, after
completion of investigations using receptor-dependent agonists, cumulative
concentration-response curves were also produced using the receptor-independent
vasoconstrictor, potassium chloride (KC1; 2.5-120 mmol/L).
2.3. Preparation ofWorking Solutions (Krebs'-Henseleit Solution)
Working solutions of Krebs'-Henseleit Solution (KHS) were prepared from stock
solutions, 'A' and 'B', as required.
Stock Solution 'A' was prepared by dissolving NaCl, (138.4g); KC1, (7.0g) and
MgSCL. 7H2O, (5.8g) in 1 litre of deionised water. Similarly stock Solution 'B' was
also prepared by dissolving NaHCCE, (42.Og) and KH2PO4, (3.2g) in 1 litre deionised
water.
Working solutions were prepared by mixing 100ml of each of solutions 'A' and 'B'
in 1.8 litres of deionised water. D-glucose, (4.2g) and the CaCl2. 6H20, (1.1 g) were
dissolved in this solution to prepare a final working KHS of composition: (mmol/L)
NaCl, 118.5; KC1, 4.7; MgS04, 1.2; KH2P04, 1.2; NaHC03, 25; CaCl2, 2.5; glucose,
11.6 and pH 7.4.
2.4. Histological Assessment of Endothelial Cell Integrity
Endothelial integrity was also assessed histologically in some vessels using the silver
nitrate stain (Poole et al., 1958). Rings, 8-10mm in length, were prepared from both
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human and porcine hepatic arteries. Each ring was opened carefully, using a
longitudinal incision, and then pinned out with the luminal surface exposed. Rings
were washed for two minutes using a freshly prepared solution, of 4.6%
weight/volume glucose and 2.4% weight/volume hepes (pH 7.4). The luminal surface
was immersed in 0.4% silver nitrate solution for 1 minute and then exposed to light
for 10 minutes to allow the stain to develop. Silver nitrate stains glycoproteins on the
cell membrane but not the endothelial cell themselves (Figure 2.3). Therefore, edges
of the cells stained dark brown whilst the cells themselves remained unstained, which
allowed visual determination of the endothelial covering (Figure 2.3).
2.5. Immunohistochemistry
Immunohistochemistry was performed using both donor and recipient hepatic
arteries for detection of immunoreactivity for inducible nitric oxide synthase (iNOS),
a-smooth muscle actin (a-SMA) and endothelial cells.
2.5.1. Preparation of the Arteries
After removing connective tissue and fat, arterial sections 1-2 cm in length were cut
from each vessel and immediately fixed in neutral buffered formalin (10%) for
paraffin embedding. Rings approximately 0.5cm in length were prepared from the
formalin fixed arteries, processed using an enclosed tissue processor (by taking the
arteries through graded alcohols into xylene) and finally embedded in paraffin wax.
Transverse arterial sections (3 pm) were cut using a rotary microtome and floated in a




Figure 2.3. Photographs of longitudinal sections of hepatic arteries stained by
silver nitrate (a) with and (b) without an intact endothelial covering.
Endothelial cells are oriented in the direction of blood flow. EC, endothelial
cells; SMC, smooth muscle cell. Scale=100pm.
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(3-aminopropyltriethoxy-saline)-coated glass slides and dried overnight at 37°C.
2.5.2. Immunohistochemical Analysis
Immunohistochemistry is a technique, which can be used to identify cellular
constituents (antigens) by eliciting antigen-antibody reactions. Antibodies
(polyclonal or monoclonal) and lectins are used as a primary reagent in this
technique. The sites of antibody binding (antigens) can be detected either by direct
labelling of the bound primary antibody (or lectin) or additional amplification of the
primary binding site using a secondary labelling procedure. For this study,
immunohistochemical investigation of the vessel wall was performed using both
direct and indirect antigen-detection techniques. In the direct method, a primary
conjugated antibody is allowed to bind to the cellular antigen and this antibody-
antigen complex is treated with an appropriate enzyme-tracer substance for proper
visualisation. In the indirect method, a second amplifying conjugated antibody was
applied, before being treated with an appropriate enzyme-tracer substance. The direct
antigen-detection method was applied for detection of the endothelium, while the
indirect method was used for identification of smooth muscle actin and inducible
nitric oxide synthase (iNOS) in the vascular smooth muscle cells. Detection of
binding sites can be achieved by interaction of tracer enzymes with a chromogen to
produce a stable, coloured end product.
The two most common enzyme-labelled conjugate methods used to detect antigens
are the peroxidase method and alkaline phosphatase method (Hsu et al1981). In the
peroxidase method, horseradish-peroxidase is combined with a chromogen, (3, 3'-
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diaminobenzidine tetrahydrochloride [DAB]) to produce a dark brown insoluble
coloured compound (Figure 2.4. a). In contrast, in the alkaline phosphatase method, a
fuschin substrate is used as a tracer, which produces a permanent, insoluble red
colour at the site of alkaline phosphatase activity (Figure 2.4. b).
2.5.2.1. Peroxidase Method
The peroxidase method was used for immunohistochemical detection of vascular
smooth muscle and endothelial cells in the vessel wall.
Smooth Muscle Cells. For the identification of a-actin in the vascular smooth muscle
cells (Figure 2.5), transverse sections (3 pm) of arteries were dewaxed in 100%
xylene for 10 minutes, rehydrated through graded alcohols and washed in tap water
for 15 minutes. The rings were treated with 1% hydrogen peroxide solution for 10
minutes at room temperature, to abolish the activity of endogenous peroxidase
without affecting the immunoreactivity of antigens.
Thereafter, rings were washed for 15 minutes in water followed by 10 minutes in
tris-buffered saline (TBS) at 37°C. The rings were treated with 0.1% trypsin (Sigma,
UK) dissolved in TBS containing 0.1% calcium chloride (pH 7.8) at 37°C for 40
minutes to unmask antigen sites and then washed with phosphate buffer saline (PBS)
for 10 minutes. The sections were incubated with goat serum, (1/1 dilution, in a
solution made with 0.5ml of bovine serum albumin (BSA) + 14.5 ml of PBS and 6















Figure 2.4. Diagram of the antibody binding cascades in (a) peroxidase method and





Figure 2.5. Photomicrograph of transverse section of hepatic arteiy stained with the
a-SMA antibody of the vascular smooth muscle cell (VSMC) in the tunica media,
using peroxidase method. L, lumen; TM, tunica media and TA, tunica adventitia.
Scale=100pm.
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The primary antibody, mouse anti-human a-smooth muscle actin (Novocastra
laboratories Ltd., UK), was diluted to a concentration of 1/100 in BSA+PBS (as
previously used in this laboratory) and 4 drops of biotin/ml of solution were added.
This biotinylated primary antibody was applied to all arterial sections except those
used as negative controls. Sections were incubated overnight (16-18 hours) at 4°C.
Following incubation, the sections were equilibrated at room temperature for 30
minutes then given 3 washes for five minutes each with PBS. The biotinylated
secondary antibody (1/100, goat anti-mouse antibody, Dako Ltd., UK; in BSA+PBS)
was added to each section and, after 30 minutes, these were washed with PBS (3
washes for 5 minutes each). The streptavidin-biotin-horseradish peroxidase complex
(Strep-ABC, Dako Ltd., UK) was then added to the sections and incubated for 30
minutes. Rings were then washed twice with PBS for 5 minutes. In order to visualise
the site of positive reactivity, the DAB substrate (Sigma, UK) was applied, colour
was allowed to develop (20-30 minutes) and then the sections were washed with
water (Gramham & Karnovsky, 1966).
Nuclei were counter-stained using Harris Haematoxylin (BDH, UK) for 3 minutes.
The sections were rinsed in water, differentiated in acid alcohol for 30 seconds and
then washed with water for 5 minutes. Finally, sections were dehydrated through
graded alcohols to xylene, mounted in Depex (Sigma, UK) and cover-slipped.
Endothelial Cells. For the identification of the endothelial cells (Figure 2.6), arterial
sections were dewaxed, rehydrated, treated with hydrogen peroxide, trypsinised and
then exposed to diluted goat serum as described previously. The endothelial cell
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(a)
Figure 2.6. Photomicrographs of transverse sections of hepatic arteries stained
with the Ulex antibody, using peroxidase method, (a) presence and (b) absence
of the endothelial cells. L, lumen; EC, endothelial cell; TM, tunica media and
TA, tunica adventitia. Scale=100pm.
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antibody (Ulex, Vector Laboratories, UK; 1/200 dilution in 10% BSA/PBS) (as
previously used in this laboratory) was applied for 30 minutes at room temperature
for all sections except the negative controls. Following washing with PBS, sections
were treated with streptavidin-biotin-horseradish peroxidase complex (Dako Ltd,
UK.), exposed to DAB substrate and allowed to develop colour (30-40 minutes) for
visualisation, as described above. After washing, sections were counter-stained with
Harris-Haematoxylin, differentiated in acid alcohol and Depex mounted, as described
previously.
2.5.2.2. Alkaline Phosphatase Method
The alkaline phosphatase method was used for the detection of inducible nitric oxide
synthase (iNOS) (Figure 2.7). In this technique, arterial sections were prepared and
incubated with diluted goat serum (to reduce non-specific staining) as used
previously in this laboratory.
The primary antibody (rabbit anti-iNOS antibody, Calbiochem, UK), dilution 1/150
(as previously used in this laboratory) was added to all sections except negative
controls and incubated overnight (16-18 hours) at 4°C. The sections were washed
with PBS and exposed to secondary antibody (goat anti-rabbit, Vector Laboratories,
UK; dilution 1/100) for 30 minutes. The appropriate dilutions of antibodies and time
of incubation were followed as determined previously in this laboratory. After
washing with PBS, levamazole (lOmM) (Sigma, UK) was applied to block
endogenous phosphatase activity. In order to amplify the staining, fuschin (new
fuschin kit, Dako Ltd., UK) was added to the sections and colour was allowed to
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Figure 2.7. Photomicrograph of transverse section of rabbit thoracic aorta stained
with the anti iNOS antibody using alkaline phosphatase method. L, lumen; TM,
tunicamedia and TA, tunica adventitia. Scale=100pm.
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develop (7-10 minutes). The sections were counter stained with Harris-
Haematoxylin, differentiated in acid alcohol and aqua-mounted (BDH, UK) as
described previously.
2.5.3 Preparation ofWorking Solutions
2.5.3.1. Tris Buffered Saline (0.05M, pH 7.6)
Tris base (6.04g) was dissolved in 1 litre deionised water and, after addition of
thymol (lmg), the pH was adjusted at 7.6 by adding concentrated HC1 solution. This
tris buffered saline was suitable for use for up to 14 days.
2.5.3.2. Phosphate Buffered Saline (0.01M, pH 7.6)
Di-sodium hydrogen orthophosphate (63 .5g) was added to 400 ml of deionised water
and dissolved by microwaving for 30 seconds. Sodium di-hydrogen orthophosphate
(8.5g) was also dissolved in 400 ml of deionised water, these two solutions were
mixed and the volume increased to 5 litre using deionised water. The pH was
adjusted to 7.6 by adding concentrated HC1.
2.6. Materials
8-Arginine vasopressin acetate, 5-hydroxytryptamine creatinine sulphate, prazosin
hydrochloride, yohimbine hydrochloride, benzylpenicillin, d(CH2)sTyr(Me)AVP,
desmopressin, N°-nitro-L-arginine (L-NNA), phenylephrine hydrochloride,
acetylcholine chloride, indomethacin hydrochloride, hydrogen peroxide and trypsin
were obtained from Sigma, Poole, Dorset, UK. University of Wisconsin solution
(UWS) was obtained from NPBI International BY, Emmer-Compascuum, The
60
Netherlands and Du-Pont Pharmaceuticals Ltd., Herts, UK. Dexamethasone sodium
phosphate from Faulding Pharmaceuticals, Warwick, UK. Insulin (velosulin) from
NovoNordisk, Sussex, UK. 3'-Morpholinosydnonimine (SIN-1), ketanserin tartrate,
NG-nitro-D-arginine (D-NNA) and endothelin-1 were purchased from Alexis
Corporation (UK) Ltd., Bingham, Nottingham, UK. 5-Carboxamidotryptamine
maleate and methiothepin maleate were a gift from Glaxo-Wellcome Ltd. and Roche,
Hertfordshire, UK., respectively. All salts were obtained from BDH, Poole, Dorset,
UK. Stock solutions of drugs were prepared in deionised water except for
indomethacin, which was prepared in ethanol (final bath concentration of ethanol did
not exceed 0.1% v/v). As SIN-1 is sensitive to light, stock solutions were prepared in
a strictly light controlled room and preserved in a light protective covering. Drugs
were stored in 1.5 ml aliquots at -20° C, thawed as required and any residual amounts
were discarded at the end of the experiments. Concentrations given are the final
molar concentrations in the organ bath.
2.7. Statistics
Results are expressed as mean ± standard error of the mean (SEM), where 'n'
represents the number of subjects. For each artery, mean values were calculated from
the results of analysis of 2-4 rings where appropriate. The maximum contractile
response of the receptor-dependent agonists was expressed both in grammes and as a
percentage of the maximum contraction to KC1 (to minimise any discrepancy in the
sizes of the arterial rings (Lew & Angus, 1992)). The contractile responses to the
receptor-independent vasoconstrictor, KC1, were expressed as a percentage
maximum contraction and also in grammes. Sensitivity (pD2 or IC50) values were
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determined for each concentration-response curve, using curve-fitting software (Fig.
P., Biosoft, Cambridge, UK). For determining the relaxation effect, the initial sub-
maximal contraction with PE was considered as 100% response and relaxation
responses were calculated relative to this value. The sensitivity of relaxation
responses to SIN-1 or acetylcholine is expressed as a negative log of the effective
concentration (M, mol/L) of the drug required, producing 50% of the maximum
response (-loglCso)- Statistical analysis of entire curves was performed using two
way analysis of variance (ANOVA) followed by the Tukey post-hoc test where
appropriate. Maximum contraction and sensitivity (pD2; -loglCso) values were
compared using Student's unpaired or paired t-test, as appropriate, and values were
considered significant when P < 0.05.
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CHAPTER THREE
FUNCTIONAL RESPONSES OF PORCINE SPLANCHNIC (HEPATIC AND




Vascular complications have a significant impact on the morbidity and mortality of
patients with hepatic cirrhosis (Liach et al., 1988). Splanchnic vessels, both from
patients and from animal models of cirrhosis, have been used to investigate the
manifestation and pathophysiology of abnormal vascular function associated with
this condition. A complete understanding of normal vascular function is necessary to
determine the alterations caused by the presence of disease. This is particularly
important for agonists, such as 5-HT, because actions of this agonist can be mediated
by several heterogeneous receptor sub-types (Martin & Humphrey, 1994) and the
activity of some of these receptors may depend on the basal contractile state of the
vessel (Yildiz et al., 1998). For example 5-HTi-like receptors only become active in
some arteries in vitro following partial pre-contraction (Choppin & O'Connor, 1994,
1995).
One of the major limitations of in vitro studies of vascular dysfunction in cirrhosis is
the unavailability of suitable human arteries. Whilst hepatic and mesenteric arteries,
as well as portal veins, can be obtained from donors during liver transplantation
(Smith et al., 1997; Hadoke et al., 1998; Heller et al., 1999), these are still relatively
scarce. Furthermore, it is possible that resuscitative procedures and liver preservation
affect the normal physiological response of these vessels (Nataf et al., 1995; Sorajja
et al., 1997). Therefore, it is necessary to investigate functional responses of
splanchnic arteries from a suitable animal model as this will: (i) determine the
normal physiological function of these vessels and (ii) provide data allowing
development of a suitable protocol to investigate the effect of cirrhosis on these
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responses. Vascular function has been studied in splanchnic arteries from rats
(Cummings et al., 1986; Ralevic et al., 1996) and rabbits (Sitzman et al1995;
Cahill et al., 1994) using a variety of vasoactive factors. However, the anatomy and
physiology of the liver and splanchnic vessels in these small animals are different
from those in humans (Vagianos et al., 1990). In contrast, there is a close similarity
in the liver and splanchnic vascular system in humans and pigs (Changani et al.,
1999; Swindle, 1984). Indeed, the function of porcine mesenteric arteries has been
used as a model for responses of human vessels in previous studies of hepatic artery
function in cirrhosis (Heller et al., 1999). Therefore, porcine hepatic arteries provide
a suitable model for developing the methodology required to assess the effect of
cirrhosis on the responses of human hepatic arteries to AVP and 5-HT.
3.2. Aim
This study aimed to determine the normal functional responses of porcine splanchnic
arteries in vitro and, thus, provide a basis for subsequent investigations using human
hepatic arteries. Functional responses to be investigated included contractile
responses to (i) the receptor-dependent agonists AVP and 5-HT and (ii) the receptor-
independent vasoconstrictor, KC1, as well as (iii) relaxant responses to endothelium-
dependent and endothelium-independent vasodilators.
3.3. Methods
3.3 I. Acquisition ofPorcine Hepatic andMesenteric Arteries
Hepatic arteries and a section of the superior mesenteric artery were obtained from
male and female, large white adult pigs (6-8 months old, 45-60 kg weight) from a
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local abattoir. Arteries were placed immediately into ice-cold, oxygenated KHS and
transported to the laboratory as described (Chapter 2.1). Hepatic and mesenteric
arteries were also obtained from piglets (male and female; small white; 12-15 kg;
aged 3-4 weeks), which had been killed for the purposes of another study (as
described in Chapter 2.1).
3.3.2. Functional Analysis
3.3.2.1. Preparation of Arterial Rings
Adherent connective tissue and fat were cleaned from the arterial wall and rings,
approximately 2mm in length, were cut from each vessel. Each ring was suspended
in an organ bath containing freshly prepared KHS at 37°C and continuously gassed
with a mixture of 95% O2 - 5% CO2, for the measurement of isometric force
development (Chapter 2.2).
3.3.2.2. Assessment ofViability and Endothelial Cell Function
The rings were stretched gradually to their optimum resting force, (4g; Hadoke et al.,
1998) and allowed to equilibrate for 55-60 minutes. Viability and reproducibility of
contraction were tested using (lOOmmol/L) KC1 (as described in Chapter 2.2).
Initially, the presence of a functional endothelium was determined (adult pigs, n=7-8;
piglets, n=4-5) by exposing the rings to ACh (10"9-3xl0"5 mol/L), following
precontraction with PE (10"6-3xl0"5 mol/L) (Vanhoutte & Miller, 1985; Jeng et al.,
1996a,b). Endothelium-independent relaxation in the hepatic arteries was also
assessed by treating the precontracted rings with SIN-1 (10~9-3xl0~5 mol/L). At the
end of the functional study, the rings were removed from the organ baths and
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endothelial cell integrity was assessed histologically by silver nitrate staining
(Chapter 2 .4). For the rest of the study any residual endothelium was removed from
the arteries as described (Chapter 2.2).
3.3.3. Assessment of Contractile Function in Porcine Hepatic and Mesenteric
Arteries
Cumulative concentration-response curves were produced using AVP (10~n-3xl0~7
mol/L), 5-HT (10"9-3xl0"5 mol/L) and KC1 (2.5-120mM) in arteries from adult pigs
(hepatic, n=28; mesenteric, n=24) and piglets (hepatic, n=9; mesenteric, n=7). The
rings were washed repeatedly following completion of each curve and equilibrated
for 40 minutes before the next concentration-response curve was obtained.
3.3.4. The Influence of Partial Pre-Contraction on 5-HT-Mediated Contraction of
Porcine Hepatic Arteries
3.3.4.1. Preparation ofHepatic Arterial Rings
Four rings were prepared from each hepatic artery taken from adult pigs (n=ll) or
piglets (n=8), and prepared for measurement of isometric force generation, as
described (Chapter 2.2). Any endothelium was removed from these arterial rings by
rubbing the luminal surface (as described in Chapter 2.2). An ai-(prazosin; 10"6
mol/L) and an a2-(yohimbine; 10"6 mol/L) adrenoceptor antagonist were added to the
KHS for the duration of the experiment. The viability and reproducibility of the
contraction of each ring was tested using KC1 as described (Chapter 2.1.3.3).
67
3.3.4.2. Functional Protocol
Two of the four rings were partially pre-contracted with KC1 (20-40mM) to produce
25%-30% of the maximal response to KC1 whilst the remaining two rings were not
pre-contracted. One pre-contracted and one non-contracted ring were incubated with
the 5-HT2A-i"eceptor antagonist, ketanserin (10"6 mol/L) for 40 minutes. The
remaining two rings were not treated with the antagonist and served as controls.
Cumulative concentration-response curves were then constructed in control and
incubated (in the continued presence of ketanserin) arterial rings using 5-HT (10"9-
3x10"5 mol/L). Finally, the arteries were washed and allowed to equilibrate for
40mins, after which cumulative concentration-response curves were produced in the
absence of ketanserin, using KC1 (2.5-120mM).
3.4. Statistics
Statistics analysis was performed as described in Chapter 2.7.
3.5. Results
3.5.1. Assessment ofEndothelium
None of the arterial rings from adult pigs (8 hepatic, 7 mesenteric) tested for
endothelial cell function relaxed in response to ACh (indicated by positive value).
Instead, ACh produced a cumulative concentration-dependent contraction (indicated
by negative value) in both hepatic (Emax., -35.82 ± 7.61%;) and mesenteric (Emax.,
-41.75 ± 7.15%) arteries (Figure 3.1a). In contrast, low concentration of ACh
produced small relaxations in hepatic (Emax., 11.17 ± 6.02 %; n=5) and mesenteric
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Figure 3.1 Cumulative concentration-response curves to acetylcholine (ACh; I0"9-
3xlO"5 mol/L) in hepatic (□) and mesenteric (O) arteries from (a) adult pigs (n=7-8)
and (b) piglets (n=4-5), following pre-contraction with phenylephrine (PE; 10"f>-
3x10"5 mol/L). Responses are mean + s.e. mean for (n) individuals and expressed as a
percentage of contraction induced by PE.
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doses of ACh the response was reversed and the arteries were contracted (Figure
3.1b).
The hepatic arterial rings relaxed in response to SIN-1 (Figure 3.2) whether obtained
from adult pigs (Emax., 112.04 ± 2.45%; -loglCso, 6.48 ± 0.16) or piglets (Emax.,
106.61 ± 3.21%; -loglCso, 6.55 ± 0.18). The maximum relaxation and sensitivity of
response to SIN-1 in these arteries were similar (P=0.20 and P=0.79, respectively).
Histological assessment with silver nitrate staining indicated that neither the hepatic
nor the mesenteric arteries from adult pigs had an intact endothelium (Figure 3.3). In
contrast, both the hepatic and mesenteric arteries from piglets displayed presence of
residual endothelium (Figure 3.3).
3.5.2. Contractile Responses ofPorcine Hepatic andMesenteric Arteries
The receptor-dependent agonists AVP and 5-HT, and the receptor-independent
vasoconstrictor, KC1, caused concentration-dependent contraction of denuded adult
porcine hepatic and mesenteric arteries. The maximum contraction and sensitivity of
the responses to these agonists were similar in hepatic and mesenteric arteries
(Figure 3.4; Table 3.1a). The relative order of magnitude of maximum contraction
(Emax) and potency (pD2) of these contractile agents produced in hepatic (Emax.,
KC1>5-HT>AVP; pD2, AVP>5-HT>KC1) and mesenteric (Emax., KC1>5-HT>AVP;
pD2, AVP>5-HT>KC1) arteries were similar (Table 3.1a).
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SIN-1 [-LogM]
Figure 3.2. Cumulative concentration-response curves of hepatic arteries from adult
pigs (□) and piglets ((3), to 3'-morpholinosydnonimine (SIN-1; l0";-3xl0"5 mol/L)
following pre-contraction with phenylephrine (PE; 10~fl-3x 105 mol/L). Responses are
given as mean ± s.e. mean for (n) individuals, expressed as a percentage of the




Figure 3.3. Photomicrographs of longitudinal sections of hepatic
arteries from (a) adult pig and (b) piglet, stained with silver nitrate. The
absence of endothelium (E) in adult porcine hepatic arteries is clearly
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Figure 3.4(a and b). Cumulative concentration-response curves of hepatic (□) and
mesenteric (O) arteries from adult pigs following exposure to (a) arginine
vasopressin (AVP; n= 18-21) and (b) 5-hydroxytryptamine (5-HT; n=23-28).
Responses are mean + s.e. mean for (n) individuals and expressed as a percentage of
the maximum contraction induced by KG
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(c)
Figure 3.4(c). Cumulative concentration-response curves of hepatic (□) and
mesenteric (O) arteries from adult pigs following exposure to potassium chloride
(KC1; n=24-29). Responses are mean + s.e. mean for (n) individuals and expressed as
a percentage of the maximum contraction induced by KC1.
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Denuded hepatic and mesenteric arteries from piglets produced concentration-
dependent contractions, similar to those produced in arteries from the adult pigs,
when exposed to AVP and KC1 (Figure 3.5; Table 3.1b). In contrast, 5-HT produced
virtually no response or a very little response in these piglets arteries and the
responses were not comparable with those produced in adult porcine hepatic and
mesenteric arteries (Figure 3.5b; Table 3.1).
3.5.3. The Effect of Partial Pre-contraction on The Response of Porcine Hepatic
Arteries to 5-HT.
Following partial pre-contraction, the maximum contraction and sensitivity of the
response to 5-HT in hepatic arteries either from adult pigs or piglets (Figure 3.6;
Table 3.2) were increased, although in adult pigs the increased maximum contraction
achieved only threshold significance (P=0.09; Table 3.2). More strikingly, in piglet
hepatic arteries, after partial pre-contraction, the virtually inactive 5-HT produced a
clear contraction similar to that produced in the adult porcine hepatic arteries (Table
3.2).
3.5.4. Effect of 5-HT Receptor Antagonists on the Contractile Response ofPorcine
Hepatic Arteries
In non-contracted rings of hepatic artery from adult pigs the 5-HT2-receptor
antagonist, ketanserin, caused a rightward shift in the concentration-response curves;
causing a significant reduction in sensitivity without altering the maximum
contraction (Figure 3.7; Table 3.2). However, in the arterial rings either from adult
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Figure 3.5(a and b). Comparison of cumulative concentration-response curves
obtained in hepatic (□, n=9) and mesenteric (O, n=7) arteries from piglets in
response to (a) arginine vasopressin (AVP) and (b) 5-hydroxytryptamine (5-HT).
Responses are mean ± s.e. mean for (n) individuals and expressed as a percentage of
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Figure 3.5 (c). Comparison of cumulative concentration-response curves obtained in
hepatic (□, n=9) and mesenteric (O, n=7) arteries from piglets in response to
potassium chloride (KCl). Responses are mean + s.e. mean for (n) individuals and
expressed as a percentage of the maximum contraction induced by KCl
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5-Hydroxytryptamine [-LogM]
Figure 3.6. Cumulative concentration-response to 5-hydroxytryptamine (5-HT) in
non-pre-contracted (0,0) and partially pre-contracted (■, hepatic arteries
obtained from adult pigs (squares; n= 11), and piglets (circles; n=8). Responses are
mean + s.e. mean for (n) individuals and expressed as a percentage of the maximum
contraction induced by KC1.
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Figure 3.7(a). Cumulative concentration-response curves produced in response to 5-
hydroxytryptamine (5-HT) in non pre-contracted (open symbol) or partially-
precontracted (solid symbol) hepatic arterial rings from adult pigs (n=ll) in the
absence (control, □ and M) or presence of ketanserin"(A and A; 10"6moI/L). Each
point represents mean ± s.e. mean, expressed as a percentage of the maximum




Figure 3.7 (b). Cumulative concentration-response curves produced in response to 5-
hydroxytryptamine (5-HT) in non pre-contracted (open symbol) or partially-
precontracted (solid symbol) hepatic arterial rings from piglets (11=8), in the absence
(O and •) or presence of ketanserin (V and T, 10"6mol/L). Each point represents
mean ± s.e. mean, expressed as a percentage of the maximum contraction induced by
KC1.
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attenuated. In adult pig arteries, ketanserin produced a non-significant rightward shift
in the concentration-response curve without altering maximum contraction (P=0.57)
or sensitivity (P=0.18) (Figure 3.7a). In partially pre-contracted rings of piglet
hepatic arteries, however, ketanserin had no effect on the concentration-response
curve to 5-HT (Figure 3.7b; Table 3.2).
3.5.5. Potassium Chloride (KCl)-Mediated Response
The maximum contraction and sensitivity of responses to KCl were similar in hepatic
arteries from adult pigs or piglets, and previous partial pre-contraction and/ or
exposure to antagonist did not affect this response (Table 3.3).
3.6. Discussion
This study was designed to develop a protocol to investigate the contractile responses
of isolated human hepatic arteries to AVP and 5-HT, using porcine splanchnic
arteries as a model. It was necessary to use an alternative to human hepatic arteries,
as these are difficult to obtain for functional investigation. For this study, arteries
were used without endothelium as this was consistently shown to be damaged during
isolation of the vessels. However, the absence of endothelium was not considered to
be an obstacle because (as described in previous studies of vascular abnormalities in
cirrhosis (Hadoke et al., 1998)) human hepatic arteries obtained from the operating
theatre are likely to have no endothelium for similar reasons (Smith et a/., 1997;
Heller et al., 1999). It was demonstrated that both hepatic and mesenteric arteries
from adult pigs responded to AVP and 5-HT in the concentration-range used.
However, an unexpected observation was that 5-HT failed to contract arteries from
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Table 3.3. The maximum contraction (Emax) and sensitivity (pD2) of responses to
potassium chloride (KC1) in hepatic arteries from adult pigs and piglets following





NC 10.88+0.76 1.49+0.05 11.28+0.58 1.48+0.06
NC+Ket 11.24+0.80 1.48+0.06 10.91+1.90 1.52+0.07
PC 10.86+0.73 1.46+0.05 10.51+1.06 1.47+0.05
PC+Ket 11.59+0.88 1.50+0.05 10.88+1.12 1.49+0.04
Values are mean ± s.e. mean for (n) subjects. NC, non-contracted; PC, previously
partially pre-contracted rings; +Ket, previously exposed to ketanserin. Values were
compared using Student's unpaired t-test.
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piglets, although these did contract in response to AVP and KC1. 5-HT-mediated
contraction could be evoked in piglet hepatic arteries if they were initially contracted
with a sub-maximal concentration of KC1; a similar technique has been used in other
vessels to activate 5-HTi-like-receptors (Choppin & O'Connor, 1994, 1995; Yildiz et
al., 1998).
Isolated hepatic arteries have been used almost exclusively for investigations of
vascular function in patients with hepatic cirrhosis. The main reason for this is that
hepatic arteries from both donor and recipient can be obtained during liver
transplantation. However, this is a suitable choice for such investigations as the
hepatic artery is a part of the splanchnic vascular territory, which has been shown to
be the primary site of vasodilatation during the development of the hyperdynamic
circulation (Vorobioff et al., 1984; Iwao et al., 1997a). These ex vivo studies have
been restricted in measuring responses to a-adrenoceptor agonists (Hadoke et al.,
1998; Heller et al., 1999) reflecting the fact that most of the studies of pressor
response in cirrhotic patients have also used adrenoceptor agonists (Lunzer et al.,
1975; MacGilchrist & Reid, 1990). The other pressor agent used in vivo, All, has
been used to stimulate human hepatic arteries in vitro but was found to produce
small, erratic contractile responses (Hadoke et al., 1996). Similar problems with All-
mediated responses in vitro have been experienced in mesenteric arteries from
experimental animals (Dunn et al., 1994; Falloon et al., 1995). In both cases,
however, reproducible All-mediated contraction was observed in an isobaric system
(in which the vessels are subjected to transmural pressure) and could be induced in
the isometric system by partially pre-contracting the vessel. Vessels in an isobaric
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system become depolarised in response to transmural pressure and this depolarisation
state is mimicked by partial pre-contraction in an isometric system (Harder et al.,
1987). This suggests, therefore, that a certain amount of depolarisation of the vessel
wall is necessary before the vessel will contract in response to AIL
Few studies have assessed responses to AVP and 5-HT in splanchnic vessels; those
that are available have used arteries from rats or rabbits (Cummings et al., 1986;
Kaumann et al., 1988; Jacob et al., 1991; Huang et al., 1995) which may not be good
models for human arteries. It was, therefore, necessary to determine the
concentration ranges for AVP and 5-HT that would produce a complete
concentration-response curve in human hepatic arteries. The present study used
porcine splanchnic (hepatic and mesenteric) arteries as a model for human hepatic
arteries, as the latter are difficult to obtain in sufficient quantity for extensive in vitro
investigation. The porcine splanchnic arteries are a suitable model because: (i) pigs
have similar splanchnic anatomy to humans (Swindle, 1984) and, (ii) previous ex
vivo investigations have demonstrated that a-adrenoceptor-mediated contraction is
similar in human and porcine hepatic arteries (Hadoke et al., 1995). Both mesenteric
and hepatic arteries were used in a previous study also showed that contractile
responses to a-adrenoceptor agonists were similar in these arteries (Hadoke et al.,
1995).
This study highlighted the problems of damage to the endothelium that can occur
during vessel retrieval, as the endothelium was completely absent from arteries
isolated from adult pigs and only a small amount remained in those from piglets.
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Failure to relax in response to ACh was not a result of inability of the smooth muscle
to respond to a relaxant stimulus as these arteries retained the ability to relax when
exposed to the endothelium-independent dilator, SIN-1. The absence of endothelium
from these vessels is probably a consequence of the retrieval procedures. None of the
pigs were sacrificed specifically for the purpose of this study; in order to reduce the
number of experimental animals used, vessels were collected from a local abattoir
(adult pigs) and from piglets being used for hepatic isolation (for the purposes of a
separate project). The fact that these porcine vessels did not have a functional
endothelium was not considered problematic for this investigation, as it is likely that
hepatic arteries obtained from the transplant theatre would also not have an intact
endothelium. Indeed, there are many descriptions of human vessels obtained from the
operating theatre, which have lost their endothelium as a result of surgical
manipulation (Smith et al., 1997; Hadoke et al., 1998; Heller et al., 1999;
Haudenschild et al., 1981). In fact, intrahepatic arteries with an intact endothelium
can be obtained (Lin et al., 1994; Jeng et al., 1997) which reinforces the suggestion
that denudation results from vessel manipulation during surgery. Therefore, denuded
porcine hepatic and mesenteric arteries are still a valid model for developing a
functional protocol with AVP and 5-HT, and for this reason endothelial cell removal
was ensured in all vessels.
Previous studies have demonstrated similar contractile responses to a-adrenoceptor
agonists in human hepatic and mesenteric arteries (Hadoke et al., 1995). This is
consistent with the demonstration that contractile response to AVP, 5-HT or KC1 is
similar in porcine hepatic and mesenteric arteries. In both groups of arteries, AVP
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had the highest potency and KC1 the lowest. In contrast, KC1 produced the largest
maximum contraction and AVP the lowest. A similar pattern of response to AVP,
5-HT and KC1 has also been reported in other studies in animal vessels (Moreno et
al., 1996; Cummings et al., 1986). The concentration range of AVP, 5-HT or KC1
used in these study produced a clear maximal contraction followed by a loss of tone
at higher concentrations, enabling calculation of maximum contraction as well as
sensitivity (pD2) values for these agents in porcine arteries (Lew, 1995). In cirrhosis,
both the maximum contractile response of the vessels and sensitivity to the agonist
needs to be assessed, as some studies reported altered maximum contraction (Heller
et at1999; Cahill et al., 1996) while in others the sensitivity of the response to
vasoactive agents was affected (Cummings et al., 1986; Jacob et al., 1991). These
results suggest, therefore, that the concentration ranges used in the porcine hepatic
arteries would be suitable for functional analysis of isolated human hepatic arteries.
AVP acts via two receptor sub-types, Vi and V2, both of which are located in the
vessel wall (Phillips et al., 1991). Vascular responses to AVP could, therefore, vary
depending on the distribution of these receptor sub-types in the wall of a particular
vessel (Garcia-Villallon et al., 1996). Previous studies have indicated that vascular
V2 receptors are primarily located in the endothelium and can mediate vasodilatation
by release of nitric oxide (Aki et al., 1994; Tagawa et al., 1995). In contrast, the Vi
receptor is primarily located in the VSMCs and mediates vasoconstriction
(Thibonnier, 1992). Therefore, in this study AVP-induced contraction of denuded
porcine splanchnic arteries is probably mediated by Vi receptors on the VSMCs.
Many studies have demonstrated AVP-mediated contraction of isolated vessels and,
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furthermore, confirmed that this response was mediated by Vi receptors located on
VSMCs. Indeed Vi-mediated contraction has been shown in human renal (Medina et
al., 1996) and gastric arteries (Calo et al., 1997) as well as in rat mesenteric arteries
(Stam et al., 1998). In the present study, the effect of the V2 receptor has been
eliminated as the endothelium was removed. It is probable, therefore, that the V)
receptor in VSMCs is responsible for mediating vasoconstriction in the porcine
splanchnic arteries. However, further studies with selective Vi receptor antagonists
and V2 receptor agonists would be necessary to confirm this. As the porcine hepatic
arteries were not the primary interest for this project, performing such studies was
not considered to be a priority.
An unexpected outcome of the present study was the demonstration of a significant
functional difference between the arteries from adult and juvenile pigs. Whereas
contractile responses to AVP or KC1 were similar (Emax and potency) in arteries
from adult pigs and piglets, 5-HT failed to produce any response in the piglet hepatic
and mesenteric arteries. This striking difference of contractile response to 5-HT was
not due to size differences as it was specific to one agonist, 5-HT, and contractile
responses to the receptor-independent smooth muscle vasoconstrictor, KC1, were
unchanged. This indicated that age has an effect on 5-HT receptor-mediated
constriction of the porcine hepatic arteries and suggests that 5-HT receptors become
active during progression from juvenile to adult. An alteration in 5-HT receptor-
mediated vasoconstriction has also been reported in rabbit pulmonary resistance
arteries (PRA) between neonate (4 and 7 days) and adult individuals (Morecroft &
MacLean, 1998). In adult rabbit PRA, a co-existence of different vasoconstrictor
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5-HT receptor sub-types (5-HT2A and 5-HT)b/id) was indicated, whereas in neonates,
vasoconstriction was predominantly mediated by the 5-HT2A receptor subtype.
However, at present, no other study is found investigating the maturation of 5-HT
receptors with ageing in the vasculature. Development and ageing also have an effect
on All-mediated vascular contraction, although in contrast to 5-HT, contraction
decreases with age (Cai et al., 1994). In the rat aorta, All-mediated vascular
contraction and inositol phosphate accumulation in 6 and 24 month-old animals was
significantly reduced when compared with 1 month-old rat. However, consistent with
the present results, other studies also reported that ageing and development had no
significant effect on responses to AVP, which were similar in juvenile and adult rats
(De Novellis et al., 1994).
5-HT mediates vasoconstriction via stimulation of classical 5-HT2A receptors (Martin
& Humphrey, 1994). At present, accumulating evidence has suggested that, in some
blood vessels, an alternative 5-HT-receptor sub-type can also mediate vascular
contraction (Yildiz et al., 1998; Ishida et al., 1999). Under isometric conditions, no
contraction usually occurs via this sub-type but partial pre-contraction can activate or
amplify the response (Choppin & O'Connor, 1994; Movahedi & Purdy, 1997; Cocks
et al., 1993). This vasoconstrictor sub-type has been classified as the 5-HTi-like
receptor (Yildiz et al., 1996; Movahedi & Purdy, 1997; Morecroft & Maclean, 1998).
This study demonstrated that, in adult pig splanchnic arteries, similar to other studies
(Kaumann et al., 1988; MacLean et al., 1996; Martin & Humphrey, 1994), 5-HT-
induced vasoconstriction was mediated via 5-HT2A receptors, as this contraction was
effectively antagonised by a relatively selective 5-HT2A-receptor antagonist,
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ketanserin. However, following partial precontraction, responses were predominantly
mediated via another vasoconstrictor 5-HT-receptor sub-type, as ketanserin had only
a non-significant effect. In contrast, the failure of 5-HT to induce vasoconstriction in
non-contracted piglet splanchnic arteries suggested the absence of any activity of
vasoconstrictor 5-HT receptors. In these arteries, noticeable contraction was only
demonstrated after partial pre-contraction, on which ketanserin had no effect. These
results indicated that, in piglet hepatic arteries, 5-HT-induced contraction was
mediated by another vasoconstrictor 5-HT-receptor sub-type, probably the 5-HTi-
like receptor, which was inactive in non-precontracted condition. Although 5-HT can
also produce contraction by stimulation of a-adrenoceptors, this could not account
for the 5-HT2A receptor-independent contraction seen in the present study, as in all
experiments, ai and a2-adrenoceptors had been blocked using prazosin and
yohimbine, respectively (Choppin & O'Connor, 1994; Sahin-Erdemli etal., 1991).
The mechanisms by which pre-contraction induces 5-HT-mediated contractile
responses in porcine hepatic arteries are unclear and the presence of 5-HTi-like
receptors has not been studied in these arteries. The 5-HT2a-receptor is a G-protein-
coupled 7 transmembrane domain receptor, stimulation of which increases synthesis
of inositol phosphates (IP3) and diacylglycerol (DAG) leading to elevated
intracellular Ca2+ concentrations and thus, smooth muscle cell contraction (Martin &
Humphrey, 1994; Saxena & Villalon, 1990). The 5-HTi-like receptor is also a G-
protein-coupled receptor but is inversely coupled with adenylate cyclase. Stimulation
of this receptor reduces the levels of cytosolic cyclic adenosine monophosphate
(cAMP) and leads to a rise in intracellular calcium (Hoyer ef a/., 1994). Additionally,
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5-HTi-like receptor can also enhance intracellular calcium by stimulating calcium
influx (Movahedi & Purdy, 1997; Parsons & Whalley, 1989). As described,
stimulation of 5-HTi-like receptor does not result in contraction of some vessels
mounted in an isometric system (Choppin & O'Connor, 1994, 1995). The reason for
this is that cytosolic calcium levels are below the threshold concentration essential
for contraction. However, following partial precontraction, using another non-5-HT
agonist, intracellular calcium levels were elevated, while steady cytosolic calcium
levels were maintained by subsequent increased of cytosolic cAMP activity (Yildiz
et al., 1998). In this situation, stimulation of the 5-HTi-like receptor inhibits
synthesis of cAMP as well as induces calcium influx. Consequently, cytosolic
calcium levels are elevated and vasoconstriction is evoked. The current study
suggests, therefore, that 5-HTi-but not 5-HT2A-receptors are present in piglet hepatic
artery, whereas both receptor subtypes are active in similar arteries from adult pig as
evidenced in PRA of adult rabbits.
3.7. Conclusions
This study demonstrated that porcine hepatic and mesenteric arteries could be used
as a model to develop a functional protocol for the use of human hepatic arteries. It
was shown that the arteries were devoid of endothelium and consequently neither the
influence of the endothelium on contractile function nor endothelium-dependent
relaxation could be assessed. A similar lack of endothelium is expected in human
hepatic arteries. Using the porcine hepatic and mesenteric arteries as a model,
concentration ranges of AVP and 5-HT were shown to produce clear maximum
contraction enabling calculation of the pD2 value, both of which will be necessary to
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assess the effect of cirrhosis on human hepatic artery function. The demonstration of
age-dependent changes in response to 5-HT in these arteries was unexpected and
investigation of this phenomenon provided useful data on the mechanism of 5-HT-
mediated contraction in these arteries. However, it is unlikely that age-dependent
changes will be important in studying of the effect of cirrhosis in human hepatic




THE EFFECT OF ORGAN PRESERVATION ON FUNCTIONAL
RESPONSES OF THE PORCINE HEPATIC ARTERY
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4.1. Introduction.
The hyperdynamic circulation of cirrhosis exhibits characteristic haemodynamic
disturbances in the peripheral vasculature. In particular, marked vasodilatation has
been described in the splanchnic circulation (Iwao et al., 1997a) but the cause of this
abnormality has yet to be confirmed. Human hepatic arteries have been used to
investigate the causes of altered function as they can be obtained during liver
transplantation procedures (Heller et al., 1999; Hadoke et al., 1998; Smith et al.,
1997). Donor hepatic arteries are usually used as controls whilst the effects of liver
cirrhosis on contractile function are assessed in hepatic arteries from (cirrhotic) liver
recipients. The situation is complicated by the different treatment of donor and
recipient hepatic arteries during the transplantation procedure, as hepatic arteries
from the donor, but not those from the recipient, are exposed to preservative
solutions while stored ex vivo. Conceivably, this exposure to preservative solution
could affect the functional responsiveness of the donor arteries, limiting their use as
controls for studying the effect of cirrhosis.
University of Wisconsin solution (UWS) is widely used for organ preservation and is
recognised as the best available preservative solution for hepatocytes (Muhlbacher et
al., 1999; Belzer et al., 1992). However, the structure and function of cells in blood
vessels differ considerably from those of hepatocytes. It is, therefore, important to
determine the effect of preservative solutions on the functional responses of the
blood vessel. A small number of studies have investigated the effects of UWS on the
functional response of blood vessels. These have consistently reported that
contractile responses of denuded vessels were unaffected following incubation with
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UWS (Jeng et al, 1996b, 1997; Hadoke et al., 1998). In contrast, there are
conflicting reports on the effect of UWS on vessels with an intact endothelium (Lin
et al., 1994, 1995; Jeng et al., 1997; Gryf-Lowczowski et al., 1997; Nardo et al.,
2000). Another important consideration is that dexamethasone, insulin and penicillin
are added to UWS for the preservation of liver (Sorajja et al., 1997; Abebe et al.,
1993). Glucocorticoids may affect contractile and relaxant function of blood vessels
(Changani et al., 1999; Ullian, 1999) and insulin can enhance endothelium-mediated
relaxation (Wamback & Liu, 1992). Therefore, the effects of preservative solutions
on the functional responses of donor hepatic artery have to be assessed before these
vessels are used as controls.
Normal human hepatic arteries, which have not been exposed to UWS, are difficult
to obtain, and usually have a damaged endothelium (Heller et al., 1999; Hadoke et
al., 1998; Smith et al., 1997). Although, small intra-hepatic arteries with an intact
functional endothelium can be obtained during hepatectomy, they are not ideal
models for functional studies of extra-hepatic arteries. Furthermore, these arteries are
obtained from patients with liver diseases and an influence of disease on normal
function of blood vessels cannot be discounted. For assessment of the effect of
preservative solutions on the normal functional response of hepatic arteries, it is
necessary, therefore, to use a suitable animal model. The anatomy and physiology of
the porcine liver and splanchnic vascular system closely resembles to those in
humans (Swindle, 1984; Changani et al., 1999), making porcine extra-hepatic




This study was designed to determine whether prolonged storage in preservative
solution alters contractile function or endothelium-independent relaxation in denuded
porcine hepatic arteries.
4.3. Methods
4.3.1. Acquisition ofHepatic Arteries
Hepatic arteries from, healthy, adult large white pigs of either sex (age, 6-8 months;
weight, 50-60kg; n=36) were collected from a local abattoir. Arteries were placed
immediately into ice-cold oxygenated KHS, transported to the laboratory and
prepared as described in Chapter 2.1.3.
4.3.2. Incubation ofHepatic Arteries with Preservative Solutions
Hepatic arteries from 18 pigs were divided into two sections (3-4 cm in length): one
section was stored in KHS whilst the other section was stored in UWS. The
composition of UWS was (mmol/L): K+, 125; Na+, 28; KH2PO4, 25; MgS04, 5;
raffinose, 30; lactobionate, 100; glutathione, 3; adenosine, 5; ailopurinol, 1 and
pentafraction (50g/L) (Southard & Belzer, 1995; Collins, 1997). Arteries from the
remaining 18 pigs were divided in a similar way but stored in either KHS or in UWS
containing dexamethasone, 16 mg/L (3xlO"5mol/L); insulin, 40 units/L and
benzylpenicillin, 240 mg/L (DIP), according to the liver preservation protocol used
by the Scottish Liver Transplant Unit. The arterial sections were stored at 4°C for 16
hours in 20 ml of the preservative solutions in a sterile universal container (as liver is
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preserved maximum 14 hours in Scottish Liver Transplant Unit before
transplantation).
4.3.3. Functional Analysis ofHepatic Arteries
Following incubation, two rings, 2mm in length, were prepared from each hepatic
artery. Any residual endothelium was removed by gently rubbing the luminal surface
with a wire probe and the rings were mounted on intraluminal wires in organ baths
filled with KHS as described (Chapter 2.2.2).
4.3.3.1. Assessment ofViability and Reproducibility
After equilibration of the rings at their optimum resting force (4g), the viability and
reproducibility of contractions were tested using (lOOmmol/L) KC1 (Hadoke et al.,
1998).
4.3.3.2. Functional Protocol
For the investigation of contractile and relaxation functions of the hepatic arteries
after storage either in KHS, ITWS or UWS + DIP, cumulative concentration-response
curves were constructed for the receptor-dependent agonists, AVP (10"u-3xl0~7
mol/L) and 5-HT (10~9-3xl0"5 mol/L), and the receptor-independent vasoconstrictor,
KC1 (2.5-120 mmol/L). At the end, endothelium-independent relaxation was assessed
using the nitric oxide donor, SIN-l (10~9-3xl0"5 mol/L), following sub-maximal
precontraction with PE (10"6-3xl0"5 mol/L).
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4.4. Statistics
Statistics analysis was performed as described in Chapter 2.7.
4.5. Results
4.5.1. Effect ofPreservative Solutions on Contractile Function ofArterial Rings
The receptor-dependent agonists, AVP and 5-HT, as well as the receptor-
independent vasoconstrictor, KC1, induced contraction in all arterial rings whether
they were incubated with KHS, UWS or UWS + DIP.
The maximum contractile response and sensitivity to AVP, 5-HT and KC1 were
similar in arteries stored in KHS or UWS (Figure 4.1; Table 4.1). This situation was
not altered by addition ofDIP to the UWS, as responses of the vessels stored in UWS
+ DIP were also similar to controls (Table 4.1; Figure 4.2).
4.5.2. Effect ofPreservative Solutions on Relaxation ofArterial Rings
SIN-1 produced concentration-dependent relaxation in all denuded arterial rings.
Following incubation with UWS, maximum relaxation (Emax; 106.07 ± 0.82%) and
sensitivity (-log IC50; 6.23 + 0.07) of the rings incubated in UWS were significantly
reduced when compared with those stored in KHS (Emax; 110.19 ± 1.34%, P=0.01; -
log IC50; 6.47 ± 0.04, P = 0.009) (Figure 4.3). Although, the sub-maximal
contraction produced by PE was similar (P=0.55), following incubation with UWS





Figure 4.1 (a, b). Cumulative concentration-response curves produced in response to
(a) arginine vasopressin (AVP) and (b) 5-hydroxytryptamine (5-IIT) by porcine
hepatic arteries, incubated in Krebs' -Henseleit solution, (□) or University of
Wisconsin solution (U), Responses are given as mean ± s.e. mean for (n) individuals




Figure 4.1 (c). Cumulative concentration-response curves produced in response to
potassium chloride (KC1) by porcine hepatic arteries, incubated in Krebs'-Henseleit
solution, (□) or University of Wisconsin solution (■), Responses are given as mean ±
s.e. mean for (n) individuals and expressed as a percentage of the maximum
contraction induced by KC1. In all cases n=l 8.
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Figure 4.2 (a, b). Cumulative concentration-response curves produced in response to
(a) arginine vasopressin (AVP) and (b) 5-hydroxytryptamine (5-HT by porcine
hepatic arteries incubated in Krebs'-Henseleit solution, (O) or University of
Wisconsin solution containing dexamethasone, insulin and penicillin (DIP), (#).
Responses are given as mean ± s.e. mean for (n) individuals and expressed as a
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Figure 4.2 (c) Cumulative concentration-response curves produced in response to
potassium chloride (KC1) by porcine hepatic arteries incubated in Krebs'-Henseleit
solution, (O) or University ofWisconsin solution containing dexamethasone, insulin
and penicillin (DIP), (•). Responses are given as mean ± s.e. mean for (n)
individuals and expressed as a percentage of the maximum contraction induced by
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Figure 4.3 (a, b). Cumulative concentration-response curves produced by
denuded porcine hepatic arteries in response to 3'-morpholinosydnonimine (SIN-
1), following incubation with (a) Krebs'-Henseleit solution, (A) or University of
Wisconsin solution (A) and (b) with Krebs'-Henseleit solution, (V) or University
of Wisconsin solution containing dexamethasone, insulin and penicillin (DIP),
(▼). Responses are given as mean ± s.e. mean for (n) subjects and expressed as a
percentage of the maximum relaxation induced by phenylephrine. In all cases
n=18.
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A similar but more pronounced reduction of SIN-1-mediated relaxation was detected
in arteries incubated with UWS + DIP (Emax; 103.87 ± 1.23%; -log IC50; 6.09 ±
0.07) when compared with the arteries incubated in KHS (Emax; 109.60 ± 1.57%, P
= 0.007; -log IC50; 6.52 ± 0.05, P=0.0001) (Figure 4.3). These arteries also produced
similar type (P=0.77) sub-maximal contraction in response to PE following
incubation with UWS (7.72 ± 0.64g) or KHS (7.47 ± 0.54g).
4.6. Discussion
The present study investigated the effect of UWS, with or without the addition of
dexamethasone, insulin and penicillin, on functional responses of denuded porcine
hepatic arteries. It was demonstrated that exposure to preservative solutions had no
effect on the maximum contraction and sensitivity of responses to the receptor-
dependent agonists, AVP and 5-HT, or the receptor-independent vasoconstrictor,
KC1. In contrast, the relaxation response to SIN-1 was reduced following incubation
in preservative solutions.
Donor hepatic arteries, which are preserved along with the liver in UWS, have been
used as controls in investigations studying the effect of cirrhosis on the functional
responses of hepatic arteries from liver recipients. Although arteries can be stored in
physiological salt solutions over short periods (up to approximately 2 days) without
affecting functional responsiveness (Cartier et al., 1993; Mclntyre et al., 1998),
UWS differs from physiological salt solutions in several respects. In particular, the
higher concentrations of potassium (125 mmol/L), lower concentrations of sodium
(29 mmol/L), the absence of calcium, and the presence of potential anti-oxidant
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glutathione as well as a higher osmolality (320 mOsmol/L). Raised osmolality does
not appear to influence contractile function (Goto & Aimoto, 1991) but intracellular
calcium ([Ca2+]i), which is the primary regulator of VSMC contraction, can be
modulated by the variations in extracellular concentration of potassium, sodium as
well as calcium (Gurney, 1994; McDonald et al., 1994). Furthermore, UWS also
contains adenosine, which is itself a vasodilator (Searle & Sahab, 1992).
4.6.1. Effect ofPreservative Solutions on Contraction
The demonstration in this study, that contractile function of denuded porcine hepatic
arteries is unaffected by exposure to UWS, is consistent with investigations using
denuded porcine mesenteric (Heller et al., 1999) or canine coronary (Lin et al., 1995)
arteries. Similarly, exposure to UWS had no effect on contraction in denuded hepatic
arteries from patients with cirrhosis (Hadoke et al., 1998) or hepatocellular
carcinoma (Jeng et al., 1996, 1997). In contrast, augmented contractility (to both a
thromboxane analogue [U46619] and KC1) has been demonstrated in human
saphenous veins with an intact endothelium after incubation with UWS (Anastasious
et al., 1997). The mechanism of the augmented response was unclear but the
presence of the endothelium might be significant. Alternatively, structural and
functional differences between veins and arteries may result in exposure to UWS
having a more significant impact on the former (Buckley et al., 1997; Garcia-
Villalon et al., 1996). These results confirm that exposure to UWS (for up to 16
hours) does not alter contractile function of denuded arteries.
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The clearest evidence of altered contractile function in arteries exposed to UWS is
seen under hypoxic conditions. Hypoxia-induced contraction is enhanced in arteries,
from animals (Lin et al., 1995) or humans (Jeng et al., 1997), after storage in UWS.
This enhancement, however, requires the presence of an intact endothelium,
indicating that exposure to UWS is altering the function of endothelial, rather than
smooth muscle, cells. This could be a result of either impaired activity of
endothelium-derived vasodilators or, more probably, release of an endothelium-
derived contracting factor (EDCF; e.g. endothelin-1 or a contractile prostaglandin),
under hypoxic conditions. Therefore, when using human hepatic arteries to study the
effects of cirrhosis on contractile function, it is likely that the influence of exposure
to UWS on control arteries would only become significant if the arteries have an
intact endothelium and are studied under hypoxic conditions.
Dexamethasone, insulin and penicillin are added routinely to UWS for preservation
of liver during transplantation procedures. Few studies, however, have included these
compounds when assessing the effects of UWS on vascular responsiveness. This
addition may be significant as these additives may also have vasoactive properties.
Corticosteroids, for example, can potentiate the activity of several vasoactive
mediators by up-regulating receptors in the VSMCs (Ullian, 1999), modulating post-
receptor signal transduction pathway (Calderone et al., 1994) or even attenuating the
activity of endothelium-derived vasodilators (Lockette et al., 1986). Glucocorticoids
can also directly increase the capacity of trans-membrane ion transporters (Kornel,
1993). Insulin, on the other hand, may inhibit contractile responses to various
vasoactive substances (Cleland et al., 1998a; Kahn et al., 1998; McNally et al., 1995)
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although the mechanisms of this action remain unclear. Possibilities include
enhanced NO release from the endothelium (Baron, 1999) or inhibition of
extracellular calcium influx (Goud et ah, 1998). It has also been reported that insulin
directly modulates transmembrane cation exchange through stimulation of the
Na+/K+ ATPase and Na'/K' pump in VSMCs (Moore, 1983). Activation of the
Na+/K+ pump induces hyperpolarisation of the cell membrane and thereby impaired
calcium influx via voltage-operated channels (Izhar et al., 2000; Kahn et ah, 1993).
Incubation of the arteries in non-sterile conditions possibly could induce iNOS
activation. This activation should have been prevented by penicillin and also by
dexamethasone. These results suggested that iNOS is not activated, as activation of
iNOS would lead to impaired response to contractile functions of the agonists.
The present study demonstrated that the inclusion of dexamethasone, insulin and
penicillin in the UWS had no effect on the contractile responses of denuded porcine
hepatic arteries. These results are consistent with studies using canine coronary
arteries (Sorajja et al., 1997; Abebe et al., 1993). It is unclear why these additives did
not affect vascular function although several possible explanations may be proposed.
The concentration of the dexamethasone or insulin may be significant as the effect of
these compounds is concentration-dependent (Altura & Altura, 1974; McNally et ah,
1995). The very high concentration of dexamethasone (3xlO"5mol/L) used in this
study, could be a factor, as corticosteroids may inhibit vasoconstriction at this
concentration (Altura & Altura, 1974). Similarly, insulin reduces contractile
responses in a concentration-dependent manner (0. lmU/ml-lOmU/ml) (McNally et
ah, 1995), however, at very high concentration (40mU/ml) its effect is unclear.
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Similarly, the duration of exposure may be an important consideration. The vascular
effect of steroids in vivo can be observed within seconds or minutes due to non-
receptor-mediated direct cell membrane effects, but long-term exposure (e.g. 16
hours) can produce both classical cytosolic receptor as well as direct non-receptor-
mediated effects (Walker & Williams, 1992). However, such time limit for
incubation in vitro is not well defined. In the case of insulin, inhibition of contractile
function could be observed within minutes or hours but long-term exposure in vivo or
in tissue culture could induce growth and proliferation of the vascular smooth muscle
cells (Pfeiffer & Ditschuneit, 1981) which is unexpected in isolated vessel studies.
Finally, most studies have reported altered contractile responses following exposure
of vessels to these agents at either normal room temperature or body temperature.
The lower incubation temperature (4°C) in the present study may have prevented
dexamethasone and insulin, exerting an effect on vascular function.
4.7.2. Effect ofPreservative Solutions on Relaxation
SIN-1, the active metabolite of molsidomine, which generates peroxynitrite and NO
(Singh et. al., 1999), produced an endothelium-independent relaxation of denuded
porcine hepatic arteries. Although this relaxation remained evident in arteries
exposed to UWS, there was a small but significant reduction in maximum relaxation
and impairment of sensitivity compared with vessels incubated in KHS. This
reduction was more pronounced after addition of dexamethasone, insulin and
penicillin. Impaired relaxation responses to another nitro-vasodilator, sodium
nitroprusside (SNP), have been reported in rat coronary arteries (Cartier et al., 1993)
and rabbit thoracic aorta (Gryf-Lowczowski et al., 1997) following incubation with
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UWS. In contrast, other studies have reported that response of denuded human
hepatic arteries to SNP (Jeng et al., 1996a,b) or SIN-1 (Hadoke et al., 1998) were
unaltered after such incubation. Similarly, unaltered responses to SNP have also been
reported in canine coronary arteries (Lin et al., 1994) and porcine hepatic arteries
(Flanders et al., 1996), even after addition of dexamethasone, insulin and penicillin
(Sorajja et al., 1997; Abebe et al., 1993). These differences from the present study
are difficult to explain. Methodological variations, however, including use of vessels
from a variety of species and anatomical territories, use of different agonists and,
particularly in humans, the effect of disease and treatments (Jeng et al., 1996a,b;
Hadoke et al., 1998), might be implicated. Alternatively, the inclusion of glutathione
in UWS may account for altered responses to SIN-1. Glutathione may undergo auto-
oxidation during storage, leading to the generation of oxidative radicals (Gnaiger et
al., 2000; Astier & Paul, 1989). These radicals act as pro-oxidant and could
potentially alter the balance between NO and peroxynitrite generation, resulting in a
higher proportion of peroxynitrite to NO from SIN-1 (Singh et al., 1999). This would
not explain, however, the greater impairment in SIN-1-mediated relaxation in vessels
exposed to UWS containing dexamethasone, insulin and penicillin.
The mechanism by which SIN-1 and other NO donors mediate relaxation may
account for the differences between some studies (Tseng et al., 2000; Van de Voorde
et al., 1991). Nitrovasodilators such as SNP or nitroglycerin produce vasodilatation
primarily via the nitric oxide-guanylate cyclase pathway (Walter et al., 1988;
Vanhoutte, 1989). The vasodilatation mechanisms of SIN-1 could differ from other
nitrovasodilators (Van de Voorde et al., 1991). In rat aorta (Van de Voorde et al.,
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1991), mesenteric (Plane et al., 1996) or pulmonary (Homer et al., 1999) arteries,
inhibition of guanylate cyclase by oxadiazolol quinoxalin (ODQ) reduced responses
to SNP or nitroglycerin but not SIN-1. The SIN-l-mdiated relaxation however was
significantly inhibited by potassium channel blockers. Therefore, in addition to the
nitric oxide-guanylate cyclase pathway, SIN-1 can also mediate vasodilatation via
potassium channels in the VSMCs (Magnon et al., 1998, Onoue & Katusic, 1997).
Opening of K+ channels induces VSMC hyperpolarisation, which reduces calcium
influx (by closing voltage-gated calcium channels) resulting in vasodilatation
(Gurney, 1994). Alteration of extracellular K' can affect this mechanism (Quayle et
al., 1997). In particular, very high extracellular K prevents efflux of K+ and, thus,
prevents hyperpolarisation (Cook & Quast, 1990). Therefore, the high potassium
(125 mmol/L) in UWS might be a factor in the reduction in SIN-1-mediated
vasorelaxation.
The presence of dexamethasone, insulin and penicillin with UWS, further attenuated
the relaxation response of the arteries elicited by SIN-1. It has been suggested that
corticosteroids can have a direct effect on VSMC function (Ullian, 1999).
Dexamethasone can increase extracellular calcium influx (Hayashi et al., 1991) and
release from intracellular stores (Perry & Webb, 1991), enhance sodium transport
(Stern et al., 1994) and thus increase vascular tone. As a whole, corticosteroids can
act on many individual sites (such as receptor-ligand binding, membrane G-protein,
phospholipase C, inositol triphosphate, contractile proteins as well as protein kinase
C) in the contractile pathway of VSMCs (Ullian, 1999). Furthermore, it can inhibit
synthesis of vasodilator prostaglandins (Handa et al., 1984) and inducible NO
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synthase (Rees et al., 1990; Niwa et al., 1996) in the VSMCs. The reduced relaxation
response in this experiment therefore could be the outcome of an integrated effect of
dexamethasone on the vessels. Additionally, penicillin in UWS could prevent
induction of NO synthesis resulting from non-aseptic conditions (Guarner et al.,
1993). Insulin could produce vasodilatation but this effect is mainly mediated by
endothelial cells (Wamback & Liu, 1992) or activation of potassium channels (Izhar
et. al., 2000). Absence of the endothelium in the vessels as well as higher potassium
in UWS might inhibit the response of insulin. Furthermore, it has been reported that
the vasodilatation effect of insulin can be suppressed by dexamethasone (Scherrer et
al., 1993). However, the complex interaction between various components of UWS
and the additives dexamethasone, insulin and penicillin with SIN-1 is still unclear.
More studies therefore are required if these interactions are to be clarified.
4.8. Conclusions
The present study demonstrated that preservation of denuded porcine hepatic arteries
in UWS, with or without dexamethasone, insulin and penicillin, had no effect on
contractile function. These results suggest that, although donor hepatic arteries are
exposed to UWS during liver transplant, they are suitable controls for investigating
the effect of cirrhosis on the contractile response of denuded hepatic arteries.
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CHAPTER FIVE
THE EFFECT OF CIRRHOSIS OF THE LIVER ON THE CONTRACTILE
FUNCTION OF HUMAN HEPATIC ARTERIES
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5.1. Introduction
The development of a hyperdynamic circulation (Groszman, 1996; Murray el al.,
1958) in patients with cirrhosis of the liver is associated with systemic (Schrier el al.,
1988a; Kontos et al., 1964) and splanchnic vasodilatation (Vorobioff et al., 1984;
Iwao et al., 1997). Individuals with cirrhosis also exhibit an impaired pressor
response to vasoconstrictors (MacGilchrist, et al., 1991a, b; Badalamenti et al., 1993)
but, despite many studies, the cause of this abnormality remains obscure. Impaired
contraction remains in evidence in ex vivo preparations in which vessels are isolated
from circulating vasoactive factors (Smith et al., 1997; Heller et al., 1999). This
suggests, therefore, that an abnormality in the vessel wall accounts for altered
contractile function in isolated arteries. Possible explanations of contractile
hyporesponsiveness include receptor down-regulation (Gerbes et al., 1986), a defect
in the post-receptor signal transduction pathway (Laffi et al., 1988) and/ or excessive
synthesis of vasodilators by the vessel wall itself (Vallance & Moncada, 1991).
Studies of contractility in vessels isolated from individuals with cirrhosis and/ or
portal hypertension have yielded conflicting results. These differences possibly
reflect methodological variation, with many different blood vessels, from distinct
vascular territories of several different species employed (Hadoke & Hayes, 1997). It
is apparent, however, that the impact of cirrhosis on vascular contractility is
dependent upon both the agonist studied (Liao et al., 1994; Sogni et al., 1996;
Newby et al., 1998b) and the source of the vessel under investigation. Although few
studies have assessed contractile function in human splanchnic arteries, there is some
evidence of an endothelium-independent impairment of a-adrenoceptor mediated
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contraction in hepatic arteries from patients with cirrhosis (Smith et al., 1997; Heller
et al., 1999) although a study in our own laboratory could not confirm this
observation (Hadoke et al., 1998). No studies, however, have reported the impact of
hepatic cirrhosis on contractile responses of human hepatic arteries to agonists other
than those which act on adrenoceptors. Given that the effect of cirrhosis on
contractile function is likely to be agonist-dependent, this investigation was designed
to assess the effect of cirrhosis on responses to AVP, 5-HT and ET-1 in human
hepatic arteries. These agonists are of particular interest as their activity in vivo may
be altered in patients with cirrhosis (Shah et al., 1998) and their manipulation may be
therapeutically beneficial (Freeman et al., 1998; Vorobioff et al., 1989; Nevens et
al., 1991; Gandhi et al., 1998; Reichen et al., 1998). Furthermore, studies using
animal models have suggested that contractile responses to AVP (Huang et al., 1995;
Moreno et al., 1996), 5-HT (Jacob et al., 1991; Cummings et al., 1986) and ET-1
(Cahill et al., 1998; Cailmail et al., 1995) may all be altered in cirrhosis/portal
hypertension.
5.2. Aim
The study aimed (1) to determine whether the presence of hepatic cirrhosis was
associated with alterations in contractile responses to AVP, 5-HT and ET-1 in




5.3.1. Acquisition andPreparation ofHepatic Artery
Hepatic arteries from liver donors and recipients were obtained from the Scottish
Liver Transplant Unit, during liver transplantation. Donor hepatic arteries were
obtained from surplus material after the transplantation procedure, whilst recipient
hepatic arteries (4-6cm) were dissected directly from the freshly explanted liver.
Following retrieval, arteries were immediately placed in ice-cold, oxygenated
Krebs'-Henseleit solution (KHS) and transported to the laboratory as described
(Chapter 2.1.1). Functional investigations were usually performed immediately after
the retrieval of the arteries and all experiments were performed within 24 hours of
collection. Systemic haemodynamic parameters, recorded in liver recipients before
transplantation, were obtained from anaesthetic notes.
5.3.2. Functional Analysis
5 .3 .2.1. Preparation of Arterial Rings
Hepatic arteries were cleaned of adherent connective tissue and cut into 2-4 rings
(1.5-2mm in length). In appropriate cases, endothelium was removed if necessary
(Chapter 2.1.1.) The rings were mounted in organ baths filled with KHS, at 37°C,
and continuously bubbled with 95% O2 - 5% CO2 for the measurement of isometric
force development (Chapter 2.2.2). All analyses were performed in the presence of
indomethacin (10"5 moI/L).
5.3.2.2. Assessment of Vessel Viability and Endothelial Cell Function
The arterial rings were equilibrated at their optimum resting force (4g) (Hadoke et
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a/., 1998) for 50-60 minutes and the viability and reproducibility of contractions of
each ring was tested using at least 3 consecutive applications of (100 mmol/L) KC1
(Chapter 2.2.3). Existence of functional endothelium was assessed in six donor and
six recipient hepatic arteries, by adding the endothelium-dependent vasodilator, ACh
(10"7-3x10"5 mol/L) (Vanhoutte & Miller, 1985; Jeng et al., 1996a, b), following
precontraction with PE (10"6-3xl0"5 mol/L). Endothelium-independent relaxation was
also assessed by exposing precontracted rings to SIN-1 (10"9-3xl0"5 mol/L). At the
end of the functional assessment, the rings were removed from the organ baths and
endothelial cell integrity was assessed histologically by staining the luminal surface
with silver nitrate (Chapter 2.4). In the subsequent experiments, any residual
endothelium was removed by gently rubbing the luminal surface of the rings as
described (Chapter 2.2.1).
5.3.2.3. Immunohistochemical Assessment ofEndothelial Cell Integrity
The presence of endothelium both in the donor and recipient hepatic arteries was also
studied using an immunohistochemical technique. Transverse sections from donor
(n=6) and recipient (n=6) hepatic arteries were stained using the Ulex antibody as
described in Chapter 2.5.2.1.
5.3.3. A VP and 5-HT-Mediated Contraction
5.3.3.1. Subjects
Hepatic arteries were obtained from 42 liver donors (non-cirrhotic; 22 male, 20
female) and 36 recipients (cirrhotic; 14 male, 22 female). The donors (47 ± 2 yrs.)
and recipients (51+2 yrs.) were similar in age (P=0.19) and the mean duration of
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liver disease in the recipients was 9 ± 1 yrs. Causes of death in the donors and of
hepatic cirrhosis in the recipients are given in Table 5.1.
5 .3 .3 .2. Effect of Cirrhosis on AVP and 5-HT-Mediated Contraction
Cumulative concentration-response curves were constructed in denuded hepatic
arteries using receptor-dependent agonists, AVP (10~u-3xl0~7 mol/L) and 5-HT (109-
3x10~5 mol/L) and the receptor-independent vasoconstrictor, KC1 (2.5-120mmol/L).
The rings were washed repeatedly after completion of each curve and equilibrated
for 30 minutes before the next agonist was applied.
5 .3 .3 .3. Analysis ofNitric Oxide Synthase Activity in the Hepatic Arteries
5.3.3.3.1. Influence of Nitric Oxide Synthase Activity on
Contractility.
Four rings were prepared from each donor and recipient hepatic artery and mounted
in organ baths. Two rings were incubated with the nitric oxide synthase (NOS)
inhibitor, NG-nitro-L-arginine (L-NNA; 10"4 mol/L) and the remaining two rings with
its inactive isomer N°-nitro-D-arginine (D-NNA; 10"4 mol/L) for 45 minutes.
Cumulative concentration-response curves were then constructed using AVP (10"n-
3xl0~7 mol/L), 5-HT (10"9-3xlCT5 mol/L) and KC1 (2.5-120mM) in the continued
presence of L-NNA or D-NNA. Finally, endothelium-independent relaxation was
assessed using SIN-1 (10~9-3xl0"5 mol/L) following sub-maximal precontraction with
PE (10"6-3x10"5 mol/L).
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Table 5.1. Causes of death in liver donors and of cirrhosis in recipients undergoing
liver transplantation. Hepatic arteries from these individuals were isolated for studies
ofAVP and 5-HT-mediated contraction.
Cause ofDeath in Donor No, Cause ofCirrhosis in Recipient No.
Sub-arachnoid Haemorrhage 24 Primary Biliary Cirrhosis 14
Intra-cerebral Bleeding 9 Alcoholic Liver Disease 8
Head Injury 5 Cryptogenic Cirrhosis 7
Hypoxia 3 Primary Sclerosing Cholangitis 5
Bleeding Aneurysm 1 Secondary Biliary Cirrhosis 1
Cirrhosis in Wilson's Disease 1
Total: 42 Total: 36
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5.3.3.3.2. lmmunohistochemical Assessment of Nitric Oxide Synthase
in Human Hepatic Artery
The presence of inducible nitric oxide synthase in the donor and recipient hepatic
arteries was assessed immunohistochemically using the alkaline phosphatase method
(Chapter 2.4). Recipient hepatic arteries were obtained from patients with cirrhosis
caused by: alcoholic liver disease (ALD; n=3), primary biliary cirrhosis (PBC; n=3),
cryptogenic cirrhosis (CC; n=2) or chronic active hepatitis (CAH; n=l). In this study,
arterial rings prepared from the rabbit thoracic aorta for the purpose of a different
investigation were used as a positive control. Induction of nitric oxide synthase
activity was accomplished by intraperitoneal injection of lipopolysaccharide (E. coli,
055:B5; Sigma Ltd, UK), 30mg/kg body weight and the rabbit was sacrificed after 5
hours.
5.3.3.4. Identification of the Receptors Mediating AVP-Induced Contraction
ofHuman Hepatic Artery
5.3.3.4.1. The Role of V2-receptors
Arterial rings from either donor (n=6) or recipient (n=6) hepatic arteries were
mounted in organ baths. After equilibration and confirmation of viability, cumulative
concentration-response curves were constructed using a selective V2-receptor
agonist, desmopressin (DDAVP, 10"u-3xl0"6 mol/L) followed by AVP (10"n-3xl0"7
mol/L) and KC1 (2.5-120 mmol/L).
5.3.3.4.2. The Role ofV)-receptors
The Role of V)-receptors was assessed in separate arterial rings from these
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individuals. Four rings from either donor (n-10) or recipient (n=ll) hepatic arteries
were freshly mounted in organ baths. Three rings were incubated for 15 minutes with
different concentrations (10"8 mol/L, 10"7 mol/L and 10"6 mol/L) of a selective Vi-
receptor antagonist, d(CH2)s Tyr(Me)AVP. The fourth ring was not exposed to the
antagonist and served as a control. Following the incubation, cumulative-
concentration response curves were constructed using AVP (10"n-3xl0~6 mol/L).
Subsequently, the agonist and antagonist were washed from the organ baths and,
following 30 minutes equilibration, cumulative concentration-response curves were
constructed using KC1 (2.5-120 mmol/L).
5.3.4. ET-J Mediated Contraction ofHuman Hepatic artery
5.3.4.1. Subjects
Hepatic arteries were collected from 8 non-cirrhotic donors (3 male, 5 female) and 9
cirrhotic recipients (5 male, 4 female) of a similar age (43 ± 6 yrs. and 52 ± 4 yrs.
respectively; P=0.20) at the time of liver transplantation. The mean duration of liver
disease in recipients was 11+2 yrs. Causes of death in the donors and of hepatic
cirrhosis in the recipients are given in Table 5.2. Systemic haemodynamic parameters
recorded in liver recipients before transplantation were obtained from anaesthetic
notes. Arteries were collected, stored and transported to the laboratory as described
(Chapter 2.1.1).
5.3.4.2. Functional Protocol
Connective tissue was cleaned from the hepatic arteries and 4 rings (approximately
1.5mm in length) were prepared from each artery. Any residual endothelium was
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Table 5.2. Causes of death in liver donors and of cirrhosis in recipients undergoing
liver transplantation. Hepatic arteries from these individuals were isolated for studies
ofET-1 -mediated contraction.
Cause ofDeath in Donor No. Cause ofCirrhosis in Recipient No.
Sub-arachnoid Haemorrhage 3 Alcoholic Liver Disease 4
Intra-cerebral Bleeding 2 Primary Biliary Cirrhosis 3
Head Injury 1 Cryptogenic Cirrhosis 1
Intra-cranial Haemorrhage 1 Cirrhosis from Autoimmune Hepatitis 1
Road Traffic Accident 1
Total: 8 Total: 9
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removed and rings were mounted in organ baths for the measurement of isometric
force development. After equilibration of the arterial rings, the viability and
reproducibility of contractions were tested, using (100 mmol/L) KC1 as described
(Chapter 2.2) and then cumulative concentration-response curves were constructed
using KC1 (2.5-120 mmol/L). The rings were washed repeatedly and, after
equilibrating for 30 minutes, three rings were incubated for 40 minutes with an ETa
receptor antagonist, BQ-123, at different concentrations (3xl0"7 mol/L, 10"6 mol/L
and 3xl0"6 mol/L). The fourth ring was not exposed to the antagonist and served as a
control. Following the incubation, cumulative-concentration response curves were
constructed using ET-1 (10"n-3xl0"6 mol/L).
5.4. Statistics
Statistical analysis was performed as described in Chapter 2.7.
5.5. Results
5.5.1. Testfor Endothelium
None of the hepatic arterial rings (6 donor, 6 recipient) tested for endothelial cell
function relaxed in response to ACh. Indeed, ACh produced contractions in both
donor and recipient hepatic arteries, which became more pronounced as the
concentration of ACh was increased (Figure 5.1a,b). In contrast, all of these rings
relaxed in response to SIN-1 (maximum relaxation, 103.21 ± 1.85 % and 106.80 ±
1.93 %, P=0.21; sensitivity (-log IC50), 6.72 ± 0.04. and 6.68 ± 0.02, P=0.78, in
donor and recipient hepatic arteries respectively) (Figure 5.1c), following sub-
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Figure 5.1(c). Test for endothelium-independent vasodilatation. Cumulative
concentration-response curves produced by 3'-morpholinosydnonimine (SIN-1, 10"9-
3x 10"5 mol/L) in recipient (O) and donor (□) hepatic arteries after sub-maximal
contraction with phenylephrine (PE, 10"6-3xl0~5 mol/L). Responses are given as
mean + s.e. mean for (n) individuals, expressed as a percentage of the maximum
contraction to phenylephrine (PE).
126
hepatic arteries, respectively).
Similarly, histological assessment with silver nitrate indicated that none of the donor
hepatic arteries had an intact endothelium, whilst, in a small number of recipient
hepatic arteries, only a tiny patch of endothelial cells was observed (Figure 5.2).
Immunohistochemical staining with the Ulex antibody confirmed that none of the
donor arterial rings had an intact endothelial cell layer, whilst rings from recipient
arteries had only small patches of endothelium (Figure 5.3).
Therefore, in all subsequent experiments the absence of any functional endothelium
was ensured by rubbing the luminal surface of the vessels, as described (Chapter
2.2.1).
5.5.2. Analysis ofAVP and5-HT-MediatedContraction
5.5.2.1. Haemodynamic Profile
The cirrhotic liver recipients had elevated heart rate (100 ± 3 b/min, n=36; normal
range 60-90 b/min) and cardiac output (10.5 ± 0.6 L/min, n=33; normal range 4-8
L/min) with low systemic vascular resistance (699 ± 35 dyne.sec/cm , n=31; normal
range 1200-1500 dyne.sec/cm5). These haemodynamic parameters indicated the
presence of a hyperdynamic circulation.
5.5.2.2. Effect ofCirrhosis on AVP and 5-HT-Mediated Contraction
Endothelium-denuded hepatic arteries from non-cirrhotic donors and cirrhotic
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(a) Recipient Hepatic Artery
(b) Donor Hepatic Artery
Figure 5.2. Photomicrographs of longitudinal sections of (a) recipient and (b) donor
hepatic arteries, stained with silver nitrate. The presence of small residual
endothelium (E) observed in recipient but not in donor and hepatic arteries.
Scale=100pm.
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Figure 5.3. Photomicrographs of immunohistochemical staining using the antibody
to demonstrate the presence of endothelial cells (E) in transverse sections of (a)
recipient and (b) donor hepatic arteries. L, lumen; TI, tunica intima; TM, tunica
media and TA, tunica adventitia. Scale=100jum.
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recipients contracted, in a cumulative, concentration-dependent way, when exposed
to receptor-dependent agonists, AVP and 5-HT, and the receptor-independent
vasoconstrictor, KC1.
The maximum contractile response to AVP in recipient hepatic arteries (Emax, 3.53
± 0.35g, n=22) was significantly smaller (P=0.003) than that produced in donor
hepatic arteries (Emax, 5.73 ± 0.61g, n=23). This difference was also evident
(P=0.0002) when the results were expressed as a percentage of maximum contractile
response to KC1 (Emax, 34.03 ± 3.42% and 60.69 ± 5.56%, respectively) (Figure
5.4.a). However, the sensitivity (pD2) to this agonist was similar (P=0.86) in
recipient (8.21 ± 0.08) and donor (8.16 ± 0.07) hepatic arteries.
In contrast, the maximum contractile response to 5-HT in recipient hepatic arteries
(Emax, 8.60 ± 0.46g, n=25) was greater than the donor hepatic arteries (Emax, 7.12
± 0.58g, n=26), but achieved only threshold significance (P=0.06). However,
significance was achieved (P=0.01) when the results were expressed as a percentage
of maximum contraction to KC1 (Emax, 88.81 ± 5.43% and 71.63 ± 4.55%,
respectively) (Figure 5.4.b). The sensitivity (pD2) of the response to 5-HT was
similar in recipient (6.60 ± 0.08) and donor (6.45 ± 0.08) hepatic arteries (P=0.20).
In spite of altered maximum contractile responses to the receptor-dependent agonists,
AVP and 5-HT, the maximum contractile response to the receptor-independent
vasoconstrictor, KC1, was similar (P=0.81) in recipient (Emax, 10.32 ± 0.70g, n=25)
and in donor (Emax, 10.09 ± 0.71g, n=26) hepatic arteries (Figure 5.4.c). The





Figure 5.4 (a,b). Cumulative concentration-response curves comparing contractile
responses of recipient (cirrhotic, O) and donor (non-cirrhotic, □) hepatic arteries
following exposure to (a) arginine vasopressin (AVP; n-22-23) and (b)
5-hydroxytryptamine (5-HT; n=25-26). Responses are mean + s.e. mean for (n)
individuals and expressed as a percentage of the maximum contraction induced by
KC1. Differences between curves were detected using two-way analysis of variance.
*P < 0.0001 when individual points were compared using the Tukey post-hoc test.
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(C)
Figure 5.4(c). Cumulative concentration-response curves comparing contractile
responses of recipient (cirrhotic, O) with donor (non-cirrhotic, □) hepatic arteries
following exposure to potassium chloride (KC1; n=26). Responses are mean + s.e.
mean for (n) individuals and expressed as a percentage of the maximum contraction
induced by KC1.
5.0 10.0 20.0 40.0 80.0
Potassium Chloride [mM]
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was also not different (P=0.34).
5.5.3. Role ofNitric Oxide Synthase Activity in the Hepatic Arteries
5.5.3.1. Influence ofNitric Oxide Synthase Activity on Contractile Function
Denuded hepatic arteries obtained from cirrhotic recipients (n=9) and non-cirrhotic
donors (n=8), produced cumulative concentration-dependents contraction in response
to AVP, 5-HT and KC1 whether incubated with L-NNA or D-NNA. Neither L-NNA
nor D-NNA had any effect on basal tone in recipient or donor hepatic arteries (Table
5.3). In arteries treated with D-NNA, responses (Emax but not PD2) to AVP were
smaller in recipient than donor, whereas responses (Emax but not PD2) to 5-HT were
larger in the recipient vessels (Table 5.3; Figure 5.5). This is consistent with results
obtained using untreated arteries in the earlier part of this study.
In both recipient and donor hepatic arteries, responses to AVP, 5-HT and KC1 were
also unaffected by exposure to L-NNA producing contraction similar to those
obtained using arteries incubated with the inactive isomer, D-NNA. (Figure 5.5;
Table 5.3). However, the rings, from both group of arteries, following exposure to L-
NNA, relaxed in response to SIN-1 (Emax, 108.13 ± 1.21 % and 105.22 ± 1.84 %,
P=0.19 and -log IC50, 6.67 ± 0.10 and 6.66 ± 0.09, P = 0.92, in recipient and donor
hepatic arteries respectively).
5.5.3.2. Nitric Oxide Synthase Immunoreactivity
Intense immunoreactivity in the rabbit aortic ring indicated the induction of iNOS in
this vessel (positive control) following endotoxaemia (Chapter 2, Figure 2.7). In the
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Table 5.3. Maximum contractile response (Emax) and sensitivity (pD2) to arginine
vasopressin (AVP), 5-hydroxytryptamine (5-HT) and potassium chloride (KC1)
obtained in recipient and donor hepatic arteries following incubation with D-NNA or
L-NNA







AVP 4.21±0.56 41.05+4.48 7.91±0.17













AVP 6.8210.81* 71.5519.26** 8.0710.07
5-HT 6.9010.81 67.0418.06 6.5510.16
6.7510.73 68.8018.78 7.9010.14
7.0510.88 69.4818.32 6.5110.19
KC1 10.7411.10 1.6010.06 10.2110.88 1.5810.07
Values are mean + s.e. mean for (n) subjects. *P<0.01 and **P<0.005, when




























Figure 5.5(a). The effect ofNitric Oxide Synthase (NOS) inhibition on the contractile
responses of recipient (O, n=9) hepatic arteries. Cumulative concentration-response
curves produced by these arteries after incubation with D-NNA (open symbol) and L-
NNA (solid symbol), in response to (i) arginine vasopressin (AVP) and (ii) 5-
hydroxytryptamine (5-HT). Responses are given as mean + s.e.mean for (n)
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Figure 5.5(b). The effect of Nitric Oxide Synthase (NOS) inhibition on the contractile
responses of donor (Q, n=8) hepatic arteries. Cumulative concentration-response
curves produced by these arteries after incubation with D-NNA (open symbol) and L-
NNA (solid symbol), in response to (i) arginine vasopressin (AVP) and (ii) 5-
hydroxytryptamine (5-HT). Responses are given as mean + s.e.mean for (n)
individuals and expressed as a percentage of the maximum contraction induced by
KCl.
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recipient group (Figure 5.6a), only hepatic arterial rings from patients with alcoholic
liver diseases (n=3) had mild staining for iNOS (Figure 5.6a(i)). iNOS was not
detected in arteries from patients with primary biliary cirrhosis (n=3), cirrhosis from
chronic active hepatitis (n=l) or cryptogenic cirrhosis (n=2) (Figure 5.6a(ii, iii or
iv)). None of the arterial rings obtained from the donor hepatic arteries demonstrated
any staining for iNOS (Figure 5.6b).
5.5.4. Identification of the ReceptorsMediating A VP-induced Contraction ofHuman
Hepatic Arteries
5.5.4.1. The Role of V2-receptors
Hepatic arterial rings either from the recipient (n=6) or from the donor (n=6) groups
failed to contract in response to the selective Wreceptor agonist, DDAVP (Figure
5.7a). These arteries did, however, contract in response to AVP (Figure 5.7b) and
KC1 (Figure 5.7c).
As demonstrated previously, the AVP-mediated contraction was smaller in recipient
(Emax, 4.35 ± 0.50g) than in donor hepatic arteries (Emax, 6.75 ± 0.45g; P=0.005),
whereas, the sensitivity of response was unchanged (pD2, 7.97 ± 0.19 and 8.04 ±
0.12, in recipient and donor hepatic arteries respectively; P=0.71). KCl-mediated
responses of recipient (Emax, 10.32 ± 1.13g; pD2, 1.63 ± 0.08) and donor (Emax,
10.16 ± 0.1.23g; pD2, 1.64 ± 0.05) hepatic arteries were similar.
5.5.4.2. The Role of V)-receptors
Incubation of recipient and donor hepatic arterial rings, with a V) -receptor antagonist
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Figure 5.6a. Immunohistochemical identification of inducible nitric oxide synthase
(iNOS) in the vessel wall (VSMCs). Photomicrographs demonstrating
immunoreactivity for iNOS (red colouration) in transverse sections of hepatic
arteries from patient with (i) alcoholic liver disease but not in that from patient with
(ii) primary biliary cirrhosis. L, lumen; TI, tunica intima; TM, tunica media and TA,
tunica adventitia. Scale=100pm.
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(iii) Hepatic Artery from Patient with Cryptogenic Cirrhosis
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Figure 5.6a. Immunohistochemical identification of inducible nitric oxide synthase
(iNOS) in the vessel wall. Photomicrographs demonstrating immunoreactivity for
iNOS (red colouration) in transverse sections of hepatic arteries from patient with (i)
alcoholic liver disease but not in those from patients with (iii) cryptogenic cirrhosis
and (iv) chronic active hepatitis. L, lumen; TI, tunica intima; TM, tunica media and
TA, tunica adventitia. Scale=100pm.
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Figure 5.6b. Immunohistochemical identification of inducible nitric oxide synthase
(iNOS) in the vessel wall (VSMCs). Photomicrograph demonstrating the lack of
immunoreactivity for iNOS in a transverse section of donor hepatic artery. L, lumen;
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d(CH2)5Tyr(Me)AVP, produced a concentration-dependent rightward shift in the
response to AVP with a significant reduction in sensitivity (pD2) (Table 5.4; Figure
5.8). Exposure to the Vi-receptor antagonist had no effect on the maximum
contractile responses to AVP in either recipient or donor hepatic arteries when
compared with their corresponding controls (Table 5.4). The maximum contractile
response and sensitivity to KC1 in recipient and donor hepatic arteries were also
similar following exposure to the Vi-receptor antagonist (Table 5.4).
5.5.5. Effect of Hepatic Cirrhosis on ET-1 -Mediated Contraction of the Hepatic
Arteries
5.5.5.1 Haemodynamic Profile
As with the previous group, recipients with hepatic cirrhosis had elevated heart rate
(119 + 9 b/min, n=9; normal range 60-90 b/min) and cardiac output (9.19 ± 1.02
L/min, n=8; normal range 4-8 L/min), combined with low systemic vascular
resistance (648 ± 68 dyne.sec/cm5, n=8; normal range 1200-1500 dyne.sec/cm5).
5.5.3.2. ET-1-mediated Contraction ofHepatic Arteries
Both recipient and donor hepatic arteries contracted in response to ET-1 (Figure 5.9).
The maximum contraction in recipient arteries, whether expressed in grammes or as
a percentage of maximum contractile response to KC1 was similar to the response
obtained in donor hepatic arteries (Table 5.5). Strikingly, however, the
concentration-response curve produced by ET-1 in recipient hepatic arteries was
shifted to the left, compared with donor hepatic arteries, reflecting a significant
increase in sensitivity.
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Table 5.4. The maximum contractile response (Emax) and sensitivity (pD2) of
responses to arginine vasopressin (AVP) in the absence (control) and presence of the
Vi-receptor antagonist, d(CH2)5Tyr(Me)AVP at a concentration 10"8 mol/L, 10"7
mol/L or 10"6mol/L and to potassium chloride (KC1).
(a) Arginine Vasopressin
Recipient Hepatic Arteries Cn=9-1 T) Donor Hepatic Arteries fn=8-10j
Emax(g) Emax (KC1%) pD2 Emax (g) Emax (KC1%) pD2
Control 4.18±0.59 39.81+5.75 8.03+0.12 6.93+0.77* 70.38+9.87* 8.07 + 0.16
10"8mol/L 3.89+0.73 41.89+7.69 7.25 ±0.14a 6.37+0.60 64.73+8.32 7.27 ± 0.14d
10~7mol/L 4.15+0.88 39.47+8.59 6.56 ± 0.1 lb 6.34+0.78 63.16+9.84 6.71 ±0.12b
10"6mol/L 4.30+0.82 36.47+4.21 6.15 ±0.14c 5.99+0.68 56.22+9.67 6.07 ± 0.10c
(b) Potassium Chloride.
Recipient Hepatic Arteries fn=9-l T) Donor Hepatic Arteries fn=8-10j
Emax(g) pP2 Emaxlgj pD2
Control 11.34+0.92 1.67 + 0.04 11.34+1.52 1.64 + 0.07
Ring-1 10.37+0.87 1.69 + 0.05 11.05+1.44 1.63+0.08
Ring-2 11.42+1.36 1.61 ±0.05 11.33+1.36 1.60 + 0.06
Ring-3 10.93+1.13 1.63 + 0.07 11.88+1.61 1.61 ±0.08
Values are mean ± s.e. mean for (n) subjects. P<0.02, when compared with the
control response of the recipient hepatic arteries, aP<0.0002, V<0.0001 and
VO.OOOOl, when compared with the relevant control, using Student's unpaired
t-test.
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Figure 5.8. The effect of incubation with the Vi-receptor antagonist,
d(CH2)5Tyr(Me)AVP on the contractile response of the hepatic arteries. Cumulative
concentration-response curves produced in response to arginine vasopressin (AVP)
in the absence (control; black, n=10-l 1) and presence ofVi-receptor antagonist (10"8
mol/L, green, n=10-l 1; 10"7mol/L, blue; n=8-10 and 10"6mol/L, red; n=8-9) obtained
in (a) recipient (O) and (b) donor (□) hepatic arteries. Values are mean ± s.e. mean




Figure 5.9a. The effect of cirrhosis on endothelin-1-mediated contraction of human
hepatic arteries. Cumulative concentration-response curves to endothelin-1 were
compared in recipient (cirrhotic, O; n=9) and donor (non-cirrhotic, □; n=8) hepatic
arteries. Values are mean ± s.e. mean for (n) individuals and are expressed as a
percentage of the maximum contraction induced by KC1.
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Table 5.5. The maximum contraction (Emax) and sensitivity (pD2) of the responses
to potassium chloride (KC1) and endothelin-1 (ET-1) in the absence (control) and
presence of the endothelinA (ETA) receptor antagonist, BQ-123 at a concentration of
3xlO"7mol/L, 10"6mol/L or 3xlO"6mol/L.
(a) Response to Potassium Chloride
Recipient Hepatic Arteries (n=9j Donor Hepatic Arteries (n=81
Emax(g) pD2 Emaxfg) pD2
Control 7.68+1.10 1.59+0.05 7.95+1.71 1.63+0.08
Ring-1 8.21+1.35 1.62+0.08 8.16+1.48 1.65+0.10
Ring-2 7.41+0.95 1.63+0.09 9.40+0.98 1.66+0.11
Ring-3 9.81+0.94 1.63+0.08 8.78+1.58 1.64+0.12
(b) Response to Endothelin-1
Recipient Hepatic Arteries Cn=9) Donor Hepatic Arteries (n=81
Emax pD2 Emax pD2
(g) (%KC1) (g) (%KC1)
Control 12.5+1.7 171.2+17.3 7.94+0.08 9.8+1.7 142.3+16.1 7.55+0.09*
3xlO~7mol/L 13.8+1.6 176.4+12.6 7.83+0.14 10.5+1.4 135.4+9.6 7.36+0.07
lxl0~6mol/L 13.5+1.6 186.3+17.8 7.74+0.12 11.8+1.5 146.2+17.9 7.20±0.06a
3xlO"6mol/L 16.1+1.9 162.1+7.7 7.36±0.09b 10.8+1.6 137.8+20.3 6.83+0.15b
Values are mean ± s.e.mean for (n) subjects. *P<0.01 when compared with the
control response of the recipient hepatic arteries, aP<0.01 and bP<0.001, when
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Figure 5.9(b & c). The effect of incubation with the endothelbiA (ETA)-receptor
antagonist, BQ-123 on the contractile response of the hepatic arteries. Cumulative
concentration-response curves produced in response to endothelin-1 (ET-1) in the
absence (control, black) and presence of ETA-receptor antagonist (3x10"7 mol/L,
green; 10"7mol/L, blue and 10"6mol/L, red) obtained in (b) recipient (O, n=9) and
(c) donor (□, n=8) hepatic arteries. Values are mean ± s.e. mean for (n)
individuals and are expressed as a percentage of the maximum contraction
induced by KC1.
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Incubation with the ETA receptor antagonist, BQ-123, produced a concentration-
dependent rightward shift of the contractile-response curve to ET-1 along with a
significant reduction of sensitivity, in both recipient (Figure 5.9b) and donor (Figure
5.9c) hepatic arteries, when compared with their corresponding controls (Table 5.5).
This reduction of sensitivity in donor hepatic arteries was significant at 10"6 mol/L
and 3x10"6 mol/L BQ-123, whilst, in recipient hepatic arteries the reduction only
became significant at the higher concentration (3x10"6 mol/L) (Table 5.5). However,
exposure to the ETA receptor antagonist, BQ-123, had no effect on the ET-1-
mediated maximum contractile responses in either group of arteries (Table 5.5).
In this study, the concentration-response curve to KC1 was constructed before
determination of ET-1-mediated contractile response. As in previous studies, the
magnitude of KCl-mediated contraction and sensitivity of response were similar in
rings from donor and recipient hepatic arteries (Table 5.5).
5.6. Discussion
This study investigated the effect of hepatic cirrhosis on contractile responses of
human hepatic arteries to AVP, 5-HT and ET-1. It demonstrated that, in patients with
hepatic cirrhosis, contractile responses of the hepatic arteries were altered in an
agonist-dependent manner. The mechanisms responsible for these changes were
investigated and it was shown that nitric oxide activity had no role in functional
alterations. Similarly, structural alterations of the arterial wall were not implicated, as
the contraction produced by KC1 was similar in donor and recipient hepatic arteries.
As predicted (Chapter 3), the arteries used in this study did not have a functional
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endothelium, indicating that functional changes are due to abnormalities in the
vascular smooth muscle. The lack of endothelium on these arteries, however, means
that a role for endothelium-mediated changes contributing to the functional
abnormalities in patients with cirrhosis cannot be discounted. One possible
explanation for the altered responses described in this study is selective alteration in
the activity of individual receptor types. Therefore, the receptors that mediate the
contractile responses to AVP and ET-1 were identified pharmacologically. Due to
the complexity of the 5-HT receptor system, the mechanisms of the 5-HT-mediated
contraction were investigated separately (in Chapter 6).
5.6.1. Effect ofCirrhosis on Contractile Function
Impaired pressor response to vasoconstrictors is a consistent finding in patients with
hepatic cirrhosis (Lunzer et al., 1975; MacGilchrist et al., 1991a, b; Newby et al.,
1998a, b). Studies using isolated vessels from the patients with cirrhosis (Ryan et al.,
1996; Smith et al., 1997; Heller et al., 1999), or from animal models of this condition
(Seiber & Groszmann, 1992; Karatapanis et al., 1994; Huang et al., 1995), have also
reported impaired contractile responses. The present study revealed for the first time
in isolated human hepatic arteries that the manifestation of the impaired response in
cirrhotic individuals is not the same for all vasoconstrictors. Strikingly, the
contraction of human hepatic arteries induced by AVP was reduced in the cirrhotic
group, whereas responses to 5-HT and ET-1 were increased. Furthermore, these
results confirmed that alterations were only evident in receptor-mediated
vasoconstriction as responses to KC1 were unchanged. Consistent with these data,
studies with vessels from animal models have also shown that abnormalities in
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function are agonist-dependent, as responses to 5-HT (Cummings et al., 1988; Silva
et al., 1998) and ET-1 (Cahill et al., 1998) have been shown to be significantly
increased whereas responses to adrenoceptor agonists are reduced (Bomzon et al.,
1991; Liao et al., 1994). The increased activity of 5-HT and ET-1 constrictor systems
is also supported by in vivo studies, in which portal pressure was reduced (in patients
or in animal models) using 5-HT2a and a mixed (ETA and ETb) ET-l-receptor
antagonist (ketanserin and bosentan, respectively) (Vorobioff et al., 1989; Sogni et
al., 1998). Therefore, it is evident that the effect of hepatic cirrhosis will vary
depending upon the agonist used to induce contraction.
5.6.2. Validation ofDonor Hepatic Arteries as Control Vessel
The altered contractile response in recipient (cirrhotic) hepatic arteries was detected
in this study while using donor hepatic arteries as controls. The donor hepatic arteries
are routinely exposed to preservative solution (University of Wisconsin solution
[UWS] to which dexamethasone, insulin and penicillin have been added) for a
considerable period of time (up to 14 hours). It is conceivable that exposure to
preservative solution could alter contractile responses in the donor hepatic arteries.
Indeed, preservation in UWS increased contraction to KC1 and U46619 in human
saphenous vein (Anastasious et al., 1997) and augmented hypoxia-induced
contraction in arteries (human intrahepatic and canine coronary arteries) with intact
endothelium (Jeng et al., 1997; Lin et al., 1995). However, the previous study
(Chapter 4), and references in the literature, suggested that exposure to UWS is
unlikely to have altered function in denuded human hepatic arteries. Several studies
have also reported that UWS has no significant effect on the contractile response of
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denuded vessels either from humans (Hadoke et al., 1998; Jeng et al., 1996b, 1997)
or animals (Heller et al., 1999; Lin et al., 1995), even after the inclusion of
dexamethasone, insulin and penicillin (Sorajja et al., 1997; Abebe et al., 1993).
Consequently, donor hepatic arteries have consistently been used as controls by
many investigators, despite previous exposure to preservative solutions (Heller et al.,
1999; Hadoke et al., 1998; Smith et al., 1997). Therefore, use of donor hepatic
arteries as a control in this study appears justified and contractile abnormalities
detected are unlikely to be due to the effects ofUWS in the control.
5.6.3. Mechanism ofAltered Contractile Function
5.6.3.1. Role of vascular remodelling, endothelium-derived and humoral
factors
It has been suggested that altered vascular responses in hepatic cirrhosis may be due
to the increased activity of circulating humoral factors and/or synthesis of vasoactive
substances by the endothelium (Benoit et al., 1984; Atucha et al., 1996). However, in
this study, altered contractile function was detected in vessels without an
endothelium and which were isolated from the effect of humoral factors. This
indicated that the altered contractile responses to AVP, 5-HT and ET-1 must be a
consequence of alterations induced in the VSMCs. Factors, which could contribute to
such alterations, are (a) vascular remodelling, (b) production of vasoactive
substances and (c) altered receptor-mediated contraction in the VSMCs of the arterial
wall. Remodelling of the vessel wall could be an important cause of altered
contractile response in cirrhosis. This is particularly important while investigating the
functional responses of vessels from the splanchnic vascular territory, the sustained
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increase of portal pressure in cirrhosis could lead to alterations in the structure of the
vascular wall. It has been suggested that prolonged alteration of blood pressure such
as chronic hypotension and hypertension can induce medial atrophy and
hyperplasia/hypertrophy, respectively (Pang & Scott, 1985). Moreover, studies in
animal models of portal hypertension have shown that extensive remodelling occurs
in the portal vein and its tributaries (Johansson, 1976). However, in the present study,
the altered contractile responses in recipient hepatic arteries were not the
consequence of vascular remodelling, as the response to KC1 in these arteries was
similar to that of the donor hepatic arteries. Moreover, the contractile response to
AVP was reduced whereas that to 5-HT and ET-1 was increased. If any structural
change had occurred within the vessel wall, it would be expected that contractile
responses of all three vasoconstrictors would be altered in a similar way.
5.6.3.2. Role of iNOS Activation
It has been suggested that increased NO synthesis accounts for the impaired pressor
response and hyperdynamic circulation in cirrhosis. Excessive NO production in
cirrhotic patients is indicated by increased plasma levels of the second messenger of
NO stimulation (cGMP) (Schneider et al., 1994) and metabolites of NO (nitrite and
nitrate) (Guarner et al., 1993) as well as by direct measurement of NO in the
circulation (Battista et al., 1997). Furthermore, it has been shown that inhibition of
NO synthesis can reverse systemic and splanchnic hypotension in cirrhosis (Pizcueta
et al., 1992; Sieber & groszmann, 1992). Similarly, studies with isolated vessels from
animal models of cirrhosis suggested that inhibition ofNO activity could also reverse
hyporesponsiveness to several vasoconstrictors (Pateron et al., 1999; Gadano et al.,
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1997). However, whether increased NO synthesis in cirrhosis is a cause or
consequence of the hyperdynamic circulation is yet not clear. Two major alterations
in the hepatic and splanchnic circulations could lead to increase NO production: (i) a
combination of enhanced back pressure (resulting from intrahepatic obstruction) and
increased blood flow in the splanchnic arteries results in excessive synthesis of NO
by the endothelial cells (via eNOS) (Sogni et al., 1995; Bomzon & Blendis, 1994;
Shah et al., 1998; Battista et al., 1997), and (ii) this increased intrahepatic pressure
also leads to opening of the porto-systemic shunts and thus, allows various gut-
derived substances, including bacterial endotoxins, to enter into the systemic
circulation. These substances, particularly the endotoxins, can increase NO
production via inducing iNOS in the VSMCs (Vallance & Moncada, 1991; Busse &
Mulsch, 1990). However, whether increased NO synthesis in cirrhosis is the result of
over activity of eNOS (Muruganandam & Mutus, 1994; Forrest et al., 1996) or iNOS
(Laffi et al., 1993; Chen & Metha, 1996) remains controversial (Bomzon & Blendis,
1994).
Many of the studies which implicated NO in altered contractile responses have
demonstrated that increased NO activity was mediated by eNOS (Weigert et al.,
1995; Castro et al., 1993; Sogni et al., 1995). However, in the current study, it was
not possible to assess the role of eNOS as the endothelium was denuded from the
hepatic arteries. Investigation of iNOS in VSMCs of these arteries demonstrated that
this isozyme is generally not present in hepatic arteries either from cirrhotic
recipients and non-cirrhotic donors. It was also shown that NO activity did not
modulate the functional responses to AVP or 5-HT. Therefore, it is apparent that
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iNOS activity does not contribute to the contractile abnormalities determined in the
present study. In contrast, with the present data, a small number of studies has
suggested that iNOS in the VSMCs could have a role in increased NO production in
cirrhosis (Vallance & Moncada, 1991; Smith et al., 1997; Ryan et al., 1996). The
apparent similarity between the vascular abnormalities in endotoxic shock and
cirrhosis suggested the responsibility of a common factor such as over activity of
iNOS in the VSMCs induced by endotoxin (Vallance & Moncada, 1991; Lumsden et
al., 1988). However, exposure of human vessels to endotoxin in vivo (dorsal hand
vein) (Bhagat & Vallance, 1996) or in vitro (internal mammary artery and saphenous
vein) (Thorin-Trescases et al., 1995), fails to activate iNOS. Similarly, studies
indicating the existence of iNOS in recipient hepatic arteries (Smith et al., 1997) or
in forearm vessels (Ryan et al., 1996), from patients with cirrhosis, have not been
supported by other studies (Hadoke et al., 1998; Shah et al., 1998; Heller et al.,
1999).
An unexpected finding in the current study was the immunoreactivity to iNOS in
hepatic arteries from patients with alcoholic liver disease (ALD), although inhibition
with L-NNA did not produce enhanced contractile responsiveness. This indicated
that iNOS has no impact on contractile function. This is consistent with a previous
study, where iNOS mRNA was detected in donor hepatic arteries but had no effect
on functional responses (Smith et al., 1997). Furthermore, the hyporesponsiveness
demonstrated in the current study was specific to AVP, whereas responses to 5-HT
and ET-1 were enhanced. Over activity of iNOS, would be expected to effect all
three agonists in a similar way and many also inhibit receptor-independent (KC1)
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vasoconstriction (Sieber & Groszmann, 1992). Therefore, it is most unlikely that
iNOS activation accounts for altered vascular functions in this study. However, the
existence of iNOS only in arteries from patients with ALD has important
implications for future research as it suggested that the mechanisms responsible for
vascular hyporesponsiveness are dependent upon the aetiology of cirrhosis. This
aetiological variation may explain the difference between the present results and the
previous studies which have used a higher proportion of subjects with ALD (Ryan et
al., 1996). In particular, the influence of aetiology may also explain the detection of
iNOS mRNA in the previous study using hepatic arteries from patients with viral
hepatitis (Smith et al., 1997).
5.6.4. Effect ofCirrhosis on Contractile Function
5.6.4.1. Effect of Cirrhosis on AVP-Mediated Contraction
In cirrhotic patients, AVP and its analogues can reduce portal pressure by decreasing
splanchnic blood flow and are used in the treatment of acute variceal haemorrhage
(Westaby et al., 1988; Freeman et al., 1998). These agents can also constrict
splanchnic vessels (in patients with cirrhosis or in animal models) and, thus, reduce
gastric and mesenteric hyperaemia (Panes et al., 1994; Heinemann et al., 1998).
Therefore, the reduced responses to AVP demonstrated in this study could be
important in the pathogenesis and treatment of the vascular abnormalities in
cirrhosis. Unfortunately, no studies have investigated contractile responses to AVP
(or its analogues) using splanchnic arteries from patients with this condition. Only a
few studies are available in animal models and these represent conflicting results.
Hyporesponsiveness to AVP has been reported in mesenteric (Sieber & Groszmann,
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1992) and tail (Huang et al., 1995) arteries from portal vein ligated rats. In contrast,
another study, using carbon tetrachloride-induced cirrhotic rats, reported unaltered
AVP-mediated response in the mesenteric arterial bed (Ralevic et al., 1996), whilst
an increased response to AVP has been reported in mesenteric veins from portal vein
ligated rats (Cummings et al., 1986; Moreno et al., 1996). These results, therefore,
reflect the heterogeneity of AVP-mediated contraction depending on the animal
model and vascular territory used. Although one study suggested that excessive NO
production was responsible for this impaired response (Sieber & Groszmann, 1992),
most others did not agree with this mechanism (Heinemann et al., 1998; Huang et
al., 1995). Similarly, the current study also demonstrated that NO was not
responsible for reduced AVP-mediated contraction. The actual mechanism of
impaired AVP-mediated response remains uncertain but could be the result of
abnormalities either in the vasoconstrictor AVP-receptor or at a post receptor level in
the VSMCs. It was, therefore, necessary to identify the receptor mediating AVP-
induced contraction in human hepatic arteries.
As discussed previously (Chapter 3) it was likely that AVP-mediated
vasoconstriction occurred via the Vi receptor located in the VSMCs (Thibonnier,
1992). The V2 receptor was not expected to have a significant role as it is found
primarily in the endothelium and mediates vasodilatation (Tagawa et al., 1995; Aki
et al., 1994). The failure of the selective V2 receptor-agonist (DDAVP) to contract
human hepatic arteries confirmed that the V2 receptor did not contribute to AVP-
mediated contraction of these vessels. The rightward shift in the AVP-mediated
contraction in the presence of the selective Vi receptor antagonist confirmed that, as
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in human renal (Medina et al., 1996) and gastric (Calo et al., 1997) arteries, this was
a V) receptor-mediated response. Therefore, the attenuated response to AVP in
arteries from cirrhotic patients is probably due to a defect in the V) receptor-
mediated contractile pathway. Whether this is due to receptor down regulation and/or
a defect in the post receptor signal transduction mechanism has yet to be established.
There is considerable evidence of changes in the AVP system in patients with hepatic
cirrhosis, which could result in receptor down-regulation. However, the evidence for
receptor down-regulation in hepatic cirrhosis is sparse and often contradictory
(Gerbes et al., 1986; Liao et al., 1994) and the activity of Vi receptors has not been
studied in cirrhotic patients. Plasma levels of AVP are not always elevated in
cirrhosis (and are more dependent upon the function of the kidney than on the liver
(Arroyo et al., 1988)), but persistently high plasma levels of AVP are generally
reported in advanced cirrhosis (as non-osmotic stimulation significantly enhances
AVP release (Martin & Schrier, 1997)). It is known that repeated or constant
exposure to AVP can reduce the response mediated by the V] receptor, as it becomes
desensitised following receptor occupancy, resulting in a reduction of either specific
binding sites or of inositol phosphate production (Thibonnier 1992; Caramelo et al.,
1989). In the present study, arteries are used from cirrhotic recipients with advanced
liver disease. Presumably, elevated plasma levels of AVP could result in receptor
down-regulation or desensitisation and, consequently, impaired AVP-mediated
contraction. However, the plasma levels of AVP and expression of Vi-receptor in
these vessels have not been assessed. Therefore, ligand binding studies and
investigation of second messenger response of Vi-receptor-mediated contractile
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pathway are required to identify the site of impaired AVP-mediated contraction.
5.6.4.2. Effect ofCirrhosis on 5-HT-Mediated Contraction
The increased response to 5-HT seen in recipient hepatic arteries in this study is
consistent with many other investigations using vessels from animal models of
cirrhosis/portal hypertension (Cummings et al., 1986; Nevens et al., 1991; Kaumann
et al., 1988). Only one study presents a conflicting picture, showing reduced
responsiveness to 5-HT in vessels from rat models (Jacob et al., 1991). However, the
mechanism responsible for altered 5-HT-mediated contraction (whether increased or
impaired) has not been identified. 5-HT can activate several distinct 5-HT receptor
sub-types of which 5-HT2A and 5-HTi-like receptors mediate contraction of VSMCs
(Hoyer et al., 1994; Martin & Humphrey, 1994; Yildiz et al., 1996). The enhanced
response to 5-HT in cirrhosis could conceivably be the result of up-regulation of
vasoconstrictor 5-HT-receptors, as in cirrhosis the plasma levels of 5-HT may be
reduced (Beaudry et al., 1994). Studies using mesenteric or portal veins from portal
hypertensive rats, however, find no evidence of receptor up-regulation with the
affinity of 5-HT2A receptor antagonists unaltered (Cummings et al., 1986; Kaumann
et al., 1988). This suggested that alterations of receptors other than the 5-HT2a
subtype, possibly 5-HTi-like receptors, may be involved. The complexity of the 5-
HT-mediated response (namely the existence of 'silent' receptors, a possible role for
several 5-HT receptor subtypes and the need to precontract the vessels), necessitated
a detailed investigation to determine the receptor subtype responsible. This study is
described in a separate chapter (Chapter 6).
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5.6.4.3. Effect of Cirrhosis on ET-l-Mediated Contraction
The current study indicated that the sensitivity of the response to ET-1 was increased
in hepatic arteries from patients with cirrhosis. Similar results have been reported in
studies using portal veins from cirrhotic rats (Petrowsky et al., 1999) or mesenteric
arteries and thoracic aortae from portal vein ligated rats (Cahill et al., 1998). Several
studies in vivo with animal models (CCI4 induced, portal vein or bile duct ligated
rats) also suggested enhanced activity of ET-1 as ET-1-receptors antagonist reduced
portal pressure (Gandhi et al., 1998; Reichen et al., 1998; Sogni et al., 1998).
Although, the mechanism of enhanced response to ET-1 in cirrhosis is uncertain.
However, it was suggested that in vivo persistent vasodilatation induced by NO in
this condition could enhance activity of ET-1 (Cahill et al., 1996, 1998) by
increasing expression ofET-1 receptors (ETA and ETB) in intra (Rockey et al., 1998;
Leivas et al., 1998) and extra (Cahill et al., 1998)-hepatic circulations. The ET-1
receptor expression has not been determined in the current study but it is likely that
cirrhosis enhanced their expression in hepatic arteries as it did in aortae and superior
mesenteric arteries from cirrhotic rats. The enhanced response had been contrasted
by studies where in vivo impaired pressor responses to ET-1 were observed in
forearm blood vessels of well-compensated cirrhotic patients (Helmy et al., 2001) or
in arterial pressure of bile duct ligated cirrhotic rats (Hartleb et al., 1994b). The
mechanism of impaired response was not explained, indeed both studies indicated
that increased NO production was the most likely contributing factor which
interacted ET-1 activity. Moreover, increased plasma levels of ET-1 in cirrhosis
(Asbert et al., 1993 Kitano et al., 1996; Trevisani et al., 1997), could conceivably
lead to down-regulation of ET-1 receptors (Rubanyi & Polokoff, 1994) and thus
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reduced ET-1-mediated response. However, in a previous study (Helmy et al., 2001),
plasma ET-1 levels were not elevated. Many studies have also reported unchanged
(Battaglia et al., 1996) or even decreased plasma levels of ET-1 (Veglio et al., 1992)
in cirrhosis. Furthermore, the plasma levels of ET-1 could not reflect the actual
vasoactive function as this peptide can modulate the contractility of the vessels by its
direct autocrine and paracrine actions. Therefore, the role of the plasma levels ofET-
1 in the altered response remains uncertain.
ET-1 acts via two distinct receptors; ETa and ETB. The ETA-receptor is located on
the VSMCs and mediates vasoconstriction, whereas the ETB receptor is
predominantly located on the endothelial cells and induces NO and prostacyclin
release (Gray & Webb, 1996). The ETB receptor is also present in VSMCs where it
mediates vasoconstriction (Touyz et al., 1995). ET-1 exhibits higher affinity for ETA
than the ETB receptor (Gerbes et al., 1995) and depending on vascular area the ratio
of these receptors could vary (Davenport & Maguire, 1994). Therefore, in the current
study an initial attempted was made to identify the ET-1 receptors in the VSMCs of
human hepatic arteries. This study demonstrated that vasoconstrictor ETA-receptors
on the VSMCs of these arteries, mediated ET-1-induced contraction. However, it
was noticeable that in the recipient hepatic arteries, a (5 fold) higher concentration of
BQ-123, (a selective ETA-receptor antagonist) was required to produce a response
equivalent to that in the donor hepatic arteries. This suggests that the activity of ETA-
receptor in the recipient hepatic arteries may be up-regulated, and this could account
for the enhanced ET-1-mediated contraction in cirrhosis. However, in this study, the
contribution of ETB-receptors in mediating ET-1-induced contraction in these vessels
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has not been investigated. Further studies therefore, are required to determine the
contribution of ETb receptors in ET-1-induced contraction of the human hepatic
arteries.
5.7. Conclusions
This study indicated that, in patients with hepatic cirrhosis, contraction of hepatic
arteries was altered in an agonist-dependent manner. Nitric oxide generation and
structural remodelling of the arterial wall were shown not to account for these
alterations. This study therefore suggested that these alterations in contractile
function were the result of changes at the receptor level (up-or down-regulation),
and/or in the post-receptor signal transduction pathways.
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CHAPTER SIX
RECEPTORS RESPONSIBLE FOR THE 5-HYDROXYTRYPTAMINE-
MEDIATED CONTRACTION OF HUMAN HEPATIC ARTERIES AND THE
INFLUENCE OF LIVER CIRRHOSIS
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6.1. Introduction
5-Hydroxytryptamine (5-HT) can modulate splanchnic blood flow (Shah el a/., 1998)
and has been considered as a possible mediator in the pathophysiology of portal
hypertension (Fernandez el al., 1993). The enhanced 5-HT-mediated contraction
demonstrated in hepatic arteries from patients with cirrhosis (Chapter 5) was
consistent with studies using splanchnic vessels from animal models of portal
hypertension and/ or cirrhosis (Cummings el a/., 1986; Kaumann el a/., 1988;
Nevens el al., 1991). This abnormal contractile response may contribute to the
pathogenesis of vascular complications in portal hypertension and, thus, is a potential
target for therapeutic intervention. It is possible that an alteration in 5-HT-receptor
activity accounts for the enhanced contraction in cirrhotic individuals but this has yet
to be confirmed.
Classically, 5-HT-mediated vasoconstriction occurs via stimulation of the 5-HT2A
receptor (Martin & Humphrey, 1994) but there is increasing evidence that 5-HTi-like
receptors also mediate vascular contraction (Yildiz el al., 1998; Ishida el a/., 1999).
Previously (Chapter 3) it was demonstrated that 5-HT2A and another, unidentified,
5-HT receptor, (possibly the 5-HTi-like receptor subtype) contributed to 5-HT-
mediated vasoconstriction in porcine hepatic arteries. Many studies have indicated
that the contribution of 5-HTi-like receptors varies between different vessels and, in
many cases, partial pre-contraction was necessary to observe contractile response
mediated by these receptors (Choppin & O'Connor, 1994. 1995; Yildiz el al., 1998).
Furthermore, some investigations have demonstrated that the influence of 5-HTj-like
receptors is more significant in arteries isolated from individuals with cardiovascular
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disease (e.g. angina) (Mcfadden et al., 1992). The receptors responsible for
mediating contraction of the human hepatic artery in response to 5-HT, and the effect
of cirrhosis on these receptors, have not been identified.
6.2. Aim
This study aimed to determine (i) the contribution of 5-HT2a and 5-HTi-like
receptors towards the contractile response of 5-HT in human hepatic arteries and (ii)
the effect of cirrhosis on the responses mediated by these receptors.
6.3. Methods
6.3.1. Acquisition ofHepatic Arteries
Hepatic arteries were obtained from 16 non-cirrhotic liver donors (11 female, 5 male)
and 15 cirrhotic recipients (9 female, 6 male). The donors (46 ± 4 yrs.) and recipients
(49 ± 3 yrs.) were similar in age (P = 0.47). Causes of death in donors and cirrhosis
in recipients are given in Table 1. The mean duration of liver disease in recipients
was 7.4 ± 1.0 yrs. In recipients, systemic haemodynamic values were obtained from
anaesthetic notes, which were recorded before the transplantation procedure. The
Lothian Research Ethics Committee approved the use of human tissues.
6.3.2. Functional Studies
After removing the adherent connective tissue, eight to sixteen rings (2mm in length)
were taken from each artery. Following confirmation that the vessels had no
endothelium (Chapter 2.2), the rings were mounted in organ baths containing KHS
for the measurement of isometric force development (Chapter 2.2.3).
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Table 6.1. Causes of death in liver donors and of cirrhosis in recipients undergoing
liver transplantation. Hepatic arteries from these individuals were isolated for
analysis of 5-HT-mediated contraction.
Cause ofDeath in Donor No. Cause of Cirrhosis in Recipient No.
Sub-arachnoid Haemorrhage 6 Primary Biliary Cirrhosis 6
lntra-cerebral Bleeding 4 Primary Sclerosing Cholangitis 3
Head Injury 2 Alcoholic Liver Disease 2
Road Traffic Accident 2 Cryptogenic Cirrhosis 2
Brain Stem Injury 1 Cirrhosis in Autoimmune Hepatitis 1
Cerebral Contution 1 Cirrhosis in Wilson's Disease 1
Total: 16 Total: 15
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For all experiments, prazosin (ai-antagonist, 10"6 mol/L) and yohimbine (a.2-
antagonist, 10"6 mol/L) were included in the KHS to eliminate the contribution of a-
adrenergic receptor stimulation. Similarly, indomethacin (KT5 mol/L) was also
included in the KHS to inhibit endogenous production of prostaglandins. The
viability and reproducibility of the contractile response of each ring were assessed
using KC1 (100 mmol/L) as described (Chapter 2.2.3).
6.3.3. Functional Protocol
Four rings from each artery were suspended in parallel in separate organ baths. Two
rings were partially pre-contracted with KC1 (20-35 mmol/L) to produce 25-30% of
the maximal response to KC1, but the two remaining rings were not pre-contracted.
One pre-contracted and another non-precontracted rings were incubated, either with
the 5-HT2A receptor antagonist, ketanserin (10~6 mol/L), for 40 minutes or with the
5-HTi-like receptor antagonist, methiothepin (10"7mol/L) for 30 minutes. The two
remaining rings were exposed to vehicle and acted as controls. Following incubation,
cumulative concentration-response curves were constructed using either 5-HT (10"9-
3xl0"5 mol/L) or 5-carboxamidotryptamine (5-CT, 10"9-3xl0"5 mol/L, a relatively
selective 5-HTi-like receptor agonist). Thereafter, the agonist and antagonist were
washed out of the rings using KHS, and cumulative concentration-response curves
were produced using KC1 (2.5-120 mmol/L).
6.4. Statistics




The presence of a hyperdynamic circulatory state in the liver recipients was
demonstrated by elevated heart rate (105 ± 5 b/min, n=15; normal range 60-90
b/min) and cardiac output 9.78 ± 0.62 L/min, n=14; normal range 4-8 L/min),
associated with low systemic vascular resistance (638 ± 59 dyne.sec/cm^, n=14;
normal range 1200-1500 dyn.sec/cm^).
6.5.2. Contraction ofHepatic Arteries
The vasoconstrictors 5-HT, 5-CT and KC1 caused concentration-dependent
contraction of all arterial rings used in this study.
6.6.2.1. Contractile Response ofNon-Contracted and Partially-Pre-contracted
Rings
The maximum contractile response (Emax) to 5-HT was significantly larger (P=0.03)
in recipient (8.92 ± 0.65g), than in donor (7.13 ± 0.61g) hepatic arteries (as reported
in Chapter 5). The contractile response to 5-CT was identical to that produced with
5-HT, as the maximum contraction (Emax) in recipient hepatic arteries (8.61 ±
0.44g) was significantly greater (P=0.04) than that produced in arteries from liver
donor (6.96 ± 0.62g). These differences were still evident (Figure 6.1) when the
contractile responses were expressed as a percentage of maximum response to KC1
(Table 6.2). In the recipient hepatic arteries there was a tendency towards an
increased sensitivity of response to both 5-HT and 5-CT (Figure 6.1), but this
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FIGURE 6.1. The effect of cirrhosis on the contractile responses induced by
5-hydroxytryptamine (5-HT; □, O; n=14-16) and 5-carboxyamidotryptamine (5-CT;
A, V; n=14-16). Cumulative concentration-response curves were produced in
recipient (Oand V) and donor (□ and A) hepatic arteries using 5-HT and 5-CT in (a)
non-contracted (open symbols) and (b) partially-precontracted (closed symbols)
arterial rings. Each point represents mean ± s.e. mean, expressed as a percentage of
the maximum contraction induced by KC1.
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Strikingly the sensitivities of responses to both 5-HT and 5-CT were enhanced in
both recipient and donor hepatic arteries following partial precontration (Table 6.2).
The difference between maximum contraction in recipient hepatic arteries to 5-HT
(8.29 ± 0.52g) and 5-CT (8.31 ± 0.41g), when compared with responses in donor
hepatic arteries (7.74 ± 0.61g and 7.15 ± 0.63g, respectively) was abolished.
Although there was a trend towards enhanced maximum contraction these
differences did not achieve significance (P=0.49 and P=0.14, respectively), even
when expressed as a percentage of the maximum response to KC1 (P=0.13 and
P=0.11, respectively) (Table 6.2).
6.5.2.2. Effect of 5-HT Receptor Antagonists on the Contractile Response of
Non-Contracted Rings
The 5-HTi-like receptor antagonist, methiothepin, caused a rightward shift in the
concentration-response curves to both 5-HT (Figure 6.2) and 5-CT (Figure 6.3) in
non-precontracted rings of donor or recipient hepatic artery. There was a
corresponding reduction in the sensitivity of these responses but the amplitude of
contraction (Emax) was unchanged (Table 6.3). In contrast, the 5-HT2A-receptor
antagonist, ketanserin had no effect on the response to 5-CT (Figure 6.3) in donor or
recipient hepatic arteries. Ketanserin produced a rightward shift in responses to 5-HT
(Figure 6.2); this achieved significance in the donor (P=0.04), but failed to achieve
significance (JP=0.11) in the recipient hepatic arteries (Table 6.3).
170
5-Hydroxytryptamine [-LogM]
FIGURE 6.2. The effect of 5-HT-receptor antagonism on contractile responses
to 5-HT in (a) recipient (O) and (b) donor (□) hepatic arteries. Cumulative
concentration-response curves were produced in non-contracted arterial rings in
the absence of antagonists (O, □; n=15) and following incubation with either
10"7 mol/L methiothepin (O, □, n=l 1-12) or 10"6 mol/L ketanserin (O, □; n=9-
11). Each point represents mean ± s.e. mean expressed as a percentage of the
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FIGURE 6.3. The effect of 5-HT-receptor antagonism on contractile responses to
5-carboxyamidotryptamine (5-CT) in (a) recipient (V) and (b) donor (A) hepatic
arteries. Cumulative concentration-response curves were produced in non-pre-
contracted arterial rings in the absence of antagonists (A, V; n=15) and following
incubation with either 10"7 mol/L methiothepin (A, V; n=ll-12) or 10"6 mol/L
ketanserin (A, V; n=9-ll). Each point represents mean ± s.e. mean expressed as a
percentage of the maximum contraction induced by KC1.
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6.5.2.3. Effect of 5-HT Receptor Antagonists on the Functional Response of
Partially Pre-Contracted Rings.
In partially precontracted rings from both donor and recipient hepatic arteries,
methiothepin caused a rightward shift in responses to 5-HT (Figure 6.4) and 5-CT
(Figure 6.5) similar to that produced in non-precontracted arteries (Table 6.3). In
contrast, ketanserin had no effect on responses to either 5-HT (Figure 6.4) or 5-CT
(Figure 6.5) following partial pre-contraction (Table 6.3).
6.5.2.4. Potassium Chloride (KCl)-Mediated Contraction
The contractile response produced by KC1 was similar in arteries following exposure
to either 5-HT or 5-CT. Responses to KC1 were also unaltered in rings which had
been partially precontracted or incubated with antagonists (methiothepin and
ketanserin) before exposure to 5-HT or 5-CT (Table 6.4).
6.6. Discussion
This study assessed the contributions of 5-HT2a and 5-HTi-like receptor subtypes to
5-HT-mediated contraction of the human hepatic artery. The use of arteries from
patients with hepatic cirrhosis also allowed an assessment of whether the presence of
disease altered the contribution made by these receptors in hepatic arteries. It was
shown that, as in the adult pig (Chapter 3), both 5-HT]-like and 5-HT2a receptors
mediate the contractile response to 5-HT in the human hepatic artery. However,
selective stimulation of the 5-HT]-like-receptor also produced a greater contraction
in recipient, compared with donor, hepatic arteries. This indicates that functional
changes in cirrhosis are not solely due to changes in the 5-HT2a receptor sub-type.
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FIGURE 6.4. The effect of 5-HT-receptor antagonists on the contractile responses
of (a) recipient (O) and (b) donor (□) hepatic arteries to 5-hydroxytiyptamine
(5-HT). Cumulative concentration-response curves were produced in partially-
precontracted arterial rings in the absence of antagonists (0,Q; n=15-16) and
following incubation with either 10"7 mol/L methiothepin (0,Q; n=Tl-12) or 10"6
mol/L ketanserin (0,0; n=9-l 1). Each point represents mean ± s.e. mean expressed
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FIGURE 6.5. The effect of 5-HT-receptor antagonism on contractile responses to
5-carboxyamidotryptamine (5-CT) in (a) recipient (▼) and (b) donor (A) hepatic
arteries. Cumulative concentration-response curves were produced in partially-
precontracted arterial rings in the absence of antagonist (A, T; n=15-16) and
7 ft
following incubation with either 10" mol/L methiothepin (▲, T; n=l 1-12) or 10"
mol/L ketanserin (A, ▼; n=9-ll). Each point represents mean ± s.e. mean
expressed as a percentage of themaximum contraction induced by KC1.
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Furthermore, there was an indication that the contribution of the 5-HT2a receptor was
diminished in arteries from patients with cirrhosis. This is reflected by the
demonstration that the 5-HT2a receptor antagonist, ketanserin, failed to produce a
significant inhibition of 5-HT-mediated contraction in the recipient hepatic artery.
6.6.1. Contribution of5-HTu Receptor to 5-HT-MediatecL Contraction in Cirrhosis
As discussed previously (Chapter 5), several studies have reported enhanced 5-HT-
mediated contraction in animals with portal hypertension and/or cirrhosis (Mastai et
a/., 1990; Fernandez et al., 1993; Nevens et al., 1991; Kaumann et al., 1988;
Cummings et al., 1986). No previous studies have assessed 5-HT-mediated
contraction in vessels isolated from patients with this condition but enhanced 5-HT-
mediated contraction has been demonstrated in the systemic and splanchnic
circulations (Vorobioff et al., 1989; Hadengue et al., 1987). The use of 5-HT2A
receptor antagonists in these patients significantly reduced portal pressure. These
studies have also suggested that the increased responsiveness to 5-HT occurs
primarily in the splanchnic, intrahepatic and portocollateral circulations (Fernandez
et al., 1993; Shah et al., 1998; Mosca et al., 1992). This is consistent with the
enhanced responsiveness to 5-HT in hepatic arteries from cirrhotic patients
demonstrated in the present study. Therefore, investigation of the mechanisms of
5-HT-mediated contraction in these arteries could provide information relevant to
both the pathogenesis of this condition and the development of therapeutic
interventions.
The underlying mechanisms of enhanced response to 5-HT in cirrhosis in vitro and in
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vivo remain unclear. Although 5-HT2A-receptor antagonists (ketanserin, ritanserin,
ICI 169369) reduce portal pressure (Cummings et al., 1986; Fernandez el al., 1993;
Kaumann et al., 1988), it has not been established that this is the result of action
upon the 5-HT2A-receptor. In addition to blocking 5-HT2A-receptors, these
antagonists can also block responses mediated by a-adrenoceptors in the systemic
and splanchnic circulations (Yildiz et al., 1998; Xu et al., 1990). In portal
hypertensive subjects, 5-HT2A-receptor antagonists reduced systemic vascular
resistance, heart rate and cardiac output which consequently decreased portal venous
inflow and reduced portal pressure (Vorobioff et al., 1989; Hadengue et al., 1987).
This portal pressure reduction could be a combined effect due to 5-HT2A and a-
adrenoceptor inhibition (Kaumann et al., 1988). It has been suggested that ritanserin
may slightly reduce resistance in both the porto-collateral and porto-hepatic
circulation (Fernandez et at., 1993; Mastai et al., 1990). Small reductions of
resistance in these territories may combine to produce a significant reduction in
portal pressure (Fernandez et al., 1993). The data obtained using antagonists have
suggested that portal hypertension is due, in part, to over activity in the 5-HT system.
This could be due to increased availability of 5-HT or up-regulation of 5-HT
receptors. However, there was evidence that 5-HT2A receptor affinity was not
enhanced in vessels from portal hypertensive animals (Cummings et al., 1986;
Kaumann et al., 1988). Therefore, it seems likely that 5-HT2A receptors are not the
key mediator of the enhanced responses to 5-HT in cirrhosis. This suggests a role for
other 5-HT receptor sub-types, which would be consistent with the demonstration of
both 5-HT2A and 5-HT,-like receptors in the human hepatic artery.
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6.6.2. Contribution of the 5-HT\-like Receptor to 5-HT-Mediated Contraction in
Cirrhosis
The current study extended observations obtained in porcine hepatic arteries
(Chapter 3) to show that 5-HT2A receptor-independent responses to 5-HT are
mediated by the 5-HTi-like receptor sub-type in human hepatic arteries. This was
achieved using two approaches: (i) use of a 5-HTi-like receptor agonist, 5-CT, and
(ii) partial pre-contraction of the arteries with KC1. It was shown in donor hepatic
arteries that both 5-HT2a and 5-HTi-like receptors mediated the response induced by
5-HT, whilst in the recipient this effect was predominantly mediated by the 5-HTi-
like receptor. This is demonstrated by the fact that both methiothepin and ketanserin
significantly antagonised 5-HT-mediated responses in donor hepatic arteries but
ketanserin failed to produce a significant effect in arteries from liver recipients. As
with porcine hepatic arteries (Chapter 5), partial pre-contraction augmented the
response to 5-HT and also to 5-CT in these arteries. A trend towards an increased
response in recipient hepatic arteries was still evident but the significance of this
difference was lost. The ability of methiothepin, but not ketanserin, to antagonise
5-HT-medediated contractions in partially pre-contracted arteries indicated that these
responses were mediated by the 5-HTi-like receptor (Saxena et al., 1998; Bradley et
al., 1986). This confirms that partial pre-contraction inhibits the 5-HT2A receptor
contribution to 5-HT-mediated contractions in these vessels. These results therefore
indicated that, in cirrhosis the 5-HTi-like receptor has a key role in mediating 5-HT-
induced contraction in the hepatic arteries.
In the vasculature, the 5-HTi-like receptor is widely distributed and, depending on
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species and vascular territory, can exist in functional or non-functional states (Martin
& Humphrey, 1994; Choppin & O'Connor, 1995; Gerhardt & VanHeerikhuizen,
1997). The existence of a functional 5-HTi-like receptor has also been reported in
human pulmonary (MacLean et al., 1996), internal mammary (Yildiz et al., 1996)
and coronary (Cocks et al., 1993) arteries. However, many recent studies have
indicated that the distribution of 5-HTi-like receptors is more extensive than was
anticipated (Hoyer et al., 1994; Yildiz et al., 1996; Gerhardt & VanHeerikhuizen,
1997). Their existence has also been suggested in arterio-venous anastomoses,
collateral vessels and even in the hepatic stellate cells (Martin & Humphrey, 1994;
Mosca et al., 1992; Shah et al., 1998). Additionally, the presence of disease can alter
the expression of the 5-HTi-like receptor. This is shown by the demonstration that
the activity of this receptor is increased in the epicardial coronary artery of patients
with angina (Jansen et al., 1993) or in intra-hepatic and portocollateral vessels in
portal hypertension (Mosca et al., 1992; Shah et al., 1998). Furthermore, the 5-HTi-
like receptor is more predominant in the distal vessels of a circulation, such as in the
venular part of the splanchnic vascular territory (Mosca et al., 1992; Blackshear et
al., 1985). Consequently, 5-HTi-like receptors could be important in increasing
resistance of the mesenteric, porto-collateral and intrahepatic circulations resulting in
the development of abnormal vascular conditions associated with hepatic cirrhosis.
6.6.3. Mechanisms ofEnhanced Response to 5-HT in Cirrhosis
The results of this study indicated that over activity of 5-HTi-like receptors in
cirrhosis could be responsible for the enhanced 5-HT-mediated response in hepatic
arteries from cirrhotic patients. However, the absence of any studies addressing the
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activity of 5-HTi-like receptors in these arteries either in patients with cirrhosis or in
animal models has greatly restricted knowledge about the mechanisms of enhanced
response. This study however, indicated that partial pre-contraction could induce
alterations in the 5-HTi-like receptor-mediated contractile pathway, resulting in
amplified 5-HT-mediated contraction. It is possible that changes in patients with
hepatic cirrhosis mimic the effect of partial precontraction. For instance, the
homeostatic environment could be altered as a result of metabolic and circulatory
change (Hayes et al., 1992). Alternatively, the increased intrahepatic resistance and
splanchnic blood flow enhanced pressure in the portal venous territory, which could
cause depolarisation of the vessels in this system. These metabolic and mechanical
changes could activate, or amplify the activity of 5-HTi-like receptors. Activation or
amplification of 5-HTi-like receptors by a variety of neuro-humoral agents
(angiotensin II, histamine, a-adrenoceptor agonists, prostaglandin F2a) has also been
reported in several studies (Yildiz et al., 1998; Delalande, 1992). However, the
precise mechanism of amplification of 5-HTi-like receptor-mediated vascular
contraction is as yet unknown.
As described (Chapter 3) partial pre-contraction can activate silent 5-HTi-like
receptor but the mechanism of enhancing activity of 5-HTi-like or blunting the
response to 5-HT2A receptors following such precontraction is uncertain. Apart from
initial sub-threshold increase of intracellular calcium levels, another potential
mechanism is that the allosteric modulation of the receptors by pre-contraction,
which can alter activity of the 5-HT2A and 5-HTi-like receptors (Yildiz et al., 1998;
Purdy et al., 1993; Kaumann & Frenken, 1985). Existence of such allosteric
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modulating mechanism in the vascular 5-HT2a receptor has been described where
normal activity of 5-HT2A receptor in rabbit aorta is reduced by the allosteric
inhibition (Purdy et al., 1993). Therefore, in the present study, allosteric modulation
could be responsible for blunting the activity of 5-HT2A receptor in partially
precontracted hepatic arteries. Alternatively, the allosteric mechanism can also
modulate the receptor from a low to a high activity state (Purdy et al., 1993) and can
activate silent 5-HTi-like receptor (Xu et al., 1990; Purdy et al., 1993). It can
therefore, be suggested that this could be a mechanism, which modulated 5-HTi-like
receptors in human hepatic arteries following partial precontraction and
consequently, enhanced 5-HT-mediated contraction. Therefore, in cirrhosis, altered
plasma levels of 5-HT (described in Chapter 5) as well as alteration in the humoral
environment could induce changes within the 5-HTi-like receptor and/or in the post-
receptor contractile pathway in hepatic arteries, which could be responsible for the
enhanced 5-HT-mediated contraction.
6.7. Conclusions
The present study indicated the existence of functional vasoconstrictor 5-HTi-like
receptors in human hepatic arteries. In donor hepatic arteries, 5-HT-induced
vasoconstriction was a cumulative action of 5-HT2A and 5-HTi-like receptors, while
in recipient, it was predominantly mediated via the 5-HTi-like receptors. This study
further indicated that in cirrhosis, the enhanced response to 5-HT in the hepatic
arteries was mediated by 5-HTj-like receptors. This enhanced response may be due
to the alterations of receptor activity and/or within the post receptor signal-
transduction pathway. It can therefore be suggested that over activity of 5-HTi-like
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receptor might have a substantial role in modulating splanchnic blood flow,







It has been demonstrated that cirrhosis of the liver is associated with an impaired
pressor response to vasoconstrictors and altered contractile function in isolated
vessels. The aim of this project was to use human hepatic arteries to assess the effect
of cirrhosis on vascular contractile function. Attempts would also be made to identify
the mechanisms responsible for any abnormality detected.
The agonists chosen for assessment using human hepatic arteries (AVP, 5-HT and
ET-1) are all endogenous vasoconstrictors (Hadoke, 1999). Their relevance to the
hyperdynamic circulation of cirrhosis is indicated by the fact that plasma
concentrations of all three are altered in cirrhotic patients (Akriviadis et al., 1997;
Beaudry et al., 1994; Trevisani et al., 1997). In addition, there is clinical and
experimental evidence to suggest that manipulation of these vasoconstrictor systems
may have therapeutic benefit in patients with cirrhosis (Shah et al., 1998; Hadoke,
2001).
7.2. Method Development
The difficulties associated with obtaining human hepatic arteries, together with the
small amount of information available in the literature, made it necessary to perform
a certain amount of method development using porcine splanchnic arteries as a
model. In particular, it was necessary to determine concentration ranges of agonists




In porcine splanchnic arteries, AVP and 5-HT produced complete concentration-
response curves in the ranges used, reaching an obvious maximum (Emax) and thus
allowing calculation of the pD2. Both these values were required as Emax and/or pD2
may be altered in arteries from patients with cirrhosis (Lew, 1995; Lew & Angus,
1992). The concentration-ranges used were also consistent with the other studies
using splanchnic vessels from small animals (Stam et al., 1998; Choppin &
O'Connor, 1995) and renal or coronary vessels from humans (Medina, et al., 1996;
Kaumann et al., 1994). Therefore, it was inferred that these ranges would be suitable
for use in human hepatic arteries. Arteries in this study were shown to be devoid of
endothelium as a result of surgical and preservation procedures. Consequently, these
results can only be extrapolated to denuded human hepatic arteries. This was not
problematic, as it was expected that human hepatic arteries would also loose
endothelium during surgery/retrieval and such denuded arteries were subsequently
used by many studies (Smith et al., 1997; Hadoke et al., 1998; Heller et al., 1999).
An unexpected result observed while using splanchnic arteries from juvenile pigs
was that the response to 5-HT was age-dependent. Receptor studies showed this to be
due to differences in 5-HT receptor activity and indicated the presence of at least two
different 5-HT receptor subtypes in porcine hepatic arteries as evidenced in isolated
rabbit mesenteric and renal (Choppin & O'Connor, 1995, 1994), porcine cerebral
(Den-Boer et al., 1991) and guinea-pig iliac (Sahin-Erdemli et al., 1991) arteries.
One of these was positively identified as the 5-HT2A receptor, because it was
sensitive to ketanserin (Hoyer et al., 1994). This receptor was active in adult pig
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hepatic arteries. The other receptor was tentatively identified as the 5-HTi-like
receptor because it was activated, in both adult and juvenile pig hepatic arteries, by
partial pre-contraction: a procedure which activates 5-HTi-like receptors in a variety
of arteries from other species (Choppin & O'Connor, 1995, 1994). Furthermore,
responses mediated by this receptor were not antagonised by ketanserin as, it has no
effect on 5-HTi-like receptor (Martin & Humphrey, 1994). Selective 5-HTi-like
receptor agonists and antagonists were not used to further identify this receptor in the
porcine hepatic arteries, as this was not a primary goal of the project. Evidence
obtained in the human hepatic arteries, however, supports the identification of this
receptor.
7.2.2. Effect ofOrgan Preservation
It was demonstrated that exposure to preservative solution (UWS, with or without
dexamethasone, insulin and penicillin) under conditions similar to those used during
liver preservation before transplantation had no effect on the contractile responses to
AVP and 5-HT in porcine hepatic arteries. This suggested that donor hepatic arteries
(which are exposed to the organ preservation procedure) can be used as a control for
recipient hepatic arteries (which are not) when assessing functional responses to
AVP and 5-HT. This was consistent with the use of donor hepatic arteries from this
source as controls in many studies of a-adrenoceptor-mediated contraction in
cirrhosis (Smith et al., 1997; Hadoke et al., 1998; Heller et al., 1999). However,
damage to the endothelium in the porcine hepatic arteries prevented an assessment of
the effects of organ preservation in endothelial cell function. This is important
because previous studies suggested that most functional alterations following
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preservation are due to changes in the endothelium, rather than the smooth muscle
cells (Lin et al., 1995; Anastasious et al., 1997; Jeng et al., 1997). The small but
significant impairment of SIN-1-mediated response in arteries incubated with
preservative solutions suggests that care must be taken if relaxation responses are
compared in donor and recipient hepatic arteries.
7.3. Effect of Cirrhosis on Contractile Response of Human Hepatic Arteries
This study formed the centrepiece of the project. Method development with porcine
hepatic arteries enabled optimisation of the conditions for in vitro assessment of
human hepatic arteries. This allowed the most efficient use of arteries obtained from
the transplant theatre, which were obviously a scarce resource. Furthermore, studies
with UWS had confirmed that the donor hepatic artery was a valid control for
recipient hepatic arteries when comparing responses to vasoconstrictors.
It was demonstrated for the first time that cirrhosis of the liver is associated with
altered contractile responses to AVP, 5-HT and ET-1 in human hepatic arteries.
Furthermore, this study extended previous work using human hepatic arteries by
showing that these alterations were strictly agonist-selective (Cummings et al., 1986;
Silva et al., 1998; Cahil et al., 1998). It also demonstrated that, in hepatic arteries,
cirrhosis could alter Emax and/or pD2. The Emax to AVP was reduced whereas that
to 5-HT was increased while, in both cases, the pD2 were unaffected. In the case of
ET-1, however, Emax was unchanged but pD2 was increased, indicating an increased
sensitivity of hepatic arteries to this agonist. These results further indicated that
although cirrhosis, irrespective of species, is associated with a hyperdynamic
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circulation, responses to distinct agonists are not altered in the same way. It is,
therefore, essential to investigate individual pressor systems independently as they
can be affected in different ways by the development of hepatic cirrhosis.
7.4. Mechanisms of Altered Vascular Contraction
Many studies have attempted to identify the pathophysiology of the vascular
abnormalities of cirrhosis, but the underlying mechanism remains controversial
(Hadoke, 2001). This study demonstrated that the altered function detected in vitro
was due to abnormalities in the vascular smooth muscle cells. The absence of
endothelial cells removed the possible effect of endothelium-derived relaxing or
contracting factors (Searle & Sahab, 1992), whilst in vitro methodology excluded a
role for circulating factors (Hayes et al., 1992). It remains possible, however, that
these factors may contribute to vascular dysfunction in vivo.
The similar contractile response to KC1 in arteries from cirrhotic and non-cirrhotic
individuals indicated that differences in arterial size did not account for variations in
agonist-mediated contraction. Induction of nitric oxide production in the VSMCs was
also unlikely to be responsible, as this would be expected to reduce the contraction
produced by all vasoconstrictor agonists (Sieber & Groszmann, 1992; Karatapanis et
al., 1994; Hartleb et al., 1994b). This was confirmed by the functional investigations
which demonstrated that inhibition of NOS altered neither the basal tone nor the
contractile responses to AVP and 5-HT in recipient hepatic arteries.
Immunohistochemistry also confirmed that donor and most recipient hepatic arteries
did not express iNOS. An intriguing observation was the demonstration of weak
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iNOS immunoreactivity in hepatic arteries from patients with alcoholic liver disease.
Use of L-NNA suggested that the iNOS was not implicated on the contractile
function. However, this iNOS staining only in patients with ALD signified that the
pathogenesis of vascular abnormalities could vary depending on the aetiology of
liver cirrhosis. This variability suggested that altered contraction was due to changes
in the activity of a particular receptor and/or in the post-receptor signal transduction
pathways.
7.5. Receptor Involvement
The current study demonstrated that cirrhosis exerted selective effects on receptor-
dependent contraction of recipient hepatic arteries. This effect was not dependent on
the endothelial cell function and circulating humoral agents. Therefore, to clarify the
mechanisms of these contractile abnormalities, it was necessary to identify the
receptor(s) in the VSMCs mediating contractile function induced by these agonists.
Use of porcine vessels (Chapter 3) demonstrated that the AVP and 5-HT caused
vasoconstriction by stimulation of receptors located in the VSMCs of hepatic
arteries. The receptors that mediated contraction to AVP, 5-HT and ET-1 were
identified pharmacologically in human hepatic arteries.
It was demonstrated for AVP that similar to human renal (Medina et al., 1996) and
gastric (Calo et al., 1997) arteries, the Vi receptor was responsible for mediating
vasoconstriction in the human hepatic arteries as responses were antagonised by the
Vi receptor antagonist. In contrast, a selective V2 receptor-agonist (DDAVP) did not
produce any contraction excluding the existence of V2 receptor in these denuded
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hepatic arteries. Many studies also demonstrated that the V2 receptor was located
primarily in the endothelium, which induced vasodilatation (Aki et al., 1994; Tagawa
et al., 1995). It was therefore, apparent that abnormality in the Vi receptor-mediated
pathway was responsible for reduced AVP-mediated contraction.
In human hepatic arteries, 5-HT-mediated contraction was shown to be mediated by
both 5-HT2a and 5-HTi-like receptors as suggested by several studies (Martin &
Humphrey, 1994; Yildiz et al., 1996). In this study, the enhanced response to 5-HT
in cirrhosis was contributed by both 5-HT2a and 5-HTi-like receptors, because, in
addition to 5-HT, the response to a relatively selective 5-HTi-like receptor agonist
(5-CT) was also increased. The hepatic cirrhosis appeared to alter the relative
contribution of these receptors in mediating contractile function similar to the
changes in the vessels induced by pre-contraction (MacLean, et al., 1996; Yildiz et
al., 1996; Cocks et al., 1993). The role of 5-HTi-like receptors became more
significant whilst the contribution of the 5-HT2A receptor was impaired, in hepatic
arteries from patients with this disease. Certain other condition such as angina can
also amplify the contribution of 5-HTi-like receptors in 5-HT-mediated contraction
(McFadden et al., 1992). In hepatic cirrhosis, altered portal and systemic
haemodynamics, metabolic functions and existence of humoral factors in abnormal
amount could enhance the activity of 5-HTi-like receptors (Hayes et al., 1992; Yildiz
et al., 1998).
The study with ET-1 demonstrated the ETA-receptor mediated vasoconstriction in
human hepatic arteries. In cirrhosis, therefore, the altered activity of the ETA-receptor
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could be responsible for the enhanced sensitivity of response to ET-1. Increased
sensitivity of response to ET-1 has also been reported in mesenteric arteries and
thoracic aortae, or in portal veins from animal models of portal hypertension with or
without cirrhosis (Cahill et al., 1998; Petrowsky et al., 1999). Moreover, in the
animal models, the mixed ETA and ETb receptor antagonists, could reduced portal
pressure indicating enhanced activity of the ET-1 system (Gandhi et al., 1998;
Reichen et al., 1998; Sogni et al., 1998). The mechanism of increased activity of the
ET-1 system in cirrhosis has not been explained. It could be due to the compensatory
hyperactivation of the ET-1 pressor system as a result of persistent vasodilatation in
cirrhosis, where expression of ET-1 receptors (ETA and ETB) had been enhanced
(Rockey et al., 1998; Leivas et al., 1998; Cahill et al., 1998). In contrast, it has also
been reported that the ET-1-mediated pressor response in forearm blood vessels of
well-compensated cirrhotic patients (Helmy et al., 2001) or the arterial pressure in
cirrhotic rat model (Hartleb et al., 1994b) was impaired. Although, the mechanism of
the attenuated pressor response in vivo was uncertain, it was suggested that increased
endothelial NO production via the ETb receptor could possibly be responsible for
this effect. Alternatively, it could be due to ET-1 receptor down-regulation (Rubanyi
& Polokoff, 1994) as a result of increased plasma concentrations of ET-1 in cirrhosis
(Asbert et a/., 1993; Kitano et al., 1996; Trevisani et al., 1997). However, this
explanation appears unlikely, as previous studies found that the plasma ET-1
concentration was not increased (Helmy et al., 2001; Battaglia et al., 1996). Indeed,
one study reported a decrease in plasma ET-1 concentration in patients with hepatic
cirrhosis (Veglio et al., 1992).
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In the present study, a contribution from the ETb receptor to the altered contractile
response can not be discounted, as this was not directly investigated. The ETb
receptor mediates vasodilatation or vasoconstriction depending on its location in the
endothelial cells or VSMCs, respectively (Gray & Webb, 1996; Touyz et al., 1995).
However, in this study, altered activity of the ETA receptor in VSMCs was most
likely mediating the enhanced ET-1 response in cirrhosis. This is evidence by the
fact that in cirrhotic recipient hepatic arteries, noticeably higher (5 fold)
concentrations of ETA-receptor antagonist (BQ-123) were required to antagonise the
response to ET-1, as compared to donor hepatic arteries. Therefore, this study
indicated that the up-regulation of the ETA-receptor in the recipient hepatic arteries
could account for the increased ET-1-mediated contraction in cirrhosis. However, the
contribution of ETe-receptors in ET-1-induced contraction of human hepatic arteries
with and without cirrhosis requires to be evaluated.
7.6. Conclusions
This study investigated the effect of hepatic cirrhosis on functional responses of
human hepatic arteries. Performing method development using porcine splanchnic
arteries allowed optimum use of scarce human arteries and also demonstrated that
organ preservation procedures were unlikely to alter contractile response of donor
hepatic arteries.
The demonstration that vessel retrieval procedures (probably trauma during surgery)
led to removal of the endothelium limited the investigation to an assessment of the
effects of cirrhosis on VSMC contraction. For the first time, however, it was shown
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that altered contractile function in hepatic arteries from patients with cirrhosis is
agonist-dependent and represents more than a simple hyporesponsiveness to all
vasoconstrictors. These results have profound implications for the investigation of
the pathogenesis of the hyperdynamic circulation and for the development of
potential therapeutic interventions for complications associated with these vascular
abnormalities.
The mechanisms responsible for the alteration in contractile function remain to be
clarified. The absence of an endothelium indicates that changes are restricted to the
VSMCs but a role for endothelium-derived factors contributing in vivo cannot be
excluded. In order to determine the impact of hepatic cirrhosis on the function of the
endothelial cells it would be necessary to acquire vessels with an intact endothelium
from both cirrhotic patients and non-cirrhotic controls. One possible way of
achieving this would be to isolate sub-cutaeneous resistance arteries from elective fat
biopsies. It is also unlikely that humoral factors contribute to the changes identified,
as all functional work was performed ex vivo isolated from circulating factors.
However, such factors may have a role in vivo and future research, such as
performing functional investigations in the presence of plasma from cirrhotic patients
or exposing cultured VSMCs to cirrhotic plasma is required. More precisely, to
assess the role of both endothelium and humoral factors on the altered contractile
response, further studies such as venous occlusion plethysmography (fore arm blood
flow) and dorsal hand vein compliance can be performed using these agonists (AVP,
5-HT and ET-1) in patients with cirrhosis.
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Given that the contractile abnormality is in the VSMCs, several possible mechanisms
presented themselves. It was shown that neither NO release from the VSMCs, nor
structural remodelling were responsible for the functional changes observed. This
suggested, therefore, that changes in the receptor-mediated contractile pathways
contributed these altered arterial contractions. The receptors responsible for the
vascular contraction (V! for AVP; 5-HT2a and 5-HTi-like for 5-HT and ETa for ET-
1) were identified. These alterations could be either in these receptors or post-
receptor signal transduction pathways. Combined pharmacological and ligand-
binding studies could determine the function and expression of these receptors.
Similarly, post-receptor signal transduction pathways can be assessed by measuring
the intracellular second messengers such as inositol phosphates, calcium ions and
protein kinase C, following stimulation of these receptors. Future research should
endeavour to determine the effect of hepatic cirrhosis on expression and contractile
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Selective Alteration of Agonist-Mediated Contraction
in Hepatic Arteries Isolated From PatientsWith Cirrhosis
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Background & Aims: Impaired pressor function in cirrho¬
sis may be specific to certain agonists and vascular
territories. This investigation determined whether re¬
sponses to arginine vasopressin (AVP) and 5-hydroxy-
tryptamine (5-HT) were impaired in hepatic arteries
from cirrhotic patients. Methods: Cumulative concen¬
tration-response curves were produced for AVP (10-11
to 3 x 10-6 mol/L), 5-HT (10"9 to 3 x 10-5 mol/L), and
potassium chloride (2.5 -120 mmol/L) in hepatic arter¬
ies from liver donors (noncirrhotic) and recipients
(cirrhotic). The receptor stimulated by AVP was identi¬
fied using aVrreceptor antagonist (d[CH2]5Tyr[Me]AVP)
and a selective V2-receptor agonist (desmopressin
[DDAVP]). Results: Cirrhotic patients had a high heart
rate (98 ± 4 beats/min) and cardiac output (9.87 ±
0.51 L/min) but low peripheral vascular resistance
(711 ± 35 dyn • s/cm5). None of the arteries had a
functional endothelium. Maximal contraction (but not
sensitivity) to AVP was smaller (P = 0.0002) in hepatic
arteries from recipients (34.03% ± 3.42% KCI) than
donors (60.69% ± 5.56% KCI). 5-HT-mediated contrac¬
tion was enhanced in recipient hepatic arteries
(88.81% ± 5.43% KCI vs. 71.63% ± 4.46% KCI; P =
0.01), but sensitivities were similar (P = 0.20). KCI-
mediated contractions were similar (P = 0.87) in both
groups. Arteries did not respond to DDAVP, but
d(CH2)5Tyr(Me)AVP produced a concentration-depen¬
dent rightward shift in the response to AVP. Conclusions:
These results demonstrate a selective impairment of
Vx receptor-mediated contraction in denuded hepatic
arteries from cirrhotic patients, suggesting an abnor¬
mality within the vascular smooth muscle.
Ahyperdynamic circulatory state,' consisting of arte¬rial vasodilatation and incre s d cardiac output, is
common in patients with cirrhosis.2 The causes of these
abnormalities remain obscure but may be linked to an
impaired response to pressor hormones.3 Indeed, there is
evidence to suggest that the function of cells in the
vascular wall becomes impaired in patients with cirrho¬
sis,4 although this remains controversial.5
Studies in cirrhotic patients have suggested that
contractile hyporesponsiveness could be agonist depen¬
dent,3,6 whereas our own study has shown that a-adreno-
ceptor—mediated contraction was unaltered in hepatic
arteries isolated from cirrhotic patients.7 The effect of
cirrhosis on the pressor response to arginine vasopressin
(AVP) and 5-hydroxytryptamine (5-HT) is of particular
interest. AVP and its analogues reduce portal pressure
and are used in the treatment of acute variceal hemor¬
rhage in cirrhosis." Similarly, clinical and experimental
studies have shown that 5-HT2-receptor antagonists
reduce portal pressure in patients" and in animal models
of portal hypertension.10 Therefore, altered pressor re¬
sponses to AVP and 5-HT may be important both in the
pathogenesis and in the treatment of vascular complica¬
tions in cirrhosis. Functional investigations of AVP- and
5-HT—mediated contraction in vessels isolated from
animal models of cirrhosis have produced conflicting
results5 and are not directly applicable to the clinical
situation in humans. This study aimed to determine
whether the presence of cirrhosis was associated with
alterations in the contractile responses to AVP and 5-HT
of isolated hepatic arteries. Such studies in human hepatic
arteries have not been reported. An additional aim was to
characterize the AVP-receptor subtype present in human
hepatic arteries by employing a Vrreceptor antagonist
and a selective V2-receptor agonist.
Materials and Methods
Effect of Cirrhosis on Hepatic
Artery Contraction
Hepatic arteries were collected from 37 donors (noncir¬
rhotic; 20 men and 17 women) and 33 recipients (cirrhotic; 14
men and 19 women) of similar age (46.7 ±2.0 and 51.6 ± 1.9
Abbreviations used in this paper: ACh, acetylcholine; AVP, 8-argi-
nine vasopressin; DDAVP, desmopressin; 5-HT, 5-hydroxytryptamine;
NO, nitric oxide; PHE, phenylephrine; UW, University ofWisconsin.
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years, respectively; P = 0.09) at liver transplantation. Causes of
cirrhosis (mean duration, 9-2 ± 1.2 years) were primary biliary
cirrhosis (n = 13), alcoholic liver disease (n = 8), cryptogenic
(n = 6), primary sclerosing cholangitis (n = 5), and secondary
biliary cirrhosis (n = 1). Causes of death in liver donors were
subarachnoid hemorrhage (n = 21), intracerebral hemorrhage
(n = 8), head injury (n = 4), hypoxia (n = 3), and aneurysm
(n = 1). Donor hepatic arteries were obtained after transplanta¬
tion, having been stored (with the donor liver) in preservative
(University of Wisconsin [UW]) solution for up to 16 hours.
Recipient hepatic arceries (4—6 cm) were dissected from the
freshly explanted liver and were never stored in UW solution.
Upon retrieval, hepatic arteries were placed immediately in
Krebs-Henseleit solution. The Lothian Research Ethics Com¬
mittee approved the use of human tissues.
Arteries were cleaned of adherent connective tissue, and
rings 2 mm in length were mounted between 2 parallel hooks
in 10-mL organ baths containing Krebs—Henseleit solution
(composition in mmol/L: NaCl, 118.5; KC1, 4.7; MgSOn 1.2;
KH2PO4, 1.2; NaHC03, 25; CaCl2, 2.5; and glucose, 11.6; pH
7.4). Indomethacin (10~5 mol/L) was added to the Krebs'
solution to inhibit the production of endogenous prostaglan¬
dins. The organ baths were maintained at 37°C and bubbled
with 95% 02—5% C02. The lower hook was fixed, and the
upper hook was attached to an isometric force transducer (Grass
FT03) connected to a computerized data acquisition system.
Whenever possible, functional investigations were performed
immediately after retrieval of the hepatic arteries. However, the
irregular timing of transplant operations necessitated storing
some arteries in Krebs—Henseleit solution at 4°C for a
maximum of 14 hours before functional investigation.
The rings were equilibrated at their optimal resting force
(4g)7 for 40-50 minutes. The viability and reproducibility of
contractions were tested using 3-4 consecutive applications of
KC1 (100 mmol/L). Cumulative concentration-response curves
were constructed using AVP (10~" to 3 X 10-6 mol/L), 5-HT
(10"9 to 3 X 1(T5 mol/L), and KC1 (2.5-120 mmol/L). The
rings were washed repeatedly after completion of each curve
and equilibrated for 30 minutes before the next agonist was
applied.
Human hepatic arteries obtained during liver transplanta¬
tion are generally devoid of endothelium.4,7'n Endothelial cell
function was assessed by adding the endothelium-dependent
vasodilator acetylcholi ne (ACh; 10~6to 3 X 10~5 mol/L)12'13 to
6 donor and recipient hepatic arteries precontracted with
phenylephrine (PHE) (10-6 to 3 X 10-5 mol/L). Endothelial
cell integrity was also assessed by staining the luminal surface
using silver nitrate.14 In subsequent experiments, removal of
the endothelium was ensured by rubbing the lumen with a wire
probe.
Identification of the Receptor Activated
by AVP
Fresh rings were prepared and cumulative concentration-
response curves obtained for the selective V2 agonist desmopres¬
sin (DDAVP; 10-" to 3 X 10"6 mol/L) and KC1 (2.5-120
mmol/L). Four more rings from each artery were then sus¬
pended in parallel: 3 were incubated with the V,-receptor
antagonist, d(CH2)5Tyr(Me)AVP (10~8, 10~7, and 1()-6 mol/L),
for 15 minutes, whereas the fourth (control) was not exposed to
the antagonist. Cumulative concentration-response curves were
constructed to AVP (10~" to 3 X 10~6 mol/L) in the presence
of the antagonist. Finally, cumulative concentration-response
curves were obtained to KC1 (2.5—120 mmol/L) in the absence
of the antagonist.
Effect of Organ Preservation on Hepatic
Artery Function
Responses to a-adrenoceptor agonists and KC1 are
similar in denuded hepatic arteries from pigs and humans.15
Porcine hepatic arteries were used to confirm that preservation
of the donor liver using UW solution was not responsible for
functional differences between donor and recipient hepatic
arteries. Hepatic arteries from 8 adult pigs were obtained from
the abattoir, and the endothelium was removed. Sections of
each artery were incubated at 4°C for 14—16 hours in 20 mL of
either Krebs' solution or UW solution containing dexametha-
sone (0.016 mg/mL), insulin (0.04 U/mL), and benzylpenicil-
lin (0.24 mg/mL). Responses to 5-HT (10-9 to 3 X 10-5
mol/L), AVP (10"" to 3 X 10"7 mol/L), and KC1 (2.5-120
mmol/L) were then obtained in 2-mm rings of these arteries.
Materials
5-HT creatinine sulfate, 8-AVP, DDAVP,
d(CH2)5Tyr(Me)AVP, indomethacin HC1, PHE HCl, ACh
chloride, and benzylpenicillin sodium were obtained from
Sigma (Poole, Dorset, England). Dexamethasone sodium phos¬
phate was from Faulding Pharmaceuticals (Warwick, England),
and insulin (Velosulin) was from NovoNordisk Pharmaceuti¬
cals (Sussex, England). UW solution was obtained from NPBI
International BV (Emmer-Compascuum, the Netherlands). All
salts were obtained from BDH (Poole, Dorset, England). Stock
solutions were prepared in deionized water, except indometha¬
cin, which was prepared in ethanol (final bath concentration of
ethanol, <1% vol/vol). Aliquots of 1.5 mL were stored at
— 20°C and thawed as requited, and any residue was discarded
at the end of the experiment. Concentrations given are the final
molar concentrations in the organ bath.
Statistics
Results are expressed as mean ± SEM; n represents the
number of subjects. Maximal contractions are given in grams
and as a percentage of maximum contraction to KC1 to control
for variations in the size of the arterial rings.16 Responses to
ACh are a percentage of the precontraction induced by PHE.
Sensitivity (pD2) values were determined using curve-fitting
software (Fig.P.; Biosoft, Cambridge, England). Maximal con¬
traction and sensitivity were compared using the Student
unpaired t test. Concentration-response curves were compared
using 2-way analysis of variance (ANOVA), followed by a
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Tukey post hoc test. Differences were considered significant at
P < 0.05.
Results
Cirrhotic patients had a high heart rate (98 ± 4
beats/min; n = 33; normal range, 60—90 beats/min) and
cardiac output (9.87 ± 0.51 L/min, n = 31; normal
range, 4—8 L/min), combined with a low systemic
vascular resistance (711 ± 35 dyn - s/cm5, n = 29;
normal range, 1200—1500 dyn • s/cm5).
Test for Endothelium
None of the arteries (6 donor, 6 recipient) relaxed
in response to ACh. Indeed, ACh (10 mol/L) contracted
recipient (1.83% ± 0.47%) and donor (2.37% ± 0.35%)
hepatic arteries, with further contractions as the ACh
concentration was increased to 3 X 10~6 mol/L (6.95% ±
1.49% and 5.46% ± 1.10%, respectively) and 3 X 10~5
mol/L (9.30% i0.95% and 11.82% ± 0.68%, respec¬
tively). The absence of an endothelium was confirmed
using the silver nitrate stain.
Effect of Cirrhosis on Hepatic
Artery Contraction
The maximal contractile response to AVP (Figure
1A) was significantly (P = 0.003) smaller in recipient
(3.53 ± 0.35 g; n = 22) than in donor (5.73 ± 0.61 g;
n = 23) arteries. This difference was maintained when
contractions were expressed as a percentage of maximal
response to KC1 (34.03% ± 3.42% vs. 60.69% ±
5.56%; P = 0.0002). This impairment was also detected
(P < 0.0001) when the entire curves were compared
using 2-way ANOVA (Figure 1A). Sensitivity (pD2) to
this agonist, however, was similar (P = 0.86) in donor
(8.19 ± 0.07) and recipient (8.21 ± 0.08) hepatic
arteries.
5-HT produced a larger contraction in recipient
(8.60 ± 0.46 g; n = 25) than in donor (7.12 ± 0.58 g;
n = 26) hepatic arteries (Figure IB). This difference was
of borderline significance (P = 0.06), but significance
was achieved when contractions were expressed as a
percentage of the maximal contraction to KC1 (88.81% ±
5.43% vs. 71.63% — tt4.55%;P = 0.01). The sensitivity
(pD2) of this response was similar in donor and recipient
hepatic arteries (6.45 — 0.08 and 6.60 ± 0.08, respec¬
tively; P = 0.20). The difference between the curves was
confirmed by 2-way ANOVA (Figure IB; P = 0.04).
The maximal contraction (10.09 ± 0.71 and 10.32 ±
0.70 g, respectively; P = 0.81) and sensitivity (1.70 ±
0.05 and 1.63 ± 0.04, respectively; P = 0.34) to KC1
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Figure 1. Cumulative concentration-response curves produced in
response to (A) AVP (n = 22-23) and (8) 5-HT (n = 25-26) by donor
(noncirrhotic, □) and recipient (cirrhotic, O) hepatic arteries. Re¬
sponses are given as mean ± SEM and expressed as a percentage of
the maximal contraction induced by KCI. Differences between curves
were obtained using 2-way ANOVA. *P < 0.0001 when individual
points were compared using the Tukey post hoc test.
Identification of the Receptor Activated
by AVP
The selective V2 agonist, DDAVP, did not con¬
tract hepatic arteries from donors or recipients, although
these contracted in response to KCI (maximal contrac¬
tion, 11.23 ± 1.29 and 10.85 ± 0.64 g, respectively;
P = 0.76; pD2, 1.65 ± 0.09 and 1.63 ± 0.04,
respectively; P — 0.74). Incubation with the Vt antago¬
nist, d(CH2)5Tyr(Me)AVP, produced a concentration-
dependent rightward shift in the response to AVP (Figure
2), reducing the sensitivity (but not the maximal contrac¬
tion) to this agonist (Table 1). This effect was similar in
arteries from recipients and donors. The sizes of the
responses to KCI were unaltered after incubation with
this antagonist (Table 1). Similarly, the sensitivities (pD2)
of donor (1.64 ± 0.07) and recipient (1.67 ± 0.04)
hepatic arteries to KCI were unaltered by incubation with
10~H mol/L (1.63 ± 0.08 and 1.69 ± 0.05, respectively),
10~7 mol/L (1.60 ± 0.06 and 1.61 ± 0.05, respectively),
or 10"6 mol/L (1.61 ± 0.08 and 1.63 ± 0.07, respec¬
tively) d(CH2)5Tyr(Me)AVP.






















Figure 2. Effect of incubation in the absence (control, □) or presence
of 10~8 mol/L (♦), 10-7 mol/L (A), and 10~6 mol/L (▼) of the Vt
antagonist, d(CH2)5Tyr(Me)AVP, on responses to AVP in (A) donor (n =
11) and (8) recipient (n = 10) hepatic arteries. The sensitivities (pD2)
of donor (8.07 ± 0.16) and recipient (8.01 ± 0.11) hepatic arteries
were reduced in a concentration-dependent manner by 10" 8 mol/L
(7.27 ± 0.14 and 7.25 ± 0.14, respectively; P< 0.002), 10~7 mol/L
(6.71 ± 0.12 and 6.56 ± 0.11, respectively; P < 0.001), and 10"6
mol/L (6.07 ± 0.10 and 6.15 ± 0.14, respectively; P < 0.001) of
d(CH2)5Tyr(Me)AVP. Values are mean ± SEM and are expressed as a
percentage of the maximal contraction induced by KCI.
Effect of Organ Preservation on Hepatic
Artery Function
Maximal contractions of porcine hepatic arteries
by 5-HT (4.15 ± 0.67 g), AVP (2.83 ± 0.41 g), and KCl
(11.95 ± 1.27 g) after storage for 14—16 hours in UW
solution (n = 8) were not different from responses
produced after storage in Krebs' solution (n = 8) (3.79 —
0.48 g, P = 0.67; 2.57 ± 0.48 g, P = 0.68; and 11.29 ±
1.12 g, P = 0.70, respectively). The sensitivities (pD2) of
arteries stored in UW solution to 5-HT (6.08 ± 0.10),
AVP (8.19 ± 0.08), and KCl (1.45 ± 0.03) were also
similar to values obtained with sections stored in Krebs'
solution (5.98 ± 0.10, P = 0.50; 8.04 ± 0.13, P = 0.33;
and 1.47 ± 0.03, P — 0.57, respectively).
Discussion
This investigation demonstrates that receptor-
dependent contraction of denuded human hepatic arteries
is altered in patients with cirrhosis. This corresponds
with recent reports4-11 of attenuated oq-adrenoceptor-
mediated contraction in hepatic arteries and portal veins
from similar patients (although our previous study did
not detect an impaired response to a-adrenoceptor ago¬
nists7). The present results show that the vascular
abnormality in patients with cirrhosis is agonist depen¬
dent, because AVP-mediated contraction was reduced,
whereas the response to 5-HT was augmented. In the
absence of a functional endothelium, this suggests an
alteration in the vascular smooth muscle cells. Because
AVP and its analogues are used to treat acute variceal
hemorrhage, and may act by reducing portal hyperten¬
sion via contraction of splanchnic arteries,17 this may
have implications for clinical practice.
Investigation of hepatic artery function is relevant to
the pathogenesis of vascular abnormalities in cirrhosis,
because dilation of splanchnic arteries in early cirrhosis
contributes significantly to the hyperdynamic circula¬
tion.18 Donor hepatic arteries have been used previously,
by ourselves7 and others, -11 as controls in functional
investigations. Their suitability is demonstrated by their
functional similarity to porcine hepatic and mesenteric
arteries.15 This is reinforced by our confirmation that
organ preservation in UW solution does not alter contrac¬
tility of porcine hepatic arteries.4 Trauma during surgery
is a recognized cause ofendothelial cell loss19 and explains
the absence of endothelium in the arteries used in the
present, and previous)4-7,11 studies. Consequently, the
changes in AVP- and 5-HT—mediated contraction must
Table 1. Effect of the V, Antagonist d(CH2)5Tyr(Me)AVP on
the Maximal Contractile Responses of Donor and
Recipient Hepatic Arteries
AVP KCl
Antagonist (g) (%KCt) (g)
Donor hepatic arteries
None (10-11) 6.93 ± 0.77"
10~8 mol/L (10-11) 6.37 ± 0.60
10-7 mol/L (8-10) 6.34 ± 0.78
10"6 mol/L (8-9) 5.99 ± 0.68
Recipient hepatic
arteries
None (10) 4.18 ± 0.59
10~8 mol/L (10) 3.89 ± 0.73
10"7 mol/L (8) 4.15 ±0.88

















NOTE. Values are mean ± SEM for (n) subjects.
ap < 0.02 compared with the control responses in the recipient grou
All comparisons were made using the Student unpaired t test.
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be the result of alterations in the arterial smooth muscle
rather than release of vasoactive factors from the endothe¬
lium.
AVP and 5-HT were investigated because (1) circulat¬
ing concentrations of these hormones become altered
during the development ofcirrhosis and (2) pharmacologi¬
cal manipulations of AVP and 5-HT systems can reduce
portal hypertension. Nonosmotic secretion of AVP is
increased in cirrhosis, resulting in elevated plasma AVP
concentrations.2" In contrast, 5-HT levels in whole
blood, as well as unconjugated (active) and conjugated
(metabolites) forms in the plasma, are reduced in ad¬
vanced disease.21 AVP and its analogues reduce hepatic
blood flow and portal pressure, and are used to treat acute
variceal hemorrhage,8 while 5-HT2 receptor antagonists
reduce portal pressure in both animal models22 and
cirrhotic patients 9
Attenuated AVP-mediated contraction in recipient
hepatic arteries is consistent with the impaired pressor
response (to adrenoceptor agonists and angiotensin II)
reported in patients with cirrhosis.3-6 In contrast, the
enhanced response to 5-HT was unexpected, although
there are reports of increased pressor response (to adreno¬
ceptor agonists) in cirrhotic patients.23-24 Few studies of
vascular function in animal models of cirrhosis have used
AVP and 5-HT,5 but portal hypertension in rats is
associated with reduced arterial contraction (with unal¬
tered sensitivity) to AVP.25-26 This has been attributed to
release of endothelium-derived vasodilators,26 although a
corresponding reduction in intracellular inositol phos¬
phate accumulation suggests impaired excitation-contrac¬
tion coupling within the smooth muscle.25 Regional
variations are evident with a selective enhancement of
AVP-mediated contraction in mesenteric veins from
portal-hypertensive rats,22-27 which was not caused by
increased smooth muscle mass. The effect of cirrhosis/
portal hypertension on responses to 5-HT seems to
depend on the animal model and vascular territory
studied.5 Our results are similar to those obtained using
aortae from rats with CCLj-induced cirrhosis,28 mesen¬
teric and portal veins from portal vein—ligated rats,22-29
and portal veins from mice with schistosomiasis.30 In rat
vessels, 5-HT—induced contraction is mediated by 5-HT2
receptors, and the augmented response was independent
of smooth muscle mass and receptor affinity.22-29 This
suggests, therefore, an alteration in the post-receptor
signal transduction mechanisms within the smooth muscle
cell.
The agonist-selective alteration in contraction of he¬
patic arteries contrasted with the unaltered response to
the (receptor-independent) direct-depolarizing agent, KC1.
This is consistent with previous reports of human hepatic
artery function in cirrhosis4-11 and indicates that the
altered responses to AVP and 5-HT are not the result of
changes in smooth muscle mass or altered sensitivity of
contractile proteins to intracellular calcium. This sug¬
gests, therefore, altered function of contractile receptors
and/or the post-receptor second messenger cascade. AVP
can stimulate both V! and V2 receptors, with V! receptors
usually mediating contraction of vascular smooth muscle.
In the present study, the lack of response to the selective
V2-receptor agonist (DDAVP), combined with the inhibi¬
tion of AVP-mediated contraction by the V|-receptor
antagonist, confirms that, as in human renal and gastric
arteries,31-32 this is a Vj receptor—mediated response.
5-HT can activate several distinct 5-HT receptor sub¬
types,24 with the 5-HT2A- and 5-HTi-Like receptor
subtypes mediating contraction of vascular smooth
muscle.29 In some territories, including the splanchnic
vasculature,33 partial precontraction of the artery is
required to facilitate 5-HT-mediated contraction. We
have preliminary data to confirm that the resting tone of
the human hepatic artery influences the mechanism of
5-HT-mediated contraction,34 and, consequently, identi¬
fication of the receptor subtype responsible for 5-HT—
mediated contraction of this artery was beyond the scope
of the present investigation.
Receptor-mediated contraction rapidly becomes desen¬
sitized in response to receptor occupancy, resulting in
reductions ofeither specific binding or inositol phosphate
production.35 Consequently, the elevated AVP concentra¬
tions in patients with advanced cirrhosis could cause
receptor down-regulation, thus accounting for impaired
contraction. Unfortunately, the evidence for receptor
down-regulation in cirrhosis is sparse and often contradic¬
tory,36 and expression of V| receptors has not been
assessed in tissues from patients. Similarly, the increased
response to 5-HT could be the result of receptor up-
regulation in response to reduced circulating 5-HT,
although this was not the cause of augmented contraction
in rat mesenteric veins.22 In the absence of ligand binding
studies (which require more tissue than was available) and
assessment of second messenger responses, the sites of
impaired AVP-mediated contraction and enhanced re¬
sponse to 5-HT cannot be confirmed.
The release of nitric oxide (NO), after activation of
inducible NO synthase in the vascular smooth muscle
cells, has been suggested as the cause of impaired
contractile function in cirrhosis.11 This is unlikely in the
present study, because NO release would impair re¬
sponses to both AVP and 5-HT rather than selectively
inhibit the response to AVP. Furthermore, Heller et al.4
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reported that inhibition of NO synthesis did not alter
contractile function in hepatic arteries from patients,
which corresponds with our preliminary demonstration
that NO inhibition did not affect responses to either AVP
or 5-HT in these arteries.37
In conclusion, this study demonstrates selective alter¬
ations in receptor-mediated contraction ofhepatic arteries
from patients with cirrhosis. These are not the result of
vascular remodeling or impaired sensitivity of contractile
proteins, suggesting abnormalities at the receptor-
second messenger level, possibly as a result of altered
hormone concentrations in patients with cirrhosis. These
changes may contribute to the hyperdynamic circulation
and may also have important implications for the use of
AVP analogues and 5-HT2 antagonists for the pharmaco¬
logical reduction ofportal hypertension.
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Zollinger of the Zollinger-Ellison syndrome
Copyright holder unknown. Photo
obtained from the National Library of
Medicine website (http://www.
nlm.gov).
Robert Milton Zollinger (1903—1993) was born in Millersport, Ohio, and
received his M.D. degree from Ohio State University in 1927. His residency
training in surgery was at the Peter Bent Brigham Hospital in Boston and at
the Lakeside Hospital in Cleveland. After a stint on the faculty at Harvard
Medical School, in 1946 he was appointed professor and chairman of the
department of surgery at his alma mater, a post he held until retirement in
1974. Zollinger was an avid horticulturist and rose fancier.
—Contributed by MARKUS M. LERCH, M.D.
and WOLFRAM DOMSCHKE, M.D.
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